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ABSTRACT
MICRONUTRIENT INTAKE AND PREMENSTRUAL SYNDROME
SEPTEMBER 2011
PATRICIA O. CHOCANO-BEDOYA, M.D., UNIVERSITY OF
SAINT AGUSTIN, AREQUIPA, PERU
PH.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Elizabeth Bertone-Johnson

Premenstrual syndrome (PMS) is characterized by the presence of physical
and psychological symptoms restricted to the late luteal phase of the menstrual
cycle and associated with substantial impairment in life activities. In the U.S. about
8 to 15% of women of reproductive age suffer from PMS. Many micronutrients are
potentially involved in the development of this disorder due to their role in the
synthesis of neurotransmitters and hormones or in their regulation, but few
previous studies have evaluated the effects of micronutrients on PMS.
The first study examined the association between B vitamin intakes, and
PMS development among women participating in the Nurses' Health Study 2
(NHS2). We found that high thiamin and high riboflavin intake from food sources
were associated with lower risk of PMS. There were not significant associations
between niacin, vitamin B6, folate, and vitamin B12 dietary intake and incident
PMS. Intakes of B vitamins from supplements were not associated with lower risk
of PMS.
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The second study evaluated the association between selected mineral
intakes and PMS development in the NHS2. In this study, high iron intakes were
associated with lower risk of PMS. Although there was no association between
zinc and PMS risk, high intake of zinc relative to copper was associated with lower
risk of PMS. There were no associations between of magnesium, copper, and
manganese intakes and PMS. We observed a significantly higher risk of PMS in
women with high intakes of potassium from food sources.
The third study focused on the association between dietary intakes of B
vitamins, zinc, magnesium, iron, potassium, and sodium and some biomarkers and
PMS prevalence among younger women. In this study, we found an association
between zinc intake and lower prevalence of PMS. Each 1 mg/d increase in
vitamin B6 from foods was associated with a lower PMS symptom score. Blood
magnesium levels were higher in women with PMS compared to women without
PMS.
We observed that intakes of some micronutrients were associated with
lower risk of PMS, but further studies should be conducted. This dissertation
contributes to the research on modifiable risk factors for PMS.
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CHAPTER 1
PREMENSTRUAL SYNDROME REVIEW

A syndrome is a group of symptoms and signs with a common etiologic factor.
Accordingly, premenstrual syndrome (PMS) involves a group of psychological and
physical symptoms and signs that occur cyclically during the late luteal phase of the
menstrual cycle and resolve within a few days of the onset of menstruation (1). This
syndrome affects millions of women of reproductive age worldwide (1, 2). Despite many
decades of research, there is still controversy about the etiology and treatment of PMS.
The establishment of a universally accepted definition and set of diagnostic criteria, the
understanding of the pathophysiology and the identification of effective treatments are
problems yet to be solved. This chapter focuses on the diagnosis, burden,
pathophysiology and treatment of PMS as an introductory review

1.1 Definition and Diagnosis
The definition and diagnostic criteria of premenstrual syndrome have varied
substantially over the years, and controversy persists (3, 4). Moreover, the disagreement
about the medical definition of PMS has been used to support the position that PMS is
not a “physiologic condition but a cultural/ideological construct” (5).
“Premenstrual tension” was first described in the scientific literature by Frank in
1931 (6). However, it was not until 1953 that Greene and Dalton adopted the term
“premenstrual syndrome” because they believed that the term “premenstrual tension” did
1

not include all the potential symptoms that women experienced during the late luteal
phase (7). Despite this, some authors continued to use the term ‘premenstrual tension’ up
to the 1990’s.
Between the 1950’s and 1960’s most researchers focused on the somatic
complaints of PMS, rather than the psychological complaints (5). But at the same time,
many standardized questionnaires for symptom measurement were proposed by
psychologists (5) one of the most important ones being the Menstrual Distress
Questionnaire, designed by Moos.(8) This questionnaire included 47 symptoms evaluated
on a six-point scale and reported for different phases of a current and a past cycle (8). Up
until 1990, there were additional attempts to standardize the diagnosis of PMS and
premenstrual dysphoric disorder (PMDD), but most studies still used “non-standardized
poorly validated methods” (5, 9).
In 1990 Mortola et al. designed the “Calendar of Premenstrual Experiences”
(COPE) (9). In the validation study, behavioral items were compared to the Beck
Depression Inventory and the Profile of Mood States, both of which are well-validated
psychiatric questionnaires designed to measure depression. The authors concluded that
the COPE had a 0% false positive rate and 2.8% false negative rate, as well as high
reliability (9).
Over 150 symptoms have been associated with PMS. With regards to affective
symptoms, irritability, depression and fatigue are the most important and most frequently
reported (10). Other affective symptoms such as labile mood and frequent crying are also
very common (75% and 66% respectively) (10).Approximately 50% of women report
2

difficulty in concentrating and forgetfulness. Of physical symptoms, the most common
are bloating, headache and breast tenderness. Approximately 48% of women with PMS
have gastrointestinal upset, and 18% suffer from hot flushing (10). The nature and
frequency of the symptoms vary between women and also in different cycles in the same
women (11).
In the year 2000, the American College of Obstetricians and Gynecologists
(ACOG) (1) published a set of diagnostic criteria for PMS adapted from those suggested
by Mortola et al (9). These criteria include the presence of at least one of 6 affective
symptoms and at least 1 of 4 somatic symptoms (Table 1) during the 5 days previous to
the onset of menstruation in each of three previous menstrual cycles. Symptoms are
reported prospectively in a self-maintained diary. The intensity of the symptoms must be
severe enough to cause social dysfunction and/or to affect work performance. Symptoms
should subside completely within 4 days of the onset of menses and should not reappear
until after day 13 of the menstrual cycle. The ACOG emphasized that the symptoms
should be assessed prospectively and other differential diagnoses like clinical major
depression should be excluded (1).
Overall, definitions of PMS may vary in their criteria for symptom inclusion, but
their restriction to the luteal phase is essential (9). Another indispensable condition is
that symptoms are not caused by another physical or mental disorder. Differential
diagnoses include dysphoric disorder and generalized anxiety disorders (13).
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Premenstrual Dysphoric Disorder (PMDD) and PMS.
The revised third edition of the Diagnostic and Statistical Manual of Mental
Health Disorders (DSM-III-R)(14) of the American Psychiatric Association (APA)
included research diagnostic criteria for severe luteal phase symptoms under the name of
“late luteal phase dysphoric disorder”. For the text revision of the fourth edition of the
DSM-IV-TR (2000)(12) this condition was renamed “premenstrual dysphoric disorder”
(PMDD). The official inclusion of a diagnostic code for PMDD is very important for
medical record coding and for potential insurance reimbursement. In fact, in 2003, the
new version of the International Classification of Diseases (ICD-9-CM) included
“premenstrual tension syndrome” under the code 625-4, though it lacked specific
diagnostic criteria.(5)
The DSM-IV-TR includes four criteria for a diagnosis of PMDD. The first
criterion is the presence of at least 5 of the 11 symptoms listed in table 1, and at least one
must be emotional. The second criterion is that symptoms must cause impairment in at
least one facet of the woman’s daily life (e.g., school, work, interpersonal relationships).
The third criterion is that symptoms cannot be an exacerbation of other psychiatric
disorders. Finally, symptom experience must be confirmed by prospective daily ratings of
symptoms during two consecutive cycles.(12)
The relationship between PMS and PMDD is not clear (4). Several of the APA
criteria for PMDD overlap with the ACOG criteria for PMS. While PMDD has been
considered as a different entity than PMS by some clinicians and researchers (15), it has
been also referred to as a severe form of PMS by others (16) .
4

Table 1. Common symptoms present in the definitions of PMS and PMDD according
to the ACOG (1) and APA (12) respectively.
Symptoms

PMS (ACOG)

PMDD (DSM IV-TR)

Affective

Depression

Depressed mood

Irritability

Anxiety, tension

Anxiety

Affective lability

Angry outbursts

Anger or irritability

Confusion

Difficulty in concentrating

Social withdrawal

Decreased interest in usual activities
A sense of being overwhelmed

Somatic

Breast tenderness

Lethargy

Abdominal bloating

Change in appetite

Headache

Hypersomnia or insomnia

Swelling of extremities

Breast tenderness/swelling/joint or
muscle pain/sensation of
bloating/weight gain

Assessment of PMS: Prospective vs. Retrospective
Assessment of PMS using retrospective self-report of PMS symptoms has drawn
criticism, with some researchers asserting that accuracy could be affected by learned
expectations and stereotypes about premenstrual suffering, which in turn could lead to the
5

overestimation of PMS (5). Therefore, most of the definitions for PMS require
prospective symptom reporting. Different types of questionnaires and diaries have been
designed for prospective charting. For example, the “Daily Symptom Report” (DSR)
designed by Freeman et al. consists of a diary were patients daily indicate the presence of
17 PMS symptoms and rate their severity from 0 (“none”) to 4 (“severe”) over 2 to 3
months (17) .
Although prospective recording of symptoms appears to provide more accurate
means of diagnosis, other validated methods are also needed. Women seeking treatment
tend to be those with more severe symptoms (18), and it is important to provide them
with prompt treatment. These patients are likely to be unwilling to accept the delay in
treatment due to three months of prospective recording (18). Additionally, it may not be
feasible to use prospective symptom recording in large epidemiologic studies, which are
essential to identifying factors associated with PMS occurrence. In view of this challenge,
Bertone-Johnson et al.(2007) (19), evaluated the validity and reliability of using
prospective self report of clinical diagnosis of PMS with a retrospective menstrual
symptom questionnaire among women participating in the Nurses’ Health Study II, using
PMS cases diagnosed prospectively as an ‘alloyed’ gold standard. The authors found that
the menstrual symptom occurrence, timing, severity and personal impact of women who
met case criteria based on those proposed by Mortola et al (9) as assessed by a
retrospective questionnaire were essentially identical to those who reported having
completed prospective charts as part of their medical diagnosis (19). Therefore,
prospective self report combined with retrospective questionnaires may be a sensitive
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enough method of identifying PMS cases to study risk factors for this disorder in large
prospective studies.

Summary of definition and diagnosis
In summary, historically the definition of PMS has been controversial. Although
guidelines for PMS have been published by the ACOG, and PMDD is recognized in the
DSM-IV-TR, there is no current agreement on several aspects of PMS and PMDD
diagnosis. Prospective charting is recommended for the clinical diagnosis of PMS, but
retrospective questionnaires may be a valid option for use in large population-based
studies.

1.2 Incidence, Prevalence and Burden of PMS
Despite increasing interest in PMS over time by the medical community, the
incidence of PMS remains largely unknown due to the fact that most studies have
collected information retrospectively on symptom frequency, using different instruments
and criteria to define premenstrual disorders (3, 20). Estimation of true incidence
remains largely unfeasible. Because symptoms could develop during any menstrual cycle
from menarche to menopause and may not be present every menstrual cycle, estimation
of incidence would require study participants to prospectively record symptoms every
cycle for many years.
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Prevalence:
According to the ACOG, around 15 to 20% of women of reproductive age suffer
from PMS (1). A prevalence of 8.3% in 1994 was reported by Deuster et al.(21) who
conducted a cross-sectional population-based study in Virginia. Using random digit
dialing, 874 women were contacted and completed an interview that included a
“Shortened Premenstrual Assessment Form” (SPAF), where women recalled the
presence of 10 symptoms the week before menses and rated the severity of them on a 6point scale (1=no change, 6=extreme change). Women were classified as having PMS if
they rated five or more of the 10 symptoms as 5=severe or 6=extremely severe, and
reported at least one affective symptom.
According to the APA, 3 to 8% of women of reproductive age meet the DSM-IV
criteria for PMDD (12). In 2008, Gehlert et al.(22) conducted a study to estimate the
prevalence of PMDD according to the DSM IV criteria among 1246 women aged 13 to
55 years living in two urban sites of Chicago. Daily symptom questionnaires and urine
specimens were collected for two consecutive cycles to estimate ovulation time and
timing of symptoms. The authors found a prevalence of PMDD of 1.3% which was lower
than the prevalence previously reported by the APA. In Germany, Wittchen et al.(23)
conducted a study among 1488 women aged 14 to 24 followed over 4 years. A
questionnaire based on DSM-IV criteria was conducted by trained interviewers at the end
of every year. The authors reported a 12-month prevalence of 5.8% and an increase of
new cases of 2.5% after 4 years.
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Burden:
Some authors assert that the burden associated with PMDD is comparable to that
of major depressive disorder (24). The overall burden of PMS and PMDD is high largely
because of relatively high prevalence and long duration of the symptoms, which could
last throughout a woman’s reproductive years. Halbreich et al.(2003) (24) calculated that
the disability adjusted life years (DALYs) for PMDD are 3.8 per women, assuming a
reproductive period from ages 14 to 51 years and 2 pregnancies, for a total of 459
menstrual cycles, 6.1 days of PMS symptoms per cycle and a global burden of disease
severity weight of 0.5. If the prevalence of PMDD is estimated to be 5% in the U.S.
population as of 2000 census, the total DALYs would be approximately 14.5 million for
all women of reproductive age in the US.
The economic burden associated with PMS includes direct medical costs as well
as indirect costs. Medical costs include physician visits, laboratory tests and the cost of
treatment. Indirect costs include those related to work/school absenteeism as well as to
impaired productivity at work (2, 25).
Borenstein et al (2005) (25) estimated the direct and indirect costs of PMS among
a sample of 374 women aged 18 to 45 years in Southern California. Participants
completed a Daily Rating of Severity of Problems (DRSP) diary for 64 days, which
measured recurrence of 11 symptoms, rated from 1 to 6 (1=not at all, 6=extreme). A
diagnosis of PMS was made if participants reported an increase in score of ≥30% during
the luteal phase, with at least 3 symptoms with an average score ≥ 3. Under these criteria,
29.6% participants were diagnosed with PMS. Direct costs of PMS were quantified
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according to administrative claims and the Medicare Fee Schedule, and were estimated to
be $59 per year per person, including outpatient visits, laboratory analysis and radiology
services. Indirect costs were estimated based on number of workdays missed due to
health reasons (i.e. absenteeism) and self-reported proportion of days with at least 50%
reduced work productivity compared to typical levels (loss of productivity). Using data
on the median weekly wage of the female population from the U.S. Bureau of Labor
Statistics Report 2000, indirect costs were estimated to be higher than $4,000 per person
per year (25).
Hence, days of work loss and decreased productivity appear to contribute more
than direct costs to the economical burden of PMS. In the same population as the
previous study, Dean and Borenstein (2004) (26) concluded that participants with PMS
reported higher days of work absenteeism as compared to women without PMS (2.5 days
vs. 1.3 days, p=0.006). Impairment in work and school productivity as well as household
activities was significantly higher among women with PMS as compared to those in
women without the disorder. In a cross-sectional study by Robinson et al (2000) (18), the
authors found that 20% of women with premenstrual symptoms missed work due to PMS
during the year previous to the study. Moreover, participants surveyed reported greater
impairment of interpersonal relationships than work performance.
Direct and indirect costs both may be underestimated (2, 24). Not all women with
PMS seek medical attention (18), and symptoms of PMS mimic other psychiatric or
somatic disorders, which may lead to a substantial number of misdiagnoses (27). Days of
work lost due to PMS may be underreported because of the stigma associated with it or
because it might not be regarded as a “legitimate” reason for missing work (28).
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Assessment of impaired productivity can be challenging and requires different
methodologies for different occupations (24).
In summary, the estimated prevalence of PMS ranges substantially from 8.3 to
20% (1, 21), and depends on the criteria and methodology selected. Even if we consider
the lowest prevalence reported to be accurate, the number of women suffering from PMS
over many years is high.

1.3 Pathophysiology
The physiology of the menstrual cycle has been well studied and there is
continuous research on the associated pathologies. However, the underlying
pathophysiology of PMS remains unclear. Because of the timing and nature of the
symptoms most studies have hypothesized that PMS is caused by interactions among sex
hormones and neurotransmitters in the central nervous system.

Overview of the Menstrual Cycle
In order to describe the theories about the physiopathology of PMS, it is important
first to provide a brief overview of the menstrual cycle, as summarized well by Guyton
(2006) (29). The female hormonal system includes the hypothalamus, located in the
central part of the base of the brain, the anterior pituitary, located underneath the
hypothalamus, and the ovaries. This system is known as the hypothalamic-pituitaryovarian axis. The hypothalamus secretes gonadotropin releasing hormone (GnRH) in
short pulses, approximately once every 90 minutes. Variation in the frequency and size of
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GnRH pulses stimulates the anterior pituitary to secrete the gonadotropins folliclestimulating hormone (FSH) and luteinizing hormone (LH), which stimulate the
production of estrogen and progesterone in the ovary. FSH and LH secretion starts
around the age of 9 to 12 years in normal females (i.e., at the onset of puberty) and
changes rhythmically during the menstrual cycle in response to positive and negative
feedback from the ovarian steroid hormones as well as other factors (29, 30).
Each menstrual cycle has an average duration of 28 days, although cycle length
can range from 20 to 45 days (29, 30). The first day of menstruation is considered as the
first day of the cycle. During the first days of each cycle, there is a slight to moderate
increase in the secretion of FSH and to a lesser extent in the secretion of LH. FSH causes
proliferation of the granulosa cells surrounding oocytes in the ovary and increases FSH
receptors in these cells. A layer of cells surrounding the granulosa cells is then formed,
which is called the ‘theca’ (Figure 1). Thecal cells exposed to low levels of LH produce
androgens, which are then converted to estrogen by CYP19 aromatase in the granulosa
cells. This enzyme action is induced by FSH. Therefore there is biological interaction
between both layers of cells, which leads to increased estrogen levels. Estrogen has an
initial positive feedback on FSH production, inducing the granulosa cells to produce
more FSH receptors. As estrogen levels increase, the luminal layer of the endometrium
begins to proliferate. Therefore the first part of the menstrual cycle is also called the
proliferative phase.
Eventually, high estrogen levels down-regulate FSH secretion (i.e., negative
feedback) (29). Usually, only a single follicle maintains a high estrogen
microenvironment without the influence of FSH, and the rest of the follicles involute and
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become atresic. Two days before ovulation, there is a 6 to 10 fold increase in the
secretion of LH, which is required for the final stage of follicular growth and ovulation.
After the release of the oocyte, the remaining granulosa and theca cells are
converted into lutein cells, forming the corpus luteum (Figure 1) (29). Lutein cells secrete
large amounts of progesterone and a small amount of estrogen. Additionally, they
produce inhibin A, which suppresses the production of FSH and LH. The estrogens
secreted by the luteal cells lead to slight additional proliferation of the endometrial tissue,
whereas the high levels of progesterone lead to swelling and secretory development of
the endometrium. Therefore, this phase is alsocalled the secretory phase as well as the
luteal phase. In the absence of fertilization, the corpus luteum starts involution 8 to 12
days after ovulation, when it becomes the ‘corpus albicans’ (Figure 1). This change leads
to marked decreases in the levels of progesterone and estrogen, which eventually leads to
menstruation. After the involution of the corpus luteum and suppression of FSH, FSH
levels begin to increase again, leading to the start of a new menstrual cycle. Menstruation
occurs at the first day of every cycle through mechanisms that may involve
prostaglandin-mediated vasoconstriction and contractions of the uterine muscle.

Figure 1. Changes in the ovarian cells during the menstrual cycle.
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Theories about Premenstrual Syndrome Etiology:
•

Fluctuation in ovarian hormones
The hypothalamus not only regulates the menstrual cycle but also integrates

multiple activities such as thirst, hunger, temperature control and sexual behavior.
Consequently, there may be a relationship between the menstrual cycle and multiple
aspects of human behavior related to PMS.
PMS was initially thought to be caused by a hormonal imbalance, particularly an
estrogen excess (6) or a deficiency in progesterone secretion from the corpus luteum (7).
However most studies comparing hormonal levels have failed to demonstrate that
absolute levels of estrogen and progesterone are different in women with PMS or PMDD
compared to women without PMS or PMDD (20, 31). More recently it has been
suggested that women with PMS might have a higher vulnerability to rhythmic hormonal
changes during the menstrual cycle (20, 32). However, it is not yet clear which specific
hormonal changes are associated with PMS symptoms; the preovulatory peak in estrogen,
the postovulatory increase in progesterone and the drop in progesterone levels in the late
luteal phase have all been proposed as potential triggers for PMS symptoms. Other
hormones such as melatonin, cortisol, thyroid-stimulating hormone and prolactin have
been studied as potential contributors of symptom occurrence (20, 33). Another hormone
associated with PMS symptoms, particularly mastalgia, is prolactin. Usually under
inhibition of the hypothalamus, prolactin is secreted by the tuberoinfundibular cells in the
anterior pituitary (29). It is suspected that women with PMS have an increased secretion
of prolactin during the luteal phase (11, 34). However, at least one study did not report
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differences in fluctuations of prolactin during the menstrual cycle in women with PMS
compared to controls (35).
It appears that rhythmical changes in specific hormonal levels during the
menstrual cycle cannot alone explain the wide variety of symptoms associated with PMS
(20, 31). Many other factors may be involved in the etiology of PMS, and different
symptoms may have different underlying causal mechanisms.

•

Interaction of hormones with neurotransmitters in the brain:
The psychological symptoms of PMS (i.e., depression, irritability, anxiety)

suggest an interaction of the cyclical hormonal changes with neurotransmitters in the
central nervous system (20). After ovulation, a series of changes in neurotransmitter
functioning are triggered. Ovarian hormones have the capacity to modulate the γaminobutyric acid (GABA) and serotonin neurotransmitter systems (20, 32, 36). Because
they are steroid hormones and therefore lipophilic, they have the ability to diffuse across
the blood-brain-barrier. Therefore, plasma levels of steroid hormones are correlated with
concentrations in brain (37). We will explore in detail the association of estrogen and
progesterone with the neurotransmitters serotonin and GABA.
- Serotonin:
The neurotransmitter serotonin is synthesized by the neurons of the raphe nuclei,
located between the lower pons and the medulla. Its precursor, the amino acid tryptophan,
is hydroxylated into 5-hydroxytryptophan and then decarboxylated into serotonin. These
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reactions require the presence of micronutrients, including magnesium, zinc, and many of
the B vitamins. There are many types of serotonin receptors on the brain, spinal cord and
gut, which lead to a broad range of effects of serotonin, including regulation of body
temperature, sleep, mood, appetite, and pain, as well as to the modulation of the output of
cortisol and prolactin (29).
Estrogen levels have been positively associated with serotoninergic activity
through the regulation of synthesis and degradation of serotonin (38). Animal studies
have suggested that both serotonin and serotonin receptor levels fluctuate during the
estrous cycle (39). Decreased serotonin activity is associated with depression and specific
symptoms such as carbohydrate cravings and sleep disturbances (11).
Some studies (40-42), but not all (43, 44), have suggested women with
premenstrual disorders have lower serotonin (or serotonin metabolites) levels during the
luteal phase as compared to controls. For example, in 1987, Rapkin et al.(42) conducted a
study among 14 women aged 18 to 25 years old with moderate to severe premenstrual
symptoms and 13 age-matched controls without PMS symptoms. Timing of the late
follicular, ovulatory, midluteal, late luteal and premenstrual phases were determined
according to basal body temperature charts, and confirmed by the date of onset of the
next menstrual period. The premenstrual phase was defined as 3 days after the late luteal
phase. Blood samples were collected for every participant at each different phase to
determine whole-blood serotonin levels. Serotonin levels were found to be significantly
lower during the midluteal, late luteal and premenstrual phases among women with PMS
as compared to controls. For example, in the premenstrual phase, mean (±SE) serotonin
levels among cases was 176.5 (±13) ng/mL vs. 298.6 (±43) ng/mL among controls. There
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was no significant difference in serotonin levels during the follicular and ovulatory
phases. Moreover, cases and controls showed similar estradiol and progesterone levels
during all phases.
Dietary intake of tryptophan may affect serotonin levels. To evaluate the
serotonin response to tryptophan load, Rasgon et al. (2000) (45) conducted a clinical trial
among five women with prospectively diagnosed PMS and five controls to evaluate the
serotonin response to an infusion of intravenous L-tryptophan (LTP) over one menstrual
cycle. During the follicular phase, LTP was found to increase serotonin levels equally
among women with and without PMS. However, during the luteal phase, cases
demonstrated a blunted response to LTP infusion while controls did not. Moreover,
women who had PMS had significantly higher baseline cortisol levels during the luteal
phase, as compared to controls. To date, the underlying mechanisms by which Ltryptophan is handled differently in women with and without PMS are unknown.
Overall, this study supports a role of serotonin and its precursor tryptophan in the
pathophysiology of PMS.
- Allopregnanolone and GABA:
GABA is the major inhibitory neurotransmitter in the brain and is secreted by
neurons in the cortex, cerebellum, basal ganglia and the spinal cord. The GABA pathway
provides negative feedback from the caudal nucleus and putamen to the globus pallidus
and substantia nigra (29). GABA exerts its effects by binding to two distinct receptors,
GABA-A and GABA-B, resulting in inhibition of neural activity (46).
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One consistent finding with regards to the pathophysiology of PMS is that
symptom development during the luteal phase generally requires ovulation and the
consequent formation of the corpus luteum. The corpus luteum formed during the luteal
phase secretes a variety of hormones, one of them being allopregnanolone, a neuroactive
metabolite of progesterone that has high affinity for GABA-A receptors in the brain (32,
47). Allopregnanolone can be also be synthesized in the brain de novo from cholesterol
(48).
It has been proposed that high concentrations of allopregnanolone activate
GABA-A receptors resulting in anxiolytic, anesthetic and anticonvulsivant effects, while
low concentrations result in an anxiogenic effect (32, 47, 49). For example, in an animal
study conducted by Lovick et al. (37) among female rats, decreases in allopregnanolone
levels led to a predisposition to increased anxiety and hyperalgesia and increased
expression of the GABA-A receptor in the periaqueductal grey matter.
Women with PMDD may have decreased sensitivity to GABA-A receptor
modulators such as benzodiazepines, alcohol and pregnanolone during the luteal phase,
compared to that during the follicular phase or to controls (50-53). Some studies suggest
that fluctuations of allopregnanolone at physiologic concentration across the reproductive
cycle can be modulated by preferential sensitivity of individual GABA-R subunits (47,
54, 55). This decreased effect of allopregnanolone on GABA-A receptors is probably due
to the expression of a different type of GABA-A receptors that is insensitive to
allopregnanolone elicited by continuous exposure and withdrawal of this neurosteroid
(32, 55, 56).
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Some studies have suggested that women with PMS have lower allopregnanolone
levels in the follicular and luteal phases (57, 58), but others have found no difference (50,
56, 59). In a study by Monteleone et al. (58), blood samples from 28 women aged 18 to
32 years diagnosed with PMS and 28 age-matched controls were collected during the
follicular phase (days 5 – 8) and the luteal phase (days 22 - 26) during three consecutive
menstrual cycles. The authors found that luteal phase allopregnanolone concentrations
were significantly lower in women with PMS as compared to those in their matched
controls (mean ± SE allopregnanolone concentration at the third month =1.54 ± 0.20
nmol/l among cases vs. 3.76 ± 0.09 nmol/l among controls, p < 0.001). Progesterone
concentrations were lower among women with PMS,in both the follicular and the luteal
phases as compared to those in controls ( p < 0.001). There was no statistically significant
difference in estradiol levels among the groups. In contrast, in a study by Epperson et al.
(59), blood samples were collected during the follicular (days 3-8 of the cycle), midluteal (3 to 8 days after LH peak, approx. days 17-22 of the cycle) and late-luteal
phases(1-5 days before onset of menses) from 9 women diagnosed with PMDD and 14
healthy controls. The authors found no difference in allopregnanolone levels in any of
the phases, but observed significantly higher progesterone, pregnenolone and estradiol
levels among cases as compared to controls during the luteal phase (p =0.01 for
progesterone and pregnenolone, p =0.02 for estradiol).
Overall, there is a clear involvement of the GABA system in the pathophysiology
of PMS through its interaction with allopregnanolone. Whether women with PMS have
abnormally lower allopregnanolone levels during the luteal phase or a different
sensitivity of the GABA-A receptors to allopregnanolone is still under continuous study.
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- Other neurotransmitters:
Other neurotransmitters may also be associated with PMS. For example glutamate
is in ‘balance’ with GABA; it has an ‘excitatory effect’(29) and has been associated with
depression (60, 61). N-methyl-d-aspartate (NMDA) receptors bind to glutamate and
NMDA receptor agonists, such as zinc, show effects similar to antidepressants (62-64).
Moreover, estradiol may be associated with an increased sensitivity of the NMDA
receptor to glutamate, thereby leading to excitation of the nervous system (65). Because
depression and PMS may have some common mechanisms, glutamate and the NMDA
receptor should also be considered for the pathophysiology of PMS (49).

•

The renin-angiotensin-aldosterone system
The renin-angiotensin system (RAS) is potentially involved in premenstrual

syndrome. Renin is an enzyme secreted in the kidneys as prorenin. When arterial pressure
is low, prorenin is converted into renin and released into the circulatory system. Renin
acts on angiotensinogen to release angiotensin I and angiotensin II, which lead to
vasoconstriction and increased blood pressure. Renin also causes adrenal glands to
secrete aldosterone, a mineralocorticoid, which increases sodium and water reabsorption
and potassium secretion in the kidney, leading to increased extracellular fluids and blood
pressure. Additionally, high dietary intake of potassium, and to a lesser extent sodium,
increases the levels of aldosterone secretion (29).
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Some studies have found that aldosterone levels are higher during the luteal than
during the follicular phases of normal premenopausal women (66-68). For example,
Szmuilowicz et al.(67) conducted a randomized clinical trial among 60 women aged 25 to
41 years receiving either a high sodium (Na) (200 mEq) or a low Na diet (10 mEq) for 7
days. The authors found that among women with the high Na diet, urinary and serum
aldosterone was significantly greater among those who were in the luteal than in those
who were in the follicular phases, and that progesterone levels were positively correlated
to aldosterone levels. No differences were shown among those with a low Na diet.
Because aldosterone is associated with water and Na retention, a high excretion of
aldosterone during the luteal phase has been postulated as a contributor to symptoms of
PMS such as swelling of extremities and abdominal bloating (31).
Calcium intake and metabolism may also contribute to symptoms associated with
PMS (69). Studies have shown that calcium and calcium-regulating hormones fluctuate
during the menstrual cycle and that follicular and luteal phase calcium levels may be
different in women with PMS as compared to those in asymptomatic women (70, 71).
Additionally, PMS shares some of the same symptoms as hypocalcemia, including
fatigue, depression, anxiety and muscle cramps (69). In 2005, Bertone-Johnson et al. (72)
conducted a nested case-control study among the Nurses’ Health Study II (NHS2) PMS
subgroup to evaluate the association between calcium intake and the development of
PMS. The authors concluded that a higher dietary intake of calcium and vitamin D
(approximately 1200 mg of calcium and 400 IU of vitamin D) was associated with a
lower risk of incident PMS. For example, women in the highest quintile of calcium
intake from food sources (median=1285 mg/d) had 30% lower risk of developing PMS
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(95% confidence interval=0.50-0.97) compared to women in the lowest quintiles (P=0.02
for trend).
Summary of pathophysiology
Multiple mechanisms may be associated to the pathophysiology of PMS, but none
of them appears to completely explain all of the diverse symptoms. Hence, PMS etiology
might involve a combination of all these mechanisms.
The menstrual cycle is complex and involves interactions among different
systems in the body such as the gonadal and adrenal hormones and brain
neurotransmitters. Although differences in sex steroid hormone levels have been
proposed as contributors to PMS, most studies have not found differences in hormonal
levels in women with PMS as compared to those in women without PMS. Some evidence
suggests that women with PMS instead have increased sensitivity to normal cyclical
hormonal changes. While ample data suggests that interactions between neurotransmitters
and ovarian hormones also contribute to symptom recurrence, further research is needed
to better understand these relationships.

1.4 Treatment
Not all women who suffer from PMS seek medical attention for treating their
symptoms. In a study by Robinson and Swindle (18), women who were older, those with
more frequent and severe symptoms and women with greater overall use of medical
services were more likely to seek medical treatment for PMS.
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The competing theories for the definition and on the etiology of PMS have led to
a variety of treatments for relieving PMS symptoms, though in some cases there is little
scientific evidence supporting their use. The placebo effect in PMS is potentially high
(73). Nevertheless, various treatments have been shown to be more effective for some
symptoms than for others (74); therefore, treatment of patients with PMS should be
individualized according to the symptomatology reported (20).
Treatments for PMS recommended by the ACOG include SSRIs, oral
contraceptives and alprazolam (1), but other potential therapies have been also studied.
Currently, only three selective serotonin reuptake inhibitors (SSRIs) are specifically
approved by the U.S. Food and Drug Administration (FDA) for the treatment of PMS:
fluoxetine, sertraline and controlled release paroxetine (75-77). Treatment for PMS
symptoms may be required for many years, as cessation of any treatment may lead to
symptom reappearance. Because PMS is a disorder that lasts until menopause, treatment
options should be evaluated for long-term use, particularly in relation to efficacy, safety,
tolerability and the potential side effects. We review specific treatment options below.

Pharmacologic Treatments
•

Selective serotonin reuptake inhibitors (SSRIs):
As serotonin might be involved in the pathophysiology of PMS, SSRIs have been

studied as treatment options. Many clinical trials have found SSRIs to be effective in the
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treatment of mood symptoms and somatic complaints associated with PMS and PMDD,
as well as to improve quality of life and social functioning (73, 75). Therefore, they are
considered as a first line treatment for PMS patients with severe mood symptoms (1, 20,
76, 78).
One of the most studied SSRIs is fluoxetine (i.e. Prozac), which has shown to be
effective in reducing the frequency and severity of PMS (79-81) and PMDD(28, 90, 91,
93) symptoms in several studies. Using the COPE (Calendar of Premenstrual
Experiences(9)) to identify women with PMS, Ozeren et al.(79) conducted a randomized
clinical trial to evaluate the effects of fluoxetine on PMS symptoms. During 3
consecutive cycles, 18 women received 20 mg of fluoxetine and 17 women received
placebo. The authors found that fluoxetine was significantly better than placebo in
reducing the severity and frequency of physical and behavioral symptoms (p<0.0001).
Although fluoxetine was effective in relieving PMS symptoms, it was associated with
significant side effects. Two women receiving fluoxetine dropped from the study due to
intolerable nausea and skin rash, and five other in the treatment group had mild side
effects (gastrointestinal disturbance, insomnia, sexual dysfunction).
Other SSRIs are potentially effective, for example setraline(82-85) and
paroxetine.(86-89) Halbreich et al. in 2002 conducted a RCT among 281 women with
PMDD to evaluate the efficacy of sertraline restricted to the luteal phase as compared to
placebo. Diagnosis of PMDD was based on prospective ratings for two months and
DSM-IV criteria. The Daily Record of Severity of Problems (DRSP) and the Clinical
Global Impression Severity and Improvement (CGISI) scales were used to evaluate
efficacy of the drug. At the end of study, the authors found a significant reduction on the
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DRSP score in the sertraline group as compared to placebo (mean sertraline DRSP =27.6,
SD =26.8 vs. mean placebo DRSP =17.6, SD =23.3; p <0.002) as well as a significant
improvement of the CGISI score (mean sertraline =2.3, SD =1.1 vs. mean placebo=2.7,
SD =1.1; p <0.001) as compared to placebo. However, 11 women in the active treatment
group dropped from the study due to severe side effects, including:headache, nausea, dry
mouth and decreased libido. These were significantly higher than in the placebo group.
The benefits of SSRIs on PMS are probably beyond their antidepressant effects.
This is supported by the fact that other types of antidepressant drugs are not effective in
relieving PMDD/PMS symptoms (87, 90). The effects of SSRIs are beneficial for
physical symptoms (91) in addition to the psychological symptoms of PMS(28, 75, 92).
Moreover, the benefits of SSRIs on PMS appear in a shorter time as compared to their
effects on depression and other affective disorders (20).
Antidepressants that predominantly affect noradrenergic transmission are not as
effective as SSRIs (87, 90). For example, in a randomized controlled trial conducted by
Pearlstein et al. (1997)(90) among 34 women with PMDD, bupropion, an antidepressant
with no serotonergic effects, showed no significant improvement in symptoms as
compared to placebo. In another trial conducted by Eriksson (1995) (87) among 65
women with severe PMS, an antidepressant that inhibits noradrenaline uptake
(Maprotiline) was compared to paroxetine and to placebo. The authors found that
symptom reduction with paroxetine was significantly higher than maprotiline, and that
maprotiline was no different than placebo.
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Despite their effectiveness in ameliorating PMS symptoms, there are two
substantial limitations associated with long term use of SSRIs: the high cost of the
medications and the likelihood of significant adverse effects. Side effects of SSRIs
include nausea at the beginning of treatment, headaches, insomnia, fatigue,
gastrointestinal disturbances and sexual dysfunction, which persist for the duration of
treatment (1, 75). To reduce the recurrence of these effects, the ACOG recommends that
SSRIs can be taken only during the luteal phase of the cycle (1). This treatment regime
has shown to be as effective as continuous therapy on SSRIs (75, 89, 92, 93). Moreover,
in a recent review by Halbreich (2008), the percentage of PMDD symptom reduction
affected by SSRIs ranges from 53% to 71% in large studies, compared to placebo
response rates from 28% to 49% (73).

•

Ovulation Suppression:
The hormonal changes of ovulation appear directly related to PMS symptoms.

Therefore, ovulation suppression has been targeted as a potential treatment for PMS,
although as with SSRIs, most of these therapies have substantial adverse effects.
Ovulation suppression methods can range from oral contraceptives to surgical
sterilization.
Oral contraceptive pills (OCPs) can prevent ovulation and replace the cyclical
variation in ovarian hormones with stable hormone levels. The use of OCPs is
recommended by the ACOG for treatment of physical symptoms, but in addition, OCPs
have been associated with reduction in psychological symptoms in some studies.(1, 20,
94) A clinical trial by Yonkers et al (2005)(94) was conducted among 450 women with
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symptoms of PMDD randomized to take a new OCP containing drospirenone, an
analogue of spironolactone or to take placebo in a regimen of 24 of 28 days each cycle.
After 3 months of treatment or placebo, women taking the OCP had a significant
improvement of PMDD symptoms as compared to placebo (Total DRSP score was
reduced -37.5 points for drospirenone compared to -30.0 points for placebo, p<0.001) .
Moreover, treatment with OCPs was associated with a 49% of reduction in premenstrual
depression. Side effects associated with drospirenone were nausea, intermenstrual
bleeding and asthenia. However, in some women, OCPs may worsen psychological
symptoms. A nested case-control study was conducted by Joffe et al (2003) (95) among
658 women aged 36 to 45 years taking OCPs to evaluate the predictors of mood change
in OCP users. A questionnaire and a structured psychiatric (Structured Clinical Interview
for Diagnosis) interview were used to collect information on OCP use, mood changes
related to OCPs, and psychiatric and reproductive history. With regard to mood changes
associated with OCP use, 16.3% of participants reported mood deterioration, and 12.3%
reported mood improvement. Among women with a history of depression before start of
use of OCP, 25.4% reported deterioration of mood (OR=2.0, 95%CI: 1.1-3.8). In
contrast, an improvement of premenstrual mood was observed among those participants
who suffered from dysmenorrhea (19.4%, OR=2.3, 95%CI: 1.4-3.9) or who had an earlyonset premenstrual mood disturbance (23%, OR=3.1, 95%CI: 1.9-5.2).
Gonadotropin-releasing hormone (GnRH) agonists lower estrogen and
progesterone levels to those of menopausal women causing a ‘chemical sterilization’ and
have been shown to effectively relieve the symptoms of PMS.(56, 96) However, these
drugs lead to an increased risk of osteoporosis and cardiovascular disease because of the
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lower estrogen levels (20, 96). Studies evaluating addition of estrogen and progesterone
indicate that these may lead to symptom recurrence (56, 96). Because of these important
side effects, in addition to high cost, the ACOG recommends use of GnRH only in severe
cases of PMS that do not respond to other treatments (1).
The most radical method for preventing ovulation is the bilateral salpingooophorectomy. Because it is not reversible, this method should be restricted to severe
cases that strictly meet the diagnostic criteria and who have not responded to other
treatments but have received benefits from GnRH agonists. In fact, GnRH agonists
should be prescribed for at least 3 months prior to surgery in order to confirm the
effectiveness of oophorectomy (1).

•

Other pharmacological treatments
Some studies(97, 98) have found beneficial effects for the treatment of

premenstrual symptoms with alprazolam (Xanax), a benzodiazepine commonly used to
treat anxiety disorders, through its agonist effect on GABA receptors. In 1995,
Freeman(98) conducted a RCT to evaluate the effects of oral progesterone or alprazolam
vs. placebo among 185 women with severe PMS. Daily Symptom Records were
completed by patients to confirm PMS diagnosis during a 3-month screening period and
to evaluate effects during the 3-month treatment phase. Treatment was administered four
times a day during the days 18 to 2 of the next cycle, with an average daily dose of
alprazolam of 1.5 mg. At the end of the treatment phase, 37% of patients receiving
alprazolam reported a 50% reduction in total DSR scores. The alprazolam group had a
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significantly greater improvement of DSR scores as compared to the progesterone and
placebo groups (p=0.04).
However, not all studies have found beneficial effects of alprazolam on
premenstrual symptoms.(99, 100) In 1993, Schimdt et al. (100) conducted a double-blind
crossover trial among 22 women with PMS assessed using prospective recording.
Participants were randomized to receive alprazolam in increasing doses (0.25, 0.50 or
0.75 three times a day for each cycle) or placebo for three cycles. During the treatment
phase, patients completed daily self-report of symptoms ratings; also completed, but at
intervals of 2 months where other psychiatric tests like the Beck Depression Inventory.
At the end of the study, the authors did not find any significant difference between both
groups in the premenstrual symptom ratings. Moreover, the highest dose of alprazolam
was not well tolerated by 10 participants because of its sedative effects.
Although alprazolam is recommended by the ACOG, its use must be limited to
the luteal phase because of the potential for dependency and tolerance of this drug. It is
recommended for those patients who do not improve by other interventions and who
primarily complain of agitation and anxiety.(1)
Spironolactone is an aldosterone receptor antagonist that has antiandrogenic and
potassium-sparing diureticeffects.(101, 102) In 1995, Wang et al.(102) conducted a
cross-sectional study of 35 women aged 25 to 45 years with ‘late luteal phase dysphoric
disorder’ according to the DSM-III-R.(14) Participants received 100 mg spironolactone
(n=17) or placebo (n=16) on days 14-28 of the cycle for 3 cycles, and then crossed over
the other group for another 3 cycles. Over the entire study period, participants rated daily
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psychological and somatical symptoms and their effects using a visual analogue scale. .At
the end of the first 3 cycles, women who started with spironolactone had a significant
decrease in all symptoms (p<0.001) as compared to women who started with placebo,
and those did not worsen after cross-over to placebo. Women who started with placebo
had a significant decrease in negative mood and somatic symptoms (p<0.001) after the
crossover to spironolactone. Overall, side effects associated with spironolactone use
include breast complaints and hyperkalemia.(101)

Non-Pharmacologic Treatments
•

Psychological therapy
Supportive therapies have been recommended by the ACOG as a primary

treatment for women with mild to moderate symptoms, and as adjunctive treatment for
those with more severe symptoms (1, 78). However, the studies in this area have been
limited, and there is no conclusive evidence of the effects of psychotherapy.
Cognitive and behavioral therapy (CBT) involves a group of client-centered,
collaborative, structured and relatively brief psychotherapy techniques applied to modify
thoughts, emotions and behaviors that might be problematic.(103) Its efficacy in PMS
and PMDD is based on the theory that women may be valorizing physical premenstrual
changes (i.e., bloating, breast changes) in ways that exacerbate emotional reactions to
them (i.e., anxiety) (103, 104) .
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In a study by Hunter et al. (105), CBT was compared to fluoxetine in a
randomized trial among 108 women with PMDD confirmed by prospective recording
over 2 months, and fulfilling the DSM-IV criteria (12). Over 6 months, women were
randomized into 3 groups: CBT (10 sessions), fluoxetine (20 mg daily) and combined
therapy (CBT plus fluoxetine). The authors found that fluoxetine was associated with a
more rapid decrease on premenstrual scores, but CBT was associated with a better
maintenance of treatment effects. There was no additional benefit from combining both
treatments (105) .
Busse et al. (104) conducted a meta-analysis of 9 randomized clinical trials that
evaluated the effects psychological interventions on PMS. Although the evidence was
considered low quality due to problems in design and implementation of the studies, it
was concluded that CBT consistently reduced the symptoms of anxiety (effect size=-0.58,
95%CI:-1.15 to -0.01) and depression (effect size=-0.55, 95%CI: -1.15 to -0.01)
associated with PMS (104).
In 1990, Goodale et al.(106) conducted a randomized clinical trial of 46 women
with PMS to evaluate the effects of relaxation on their symptoms. The relaxation
response was elicited while sitting with closed eyes concentrating on a repetitive mental
activity for 15 to 20 minutes twice each day during 3 months. One control group was
instructed to spend 15 to 20 minutes daily reading leisure material and the other control
group only charted their symptoms daily, as the rest of the participants did. After 3
months, the intervention group had a significantly higher reduction in PMS symptoms, in
particular those with severe PMS, as compared to the other 2 groups (106).
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In summary, psychological therapies including CBT and relaxation may be
helpful in treating premenstrual symptoms. Their main advantage is that there are no
drug-related side effects and the potential that their beneficial effects are long-term.
Further studies are needed to compare the effectiveness of different psychological
therapies (CBT vs. relaxation alone) and to evaluate their effects on specific symptoms of
PMS.
•

Dietary supplements and herbal therapy
The overall use of herbal treatments and dietary supplements consumption has

increased over the past decade (107, 108). Approximately 16% of U.S. women who
responded to the 2000 National Health Interview Survey Cancer Supplement reported
having taken at least one herbal supplement in 1999 (109). The popularity of dietary
supplements is largely due to the belief that they are associated with less frequent side
effects as compared to pharmacologic treatments (107, 110). Among the most frequently
studied dietary supplements used to treat PMS are calcium, magnesium, and vitamin B 6.
Evening Primrose oil, vitex agnus castus and dong quai are among the most frequently
studied herbal products used for PMS treatment.
Dietary calcium has been suggested to be involved in the etiology of premenstrual
syndrome (111). Several randomized clinical trials have studied the use of calcium
carbonate as a treatment for PMS and have found a significant benefit in reducing PMS
symptoms,(111-114). In 1998, Thys-Jacobs et al.(112) conducted a randomized clinical
trial among 466 women aged 18 to 45 years of age who were diagnosed with PMS by
prospective charting. During 3 menstrual cycles, participants received 1200 mg of
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calcium or placebo on a daily basis (divided in 600 mg twice a day). After the 3rd cycle,
women receiving calcium had an overall 48% reduction of a 17-parameter symptom
complex score, compared to a 30% reduction among those who received placebo. It is
noteworthy that two subjects of this study developed renal stones as an adverse effect,
although the dose of the supplement was only moderately higher than the estimated
adequate intake for that age group (1000 mg/day) and bellow the tolerable upper intake
limit (2500 mg/day) (112).
Several studies have suggested that vitamin B6 might improve premenstrual
depressive symptoms, but most of the studies have had potential methodological bias
(115, 116). This and other B vitamins suggested as treatments for PMS will be discussed
in the next chapters.
A North American wildflower called evening primrose was used therapeutically
among Native Americans (117). Evening primrose oil (EPO) has been widely
recommended as a treatment for PMS symptoms (118), particularly for mastalgia (117,
119). The potential mechanisms by which EPO can potentially help in the treatment of
PMS is through effects on plasma fatty acids levels. The oil of the seeds contains high
levels of linoleic (65%) and gamma-linolenic (8%) acids, which are precursors of
prostaglandin E. It has been hypothesized that women with PMS have an underlying
deficiency in linoleic and gamma-linolenic acid, thereby leading to a decreased
availability of prostaglandin E, which may lead to decreased prolactin levels (119-121).
Nevertheless, most clinical trials have not found an improvement in PMS
symptoms with primrose oil as compared to placebo (122, 123). Moreover, according to a
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review by Budeiri, most studies lacked sufficient power to identify a moderate effect
(118). In 1990 Khoo et al. (122) conducted a randomized placebo controlled crossover
study to evaluate the effects of EPO on 38 women aged 20 to 40 years, with PMS defined
as at least one symptom of fluid retention or breast discomfort, and two symptoms of
mood changes. After six cycles of treatment (8 capsules per day, containing 45 mg of
gamma linolenic acid per capsule) or placebo, the authors found that both EPO and
placebo reduced a PMS score of symptoms, but with no significant difference between
treatment and placebo(122) Side effects associated with EPO are few, and include
nausea, softening of the stools and headache (120). Although its effectiveness in reducing
PMS symptoms is controversial, it has been commonly marketed for treatment of PMS
(107).
Another herbal product used for treating PMS symptoms, particularly mastalgia,
is vitex agnus castus (VAC) (117, 125). This dried ripe fruit of the chaste tree contains
essential oils, iridoids, and flavonoids as potentially active constituents (117, 125).
Progesterone, hydroxyprogesterone, testosterone, and androstenedione have been also
isolated from the flower and leaves of the chaste tree, but in very small amounts (117).
VAC may improve the symptoms of mastalgia by decreasing prolactin secretion through
its dopaminergic effects (11, 34). Moreover, it has been suggested that the flavonoids
present in VAC (particularly apigenin) have selective estrogen receptor activity (34, 124).
Benefits of VAC in treating PMS symptoms have been observed in some trials
but not in all (107, 110, 117). In a study by Berger (126) 43 women with PMS diagnosis
based on DSM-III criteria received 20 mg of VAC over 3 cycles. Patients self-reported
symptoms using a MMDQ (1968) completed at baseline at the end of the 3 cycles of
34

treatment and 3 cycles after treatment stopped. The authors found that after 3 months of
treatment there was an overall 42.5% reduction of MMDQ scores (p<0.001) compared to
baseline. Three months after treatment, reduction of the symptom was 20% compared to
baseline. There was no apparent effect on serum prolactin levels, which did not differ
between baseline and treatment.(126) VAC extract has been approved by the ‘German
Commission E’, an analogue of the U.S. Food and Drug Administration, for the treatment
of PMS symptoms, indicating that they considered that there was a reasonable proof of
efficacy and safety (125). Side effects are rare and include upset stomach, headache,
menstrual disorders, acne, and rash (107).
In summary, although there has been increased interest in herbal therapies and
dietary supplements for relieving PMS symptoms, scientific research is limited and
results are inconsistent. Additional research on each agent is needed, using large well
designed placebo-controlled trials.
•

Complementary and alternative therapies (CAM)
Many women who do not find relief from PMS symptoms with conventional

medicine, or because of the side effects of conventional medicine have opted for other
alternatives of treatment, among them CAM.(110)
Acupuncture and moxibustion are examples of CAM used to treat symptoms of
PMS.(127) Hand acupuncture therapy (HAT) is believed to relieve pain by stimulation of
the autonomic nervous system and to alleviate excess heat though cold stimulation. Hand
moxibustion therapy (HMT) acts by heating points of the hand, which in theory
stimulates the nervous system and releases chemicals that can alleviate pain or regulate
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internal systems of the body. In a recent study(127) of 22 Korean nurses aged 20 to 35
years old, women receiving 10 sessions of HAT and HMT for 4 weeks reported
significantly less abdominal pain, bloating and mood changes than those receiving no
treatment. Patients in the HAT group also reported a significant reduction of hot flashes,
and women in the HMT group reported less water retention symptoms and less anxiety
and depression, as compared to controls.(127)

Summary of treatment
Women with severe symptoms are advised to take SSRIs or to opt for ovulation
suppression.(1) However, treatments proposed are only for relieving symptoms, and may
require long term use. Side effects should be particularly considered and weighed with
respect to the other potential benefits and the severity of the disease. A variety of
treatment options exist for women with moderate to mild PMS, including behavioral
therapy or dietary supplements.

1.5 Conclusion
Despite decades of research, PMS remains an understudied condition that affects
millions of reproductive aged women. Questions remain concerning prevalence, etiology
and diagnostic criteria. Continued research in this area is of primary importance.
Moreover, the identification of modifiable risk factors and a clearer understanding of the
pathophysiology would lead to significant advances in this area, including improved
options for primary prevention as well as treatment.
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CHAPTER 2
DIETARY B VITAMIN INTAKE AND PREMENSTRUAL SYNDROME

2.1 Background

2.1.1 Introduction
Premenstrual syndrome (PMS) is characterized by the presence of physical and
psychological symptoms that appear only during the luteal phase of the menstrual cycle
and that lead to a substantial impairment and reduced quality of life. In the U.S., PMS
affects 8 to 15% of women of reproductive age (1). The economic burden associated with
PMS is high and includes not only direct medical costs but also indirect costs due to work
absenteeism and lack of productivity (2-4). Currently prescribed treatments include
antidepressants and hormones that suppress ovulation (e.g., oral contraceptives and
gonadotropin releasing hormone agonists), which involve significant side effects (5-7).
Despite several decades of research, the pathophysiology of PMS is still controversial,
and effective treatments with fewer adverse effects are still under study. Therefore, it is
of particular importance to identify modifiable risk factors such as aspects of diet that
may prevent the onset of this disorder.
The proposed theories for the pathophysiology of PMS include an interaction of
ovarian hormones with neurotransmitters such as serotonin and gamma-amino butyric
acid (GABA) and other endocrine systems (8-10). The B vitamins, in particular thiamin,
riboflavin, niacin, vitamin B6, folate, and vitamin B12, are potentially involved in the
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metabolic pathways of the neurotransmitters GABA and serotonin (11, 12). Therefore,
they may play a role in the development of PMS.
To date, some studies (13-19) have focused on vitamin supplements as potential
treatments for PMS, but few have evaluated the effects of diet on the initial development
of the disorder (20). Among the B vitamin supplements, only B6 supplements have been
individually studied as potential treatments for PMS (13-15, 17, 18). However dietary
supplements of folate and vitamin B12 have been studied as potential treatments for
major depression (21, 22), conditions with pathophysiology potentially similar to PMS
(8, 23, 24). Niacin supplements have been studied as potential treatment for
dysmenorrhea (25), a disorder characterized by cramping during menstruation (26). The
individual effects of dietary thiamin, niacin, folate and vitamin B12 on the development
of PMS remain unstudied.
This study examines the association between thiamin, riboflavin, niacin, vitamin
B6, folate and vitamin B12 and incidence of PMS among a subset of women participating
in the Nurses’ Health Study II.

2.1.2 Physiologic Mechanisms
Several potential mechanisms have been proposed to explain the pathophysiology
of PMS, including fluctuations of neurotransmitter levels in the brain in response to
cyclic changes in ovarian hormones, to which women with PMS may be sensitive (8, 9,
27). The B vitamins thiamin, riboflavin, niacin, vitamin B6, folate, and vitamin B12 are

49

involved directly or indirectly in the metabolism of the neurotransmitters serotonin and
GABA and may also be involved in the development of PMS (12).

a) Role of serotonin and GABA in PMS:
- Serotonin:
There is substantial evidence for a role of serotonin in PMS. Serotonin is involved
in the regulation of mood, appetite, sleep and other functions (28). Abnormal serotonin
metabolism has been associated with premenstrual symptoms of depression, irritability
and aggression (29, 30). Additionally, ovarian sex hormones have been proposed to have
a role in the metabolism and activity of serotonin and serotonin receptors (23, 29).
Moreover, during the late luteal phase, women with PMS may have lower serotonin
levels (30) and may be less responsive to infusion of tryptophan (31), a precursor of
serotonin (32), as compared to women without the disorder. Most importantly, selective
serotonin reuptake inhibitors (SSRIs) have been found to be effective treatments for PMS
symptoms in most studies (5, 33-37).
Serotonin is synthesized from the amino acid tryptophan, which is hydroxylated
into 5-hydroxytryptophan and then decarboxylated into serotonin. These reactions require
folate, vitamin B12 and vitamin B6 (12). There are many types of serotonin receptors in
the brain, spinal cord and gut, which are responsible for a broad range of effects of
serotonin, including regulation of body temperature, sleep, mood, appetite and pain as
well as the modulation of cortisol and prolactin (28). Estrogen has been associated with
an increase in serotoninergic activity by regulating the synthesis and degradation of
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serotonin (38). Animal studies have suggested that serotonin and serotonin receptor levels
fluctuate during the estrous cycle (39).
Some studies in humans (30, 40, 41), but not all (42, 43), have suggested women
with premenstrual disorders have lower levels of serotonin or serotonin metabolites
during the luteal phase as compared to controls. Rapkin et al. found significant
differences between whole blood serotonin levels during the luteal phase in PMS cases as
compared to controls (30). The authors recruited 14 women aged 18 to 25 years old with
moderate to severe premenstrual symptoms and 13 age-matched controls without PMS
symptoms. Blood samples were collected during the late follicular phase, ovulatory
phase, midluteal phase, late luteal phase and “premenstrual phase” (three days after the
previous sample), according to basal body temperature charts, and confirmed by the date
of onset of the next menstrual period. At the end of the study, the authors found that
whole-blood serotonin levels were significantly lower during the midluteal, late luteal
and premenstrual phases among women with PMS as compared to controls. For example,
in the premenstrual phase, mean (±SE) serotonin levels among cases was 176.5 (±13)
ng/mL vs. 298.6 (±43) ng/mL among controls. In contrast, during the follicular and
ovulatory phases, there was no significant difference between serotonin levels. Moreover,
cases and controls showed similar serum estradiol and progesterone levels during all
phases (30).
To evaluate whether serotonin response to intravenous L- tryptophan (LTP)
infusion was different between women with PMS and women without PMS, Rasgon et al.
(2000)(31) conducted a clinical study among 5 women with PMS diagnosed by
prospective symptom charting and 5 controls without PMS. The authors found that
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during the follicular phase, LTP infusion increased serotonin levels equally among
women with and without PMS. However, during the luteal phase, increases in serotonin
levels were similar to those of the follicular phase only in controls but significantly lower
in cases. To date, the underlying mechanisms by which L-tryptophan may be metabolized
differently in women with and without PMS are unknown (31).
An additional piece of evidence supporting a role of serotonin in PMS is the
association of selective serotonin reuptake inhibitors (SSRIs) with reduced symptom
severity in PMS and PMDD (1, 5, 33, 34, 36, 37, 44). For example, in 2002 Halbreich et
al.(37) conducted a randomized clinical trial among 281 women with PMDD to evaluate
the efficacy of sertraline restricted to the luteal phase as compared to placebo. Diagnosis
of PMDD was based on prospective ratings for two months and DSM-IV criteria. The
Daily Record of Severity of Problems (DRSP) and the Clinical Global Impression
Severity and Improvement (CGISI) scales were used to evaluate the efficacy of the drug.
At the end of study, the authors found a significant reduction in the DRSP score in the
sertraline group as compared to placebo (mean sertraline DRSP score=27.6 (26.8) vs.
mean placebo DRSP score=17.6 (23.3); p<0.002) as well as a significant improvement in
CGISI score (mean sertraline CGISI score=2.3 (1.1) vs. mean placebo CGISI
score=2.7(1.1); p<0.001) on mood symptoms. It is noteworthy that SSRIs may not only
be beneficial in treating mood symptoms, but also for physical symptoms of PMS.(33)
The beneficial effects of SSRIs appear in a shorter time for PMS than for other disorders
such as depression.(27) However, there are significant adverse effects associated with
SSRIs including nausea, headaches, insomnia, and sexual dysfunction,(5-7) which may
limit their use and efficacy.
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- GABA:
Another neurotransmitter system potentially involved in the pathophysiology of
PMS is gamma-amino-butyric acid (GABA). GABA is the major inhibitory
neurotransmitter in the brain and is secreted by neurons in the cortex, cerebellum, basal
ganglia and the spinal cord. GABA is synthesized by the decarboxylation of glutamate, a
reaction catalyzed by the enzyme glutamate decarboxylase and dependent on pyridoxal5’-phosphate (PLP; Figure 2.1) (28). In the mitochondria, the thiamin dependent 2oxoglutarate dehydrogenase complex (OGDHC) is a group of enzymes required for the
synthesis and degradation of glutamate and GABA during de novo synthesis of glutamate
from glucose. It includes the pyruvate dehydrogenase and the α-ketoglutarate
dehydrogenase, which converts α-ketoglutarate (also known as 2-oxoglutarate) into
glutamate (Figure 2.1) (45).
Figure 2.1 Synthesis of GABA from glucose.
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Dysfunction of the GABA system has been associated with mood disorders, such
as depression and mania (24). Some studies (46, 47) have found GABA levels in plasma
and in cortical neurons to be lower among women with PMDD compared to women
without PMDD. For example in 2002, Epperson et al.(46) conducted a study among 9
women aged 26 to 39 years old diagnosed with PMDD, based on the DSM-IV criteria,
and 14 women aged 21 to 45 years old without PMDD. Brain GABA concentrations
across the menstrual cycle were measured using serial proton magnetic resonance
spectroscopy. Additionally, on each scan day, blood samples were collected for
measuring gonadal hormones and neurosteroid levels. Compared to controls, women with
PMDD had reduced cortical GABA levels during the follicular phase (mean GABA
levels 0.78 mmol/kg among cases vs. 1.67 mmol/kg among controls, p < 0.001), but there
was no statistically significant difference during the mid luteal phase (1.27 mmol/kg
among cases vs. 1.15 mmol/kg among controls, p = 0.7) or the late luteal phase (1.27
mmol/kg among cases vs. 1.12 mmol/kg among controls, p = 0.4). The authors found
that cortical GABA levels declined across the menstrual cycle in healthy women, but for
women with PMDD there was an increase in cortical GABA levels from the follicular
phase to the mid luteal and late luteal phases. Additionally, progesterone, pregnenolone,
and estradiol levels were significantly higher among cases as compared to controls during
the luteal phase only (p = 0.01 for progesterone and pregnenolone, p = 0.02 for
estradiol). In the analyses of covariance, the authors found that estradiol, progesterone
and allopregnanolone were negatively correlated with GABA levels among healthy
women, but that there was a positive correlation of estradiol and progesterone with
GABA levels among women with PMDD. Therefore, this study contributes to the
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hypothesis that GABA concentrations in the brain fluctuate across the menstrual cycle,
and that GABA fluctuations may be different among women with PMDD than in women
without PMDD.
It has been proposed that women with PMS may have a lower sensitivity to
GABA (8, 9, 48). In 1998, Sundström et al.(48) conducted a study among 12 women
diagnosed with PMS and 12 controls aged 25 to 45 years, to measure the saccadic eye
velocity (SEV), a quantifiable and sensitive measure of central nervous system
depression and GABA-A receptor sensitivity, in response to intravenous pregnanolone. A
saccade is a rapid movement of the eye from one fixation point to another, which is
generated in brain regions rich in GABA-A receptors, like the substantia nigra. SEV has
been shown to be decreased linearly in response to benzodiazepines, which are GABA-A
positive modulators (49). At baseline, women with PMS had a lower SEV than controls
during the follicular phase, but not during the luteal phase. After pregnanolone injections
in the follicular and luteal phase, controls had a dose-dependent decrease in SEV.
Women with PMS had a dose-dependent decrease in SEV during the follicular phase but
not during the luteal phase. The authors concluded that the GABA response to
pregnanolone was reduced during the luteal phase of women with PMS as compared to
controls (48).
Despite growing evidence for a role of GABA in PMS, the effectiveness of
alprazolam, a GABA agonist, for the amelioration of PMS symptoms is still inconclusive.
Some studies (50, 51), but not all (52, 53), have found improvement in of premenstrual
symptoms after treatment with alprazolam. For example, Freeman et al.(50) evaluated the
effects of three months of oral progesterone or alprazolam vs. placebo among 185 women
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with severe PMS. Daily symptom records (DSR) were completed by patients to confirm
PMS diagnosis. Treatment was administered during menstrual cycle day 18 to day 2 of
the next cycle, four times a day, with an average daily dose of alprazolam 1.5 mg. At the
end of the treatment phase, 37% of patients receiving alprazolam reported an average
50% reduction in total DSR scores. The alprazolam group had a significantly greater
reduction of DSR scores as compared to the progesterone and the placebo groups (p =
0.04). In contrast, in a crossover study by Schmidt et al.(52) among 22 women with PMS,
participants were randomized to receive alprazolam in increasing doses (0.25, 0.50 or
0.75 three times a day) or placebo for three cycles. At the end of the study, the authors
did not find any significant difference between groups in premenstrual symptom ratings.
Moreover, the highest dose of alprazolam was not well tolerated by 10 participants
because of its sedative effects.

b) Role of B vitamins in neurotransmitter metabolism:
Thiamin (vitamin B1, recommended dietary allowance (RDA) for adults = 1.0 to
1.2 mg/day) (54) is necessary for the metabolism of glucose, and indirectly related with
the metabolism of GABA (Figure 2.1) (12). Thiamin deficiency may lead to symptoms
such as irritability, introversion, depression and cramps (11, 55). all of which are also
symptoms of PMS. Moreover, improvement of thiamin status has been associated with
improved mood and energy levels (55).
Niacin (RDA for adults = 14 - 16 mg/day)(56) is converted to nicotinamide
adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP),
which are required for many physiological reactions. In the presence of niacin deficiency,
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tryptophan is converted into niacin (Figure 2.2) in the liver by the kynurenine metabolic
pathway, thereby leading to tryptophan depletion and decreasing its metabolism to
serotonin (12, 42).
Vitamin B6 (RDA for adults = 1.3 mg/day)(56) is involved in one-carbon
metabolism and has been widely studied for a potential role in depression through its
effect on the metabolism of serotonin and other neurotransmitters (11, 56). Riboflavin
(vitamin B2, RDA for adults = 2–2.5 mg/day)(56) is the precursor of flavin-adenin
dinucleotide (FAD), which is essential for many biochemical reactions, particularly
conversion of pyridoxine (vitamin B6) into its active form: pyridoxal-5’-phosphate
(PLP). PLP is a coenzyme in the decarboxylation reactions involved in the synthesis of
serotonin (Figure 2.2), dopamine, norepinephrine, and GABA (Figure 2.1).
Lower levels of folate (RDA for adults = 400 µg/day) and vitamin B12 (RDA for
adults=2.4 µg/day)(56) have been associated with depression or with lack of response to
SSRI treatment in depression (21, 57), and may also be associated PMS. There are two
potential mechanisms recognized for the association of folate and B12 with depression.
First, folate and vitamin B12 are required for the conversion of dietary methionine
into S-adenosine-methionine (SAMe), the major methyl donor in the body (12). Among
the methylation processes in which SAMe is required are the conversion of serotonin to
melatonin (Figure 2) and of dopamine to norepinephrine.(22) The product of methylation
reactions is S-adenosylhomocysteine (SAH), a methylation inhibitor, that is later
converted into homocysteine. Homocysteine is an amino acid not present in diet that can
be metabolized either by transulfuration to cysteine, for which it requires vitamin B6, or
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by remethylation to methionine, for which vitamin B12 and folate are required (57, 58).
Homocysteine may indirectly (through SAH) inhibit monoamine neurotransmitter
metabolism (58). As described above, these pathways may be involved in the
development of PMS.
Secondly, folate and vitamin B12 are also required for the formation of
tetrahydrobiopterin (BH4). BH4 is a cofactor in the conversion of phenylalanine to
tyrosine and in the hydroxylation of tyrosine, the rate-limiting step for synthesis of
dopamine and norepinephrine. BH4 is also a cofactor of tryptophan hydroxylase, which is
the rate-limiting enzyme for the conversion of tryptophan into serotonin (Figure 2.2) (12,
58) and therefore potentially associated with the pathophysiology of PMS.

c) Summary
The pathophysiology of PMS is not well understood, but interactions between
ovarian hormones and neurotransmitters are likely to play a role in the etiology of the
disorder. B vitamins are involved directly or indirectly in the metabolic pathways
required for proper function of endocrine systems and neurotransmitter pathways.
Riboflavin, B6, folate and B12 are involved in many metabolic reactions of the synthesis
of serotonin. Thiamin, folate and B12 are additionally involved in the synthesis of
GABA. Niacin deficiency may lead to depletion of levels of tryptophan, the amino acid
required for the synthesis of serotonin. Although the mechanisms by which thiamin,
riboflavin, niacin, folate, vitamins B6 and B12 are not fully understood, there is
substantial evidence for a role of B vitamins in the pathophysiology of PMS.
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Figure 2.2 Role of B vitamins in the synthesis of serotonin and melatonin.

2.1.2 Epidemiologic Evidence
There are no previous studies of the effects of thiamin, niacin, riboflavin, vitamin
B6, folate and vitamin B12 and the incidence of PMS. Since the 1980’s the use of
vitamin B6 as a treatment for PMS has been widespread and there have been many
studies of vitamin B6 supplementation to reduce symptoms of PMS. Some studies (13,
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14, 17, 59, 60), but not all (15, 61-63), have found vitamin B6 to reduce the occurrence
and severity of symptoms.
With regards of the other vitamins of the B complex, because studies have been
restricted to randomized clinical trials of supplements that contained a wide variety of
micronutrients (64-67) it is not possible to isolate the individual effect of each vitamin on
PMS. Thiamin (25) has been studied as a potential treatment for primary dysmenorrhea, a
disorder characterized by cramping during menstruation, with results showing beneficial
effects. More recent studies have focused on the association of folate and vitamin B-12
levels with depression with inconsistent results (68-70).

a) Randomized clinical trials of vitamin B6 and prevalent PMS:
The most recent studies of vitamin B-6 supplementation as a treatment for PMS
have been conducted by Kashanian et al.(2007) (13) and Sharma et al.(2007) (14). In the
randomized clinical trial by Kashanian et al.(13) the authors recruited 94 college students
who reported at least one behavioral and one somatic symptom from a list of 17
symptoms for three consecutive cycles prior to randomization. A daily dose of 80 mg of
pyridoxine (46 women) was compared with placebo (48 women) for a period of two
consecutive menstrual cycles. Participants continued recording their symptoms during the
treatment period. At the end of the second cycle, there were statistically significant lower
PMS symptom scores in both the placebo (p < 0.05) and the pyridoxine group (p < 0.05)
as compared to baseline for both somatic and psychological symptoms. The pyridoxine
group reported a significantly greater reduction of overall and psychological symptoms (p
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< 0.05) than the placebo group but there was no significant difference in somatic
symptoms (13).
Sharma et al. (2007) (14) conducted a randomized clinical trial among 60 women
aged 20 to 45 to evaluate the effects of vitamin B6 or bromocriptine, a dopamine agonist
and prolactin blocker, on prevalent PMS for two to three menstrual cycles. During this
period, women reported symptoms of PMS occurrence and severity, following the
methodology proposed by Steiner et al. (2003). (71) Briefly, the severity of each
physical, psychological, and behavioral symptom was graded from 0 (no symptoms) to 3
(severe/disabling symptoms). Possible total scores ranged from 0 to 60, and women were
classified as having PMS if their total score was higher than 5. Over three months,
participants received one of three treatments: 100 mg/day of ferrous sulphate as placebo,
1.25 mg/day of bromocriptine, or 100 mg/day of vitamin B6. The authors found a
statistically significant reduction in symptoms after one, two, and three months of
treatment with bromocriptine, as well as after two to three months of treatment with
vitamin B6. A higher proportion of women receiving vitamin B6 reported symptom
improvement by the third month than in the bromocriptine group (14).
Although both studies found positive results with supplementation of pyridoxine,
no study has evaluated the potential of vitamin B6 to prevent the development of PMS.
Despite evidence of efficacy of B6 supplementation to treat or prevent PMS, there are
substantial limitations. The doses used in both studies were 80 mg/day (13) and 100
mg/day (14) of pyridoxine, substantially greater than the average dietary intake of
vitamin B-6 recommended for adult women of 1.3 mg/day for adult women (54). Doses
of B6 above the upper intake limit (UL) of 100 mg/day (54) have been associated with
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substantial side effects like sensory neuropathy (72). In fact, in the study by Sharma et
al., two women in the B6 group reported nausea, one reported diarrhea, and another
reported dizziness as a side effect (14). Therefore, because of potential side effects, high
doses of B6 supplementation may not be appropriate for the prevention of PMS.
To evaluate the side effects of B6 supplementation, in 1985 Dalton et al.(73)
conducted a study among 58 women (mean age 42 years) of whom 27 reported taking
vitamin B6 supplements (50 to 300 mg/day) for treatment of premenstrual syndrome. At
baseline, 23 participants taking B6 had serum levels above normal levels (range 3 to 18
ng/ml). The author found that more than 40% of all women reported depression,
headache, tiredness, irritability and bloating, but the prevalence of symptoms was even
higher among B6 users. For example, headache was reported by 48% of all women and
70% of vitamin B6 users (no statistical test reported). Then, women who took B6 were
recommended to stop taking vitamin, mineral and herbal supplements for two months.
After this time, participants reported a significant improvement in all symptoms (p <
0.02). Nevertheless, this study had substantial limitations, including the lack of controls
without PMS and lack of assessment of symptoms before B6 supplementation.
Overall, there is substantial evidence that vitamin B6 may affect PMS symptoms,
but to date no studies have evaluated whether dietary intake of vitamin B6 is involved in
the development of PMS.

b) Other B-vitamins and PMS:
Several studies have evaluated supplements that contain a variety of
micronutrients, including B vitamins, as treatment of premenstrual syndrome. Most of
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these studies have used supplements that were created specifically as over-the-counter
treatments for PMS, including SillixDonna (67) and Optivite (64, 65).
In Italy, Facchinetti et al. (1997) (67) conducted a randomized clinical trial to
evaluate the effects of a daily supplement containing 1.5 mg of vitamin B6, 200 μg of
folate, 12 mg of vitamin E, 400 mg of magnesium, 4 mg of copper, and 1g of S.
cerevisiae on premenstrual symptoms. The authors recruited 40 women aged 18 to 50
years old (mean 28 years) classified as having mild to moderate premenstrual syndrome
as assessed with prospective administration of the Moos Menstrual Distress
Questionnaire (MDQ) (76) during two consecutive menstrual cycles. Participants were
randomized to one of two groups, with 20 of them receiving the supplement and 20
receiving placebo over six menstrual cycles. Difference in MDQ scores between the
follicular and luteal phase were assessed for both groups at the end of the 2nd, 4th and 6th
months. The mean MDQ baseline difference between the follicular and luteal phase was
29.95 in the active group and 29.20 in the placebo group. In the active treatment group,
MDQ score differences (MDQ follicular – MDQ luteal) were consistently lower over
time (p<0.01), and lower than in the placebo group (p < 0.02) indicating lower
premenstrual symptom severity. At the end of 6 months, women in the supplement group
reported a mean MDQ difference of 5.55 (SD=7.71), which was substantially lower than
their MDQ scores at baseline and the MDQ of women in the placebo group (MDQ
difference 18.13, SD = 13.41). Although the authors found a significant reduction of
PMS symptoms with supplementation, the impact of individual micronutrients in relation
to alleviation of PMS cannot be determined. A limitation of the study that may have
attenuated the effect was is the low compliance with the study proposal, as 5 participants
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in the control group discontinued participation in the study at the end to the 2nd and 3rd
month due to lack of improvement of symptoms (67).
Another randomized clinical trial was conducted by London et al. (1991) (64) to
evaluate the effects of supplementation with 25 mg of thiamin, 25 mg of riboflavin, 25
mg of niacinamide, 300 mg of vitamin B6, 200 μg of folate and 62.5 μg of vitamin B12
among other micronutrients per dose (6 tablets). Participants were 44 women aged 18 to
44 years old classified as having premenstrual tension (PMT) according to a modified
version of the menstrual symptom questionnaire (MSQ) developed by Abraham et al.(75)
On the MSQ, women were asked to grade their symptoms using a four point scale (from
0=none to 3=severe/disabling), with symptoms grouped into four categories: PMT-A
(anxiety, irritability, mood swings), PMT-H (weight gain, breast tenderness, swelling and
bloating), PMT-C (cravings, fatigue, headaches) and PMT-D (depression, insomnia,
forgetfulness). To be classified as having PMT and be eligible for the study, women had
to have rated their luteal phase symptoms in at least one subgroup as moderate or severe
and to have rated all symptoms as mild or absent during the follicular phase. All
participants were randomly divided into four groups: 1) 6 supplement tablets per day
(n=15 women); 2) 12 supplement tablets per day (n=13 women); 3) 6 placebo tablets per
day containing 25 mg of riboflavin total or 4) 12 placebo tablets per day. The two
placebo groups were combined for analysis (n=15 women). Riboflavin was chosen as a
placebo as a blinding strategy to patients because it produces noticeable yellow coloration
of urine. After three months, the authors compared the MDQ scores during the luteal
phase before and after treatment. Among women receiving 12 tablets/day of the
supplement, they found a statistically significant decrease in MSQ symptoms scores for
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all symptom subgroups as compared to baseline(p < 0.003). Women receiving 6
tablets/day experienced statistically significant improvement of PMT-A (p < 0.013),
PMT-C (p < 0.009) and PMT-D (p < 0.005) symptoms but non-significant improvement
for PMT-H (p=0.28) symptoms. Interestingly, the placebo group had also a statistically
significant improvement in PMT-A (p < 0.017) and PMT-C (p < 0.022) symptoms.
Limitations of this study include the lack of a control group with no riboflavin
supplements. The decreased MSQ scores seen in the placebo group could potentially be
attributed to riboflavin, though there was no way to ascertain this. Additionally, the doses
of vitamin B6 were substantially higher than the upper limit set for this vitamin (100
mg/d) though only one participant reported tingling in the fingers, a side effect of B6
overdose.
Although in both studies the authors observed significant reduction in PMS
symptoms after supplementation with B vitamins, it is not possible to isolate the effects
of these vitamins from the other components of the supplement. Nevertheless, evaluating
the effects of multiple B vitamins simultaneously on PMS is important, as in regular diet,
B vitamins are consumed simultaneously, along with other compounds.

c) B vitamins and outcomes related to PMS:
Folate and vitamin B12 have been studied in relation to depression (21, 57), a
psychiatric disorder also suspected to be caused by serotonin deficiency. Thiamin has
been studied as a potential treatment for primary dysmenorrhea (25), which is
characterized by menstrual pain beginning at the time of menstruation (26). The
underlying pathophysiology of dysmenorrhea is also unclear but the condition may be
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associated with high levels of prostaglandins (26, 76) and inflammation, which may also
be associated with cramping during the premenstrual phase (77).
- Depression
Because folate, vitamin B12, and B6 are implicated in the metabolic pathways of
serotonin and other neurotransmitters, these vitamins have been considered as potential
treatments for depression (21, 56, 57).
Recently, Beydoun et al.(2010) (68) conducted a cross-sectional study among the
prospective Healthy Aging in Neighborhoods of Diversity across the Lifespan Study in
order to evaluate the effects of folate on depression and potential effect modification by
sex. The authors selected a subset of 1681 participants aged 34 to 64 years with
completed baseline and follow up information, including two diet recalls and plasma
folate status. Depression was assessed using the Center of Epidemiologic StudiesDepression scale (CES-D) which asks participants to rate 20 statements about six
depression symptoms: depressed mood, guilt or worthlessness, helplessness or
hopelessness, psychomotor retardation, loss of appetite and sleep disturbance. A total
CES-D score ≥ 16 is suggestive of moderate/severe level of depressive symptoms. The
authors found a significant inverse association between plasma folate levels and
moderate/severe depressive symptoms among women but not among men. Women in the
highest tertile of plasma folate had a 44% lower risk of having a CES-D score ≥ 16 (95%
CI = 0.42 - 0.86). In contrast, men in the highest tertile of plasma folate had a nonstatistically significant OR of 0.77 (95%CI = 0.48 - 1.24) as compared to those in the
lowest tertile. Although dietary consumption of total folate was higher among men (mean
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= 408.7 µg/d, SD = 281.1) than among women (mean = 316.8µg/d, SD = 203.1, p <
0.001), additional adjustment for dietary folate produced similar results. This study
suggested that there is differential impact of folate on depression in men than in women.
However as this was a cross-sectional study, it was not possible to evaluate the temporal
relationship between folate levels and depression. Moreover, dietary folate was measured
using two 24 hr diet recalls conducted over an unspecified time interval. Thus, this might
not reflect long term intake, which is likely important for the development of a chronic
state such as depression (68).
In Japan, Murakami et al.(2008) (70) conducted a cross-sectional study among
309 men and 208 women between 21 and 67 years of age to evaluate the association
between intake of riboflavin, B6, folate, and B12, as well as omega-3 fatty acids, and
depressive symptoms. Diet during the preceding month was assessed using a selfadministered brief diet history questionnaire, which included 56 food items common in
the Japanese diet. The use of dietary supplements was not included in the analysis
because of low frequency of use (3.7% for multivitamins). Depressive symptoms were
assessed using a Japanese version of the aforementioned CES-D scale. The authors found
a statistically significant inverse association between folate intake and depressive
symptoms among men only, but not among women. Men in the highest quartile for folate
intake (median = 235 μg/1000 Cal, n = 77) had a 50% lower risk of having depressive
symptoms (95%CI: 0.25-1.06) as compared to men in the lowest quartile of folate intake
(median = 119 μg/1000 Cal). Women in the highest quartile of folate intake
(median=292 μg/1000 Cal, n = 52) had a OR of 0.63 (95%CI = 0.26-1.51) as compared to
women in the lowest quartile (median = 150 μg/1000 Cal). There was no statistically
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significant association between the intake of riboflavin, vitamin B6, or vitamin B12 from
foods and depressive symptoms. However, the study had a relatively small sample size
and some associations could have been missed due to insufficient statistical power (70).
As seen in these examples, the association of folate and depression may be
modified by sex, though results are inconsistent. The underlying mechanisms by which
folate may act differently in women and in men remains unclear and underlines a
potential interaction of sex hormones with folate and depression. This is particularly
important for the potential role of folate in PMS, as the underlying pathophysiology
suggests an interaction of sex hormones with neurotransmitters. Beydoun et al.(68) and
Murakami et al.(70) used the CES-D scale to define their outcome, but exposure to folate
was measured in different ways. Beydoun et al.(68) focused on plasma folate adjusted by
folate intake reported by two diet recalls, whereas Murakami et al.(70) did not measure
plasma folate but relied on a short term frequency questionnaire. Because depression and
PMS are chronic diseases, assessment of exposure over a long period of time before
diagnosis is of particular importance.

- Dysmenorrhea
Although thiamin has not been individually studied for an association with PMS,
it has been considered as a potential treatment for primary dysmenorrhea by Gokhale et
al.(1996) (25).
The authors conducted a crossover randomized clinical trial among 556 women
ages 12 to 21 years who reported moderate to severe dysmenorrhea. Participants were
divided into two groups. The first group received 100 mg/day of thiamin for 90 days,
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followed by 60 days of placebo. The second group received placebo for 60 days,
followed by 100 mg/day thiamin for 90 days. After the first month of thiamin intake,
18.8% of women in the first group and 39.9% from the second group reported complete
disappearance of pain. During the first 60 days of placebo, women in the second group
reported no relief of symptoms. At the end of the study 87% of all participants reported
absence of pain. Although the authors concluded that thiamin has curative effects on
dysmenorrhea, no statistical test was conducted to compare their results. Additionally,
non-differential misclassification of dysmenorrhea was likely. Dysmenorrhea was selfreported and not diagnosed by a physician, and there was no procedure to confirm selfreport of pain during the follow-up (25).
Although dysmenorrhea occurs during the menstrual phase and not during the
luteal phase, it is noteworthy for research in PMS, as both disorders have common
symptoms of lower abdominal pain and cramps.

d) Summary of epidemiologic evidence:
Among the B vitamins, B6 has been the most extensively evaluated as a treatment
for PMS. Several randomized clinical trials have evaluated the effects of this vitamin on
prevalent PMS with significant benefits observed with doses ranging from 50 to 500
mg/day (13, 14, 17, 59, 60, 78). Other randomized clinical trials have evaluated the
effects of supplements containing several B vitamins on symptoms of PMS, and observed
significant improvement of symptoms (64, 65, 67). Limited evidence also suggests that B
vitamins may be beneficial as treatments for depression (21) and dysmenorrhea (25).
Results from these studies could be relevant for research on PMS because these disorders
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potentially share some common etiologic features with PMS. However, the association
between B vitamins thiamin, riboflavin, niacin, folate, B6, and B12 and the initial
development of PMS has not been studied before.

2.1.4 Summary
Premenstrual syndrome affects a substantial proportion of women of reproductive
age, resulting in reduced quality of life and impairment in social functioning during the
luteal phase when the symptoms appear. Despite its high prevalence, relatively little is
known about the pathophysiology of PMS and its prevention.
The pathophysiology of PMS likely involves multiple mechanisms. Symptoms are
likely caused by the interaction of the neurotransmitters serotonin and GABA with
ovarian hormones (8-10). B vitamins likely play a role in these interactions (11, 12). For
instance, thiamin is required for the metabolism of glucose and is a cofactor in the
formation of glutamate, a precursor of GABA (12, 45). Niacin deficiency may lead to a
depletion of tryptophan, an amino acid required for the synthesis of serotonin. Vitamin
B6, riboflavin, folate and vitamin B12 are associated with the synthesis of serotonin (12).
Hence, B vitamins provide basic elements required for the function and synthesis of
neurotransmitters.
There are no previous epidemiologic studies of the association of B vitamins and
incident PMS. Large doses of vitamin B6 have been widely studied as potential treatment
for PMS. (13, 14, 17, 59, 60) Kashanian et al.(13) and Sharma et al.(14) have reported
that doses of 80 to 100 mg/day improved symptoms significantly after two months of
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treatment as compared to placebo. Facchinetti et al.(67) and London et al.(64) evaluated
the effects of supplements containing several B vitamins and other micronutrients on
prevalent symptoms of PMS, and found them to significantly reduce PMS symptoms vs
placebo. B vitamins have been studied in relation to other disorders with similar features
to PMS. For example, Beydoun et al.(68) found a significant reduction of depressive
symptoms among women with high levels of plasma folate, but not among men, whereas
Murakami et al.(70) reported a beneficial effect of dietary folate among women but not
among men. Niacin supplementation (25) may be effective as treatment for
dysmenorrhea.
In conclusion, there is substantial evidence supporting a role of B vitamins in the
metabolism of neurotransmitters involved in PMS. Although B6 has been considered as a
potential treatment for PMS, none of the other B vitamins have been studied
independently in randomized clinical trials. Most importantly, no studies have been
conducted to date to determine the effects of dietary intake of B vitamins on the
development of PMS. Therefore, we conducted a prospective study nested in the Nurses’
Health Study II cohort to evaluate the effects of B vitamin intake before diagnosis on the
development of PMS.
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2.1.5 Specific Aims and Hypotheses
Specific Aim:
To examine the relationship between thiamin, riboflavin, niacin, vitamin B6, folate, and
vitamin B12 intake and the development of premenstrual syndrome among a subset of
women participating in the Nurses’ Health Study II.
Secondary Aims:
1) To evaluate the effects of B vitamins intake from food sources 2 to 4 years before
reference time on the development of PMS.
2) To evaluate the effects of B vitamin intake from supplement sources 2 to 4 years
before reference time on the development of PMS.
3) To compare the effects of B vitamins intake assessed at baseline (1991), and 0 to 2
years before the reference.
4) To evaluate effect modification of the association between B vitamins and PMS by
age, body mass index (BMI), smoking, and alcohol intake.
Hypothesis:
There is an inverse relationship between dietary intake of thiamin, riboflavin, niacin,
vitamin B6, folate, and vitamin B12 and the risk of developing premenstrual syndrome.
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2.2 Methods
2.2.1 Study design and population
To examine the association between B-vitamin intake and PMS we conducted a
case-control study nested within the Nurses' Health Study II (NHS II). The NHS II is a
prospective study that started in 1989 with the enrollment of 116,678 female registered
nurses aged 25 to 42 years old who lived in any of 14 states in the U.S. Participants
completed a mailed questionnaire about their medical history and lifestyle, which
included a question about physician diagnosis of PMS. Every two years, cohort members
completed follow up questionnaires to update information on risk factors and medical
events, including reporting a new diagnosis of PMS. As of 2003, the response rate for all
questionnaire cycles has been at least 89%.
The establishment of the NHS II PMS Sub-study has been described in detail in
previous studies (20, 79). From among all NHS II participants who had not reported a
diagnosis of PMS in 1989 or 1991, 3,430 women reported a new clinician-made
diagnosis of PMS on an NHS2 questionnaire between 1993 and 2001 and were
considered as potential cases. The authors assigned each woman a “reference year” equal
to their diagnosis year, which was used to determine eligibility for the study, as well as to
assess menstrual symptom experience and diet. The authors then identified 2,570 women,
selected from a random sample, who did not report a diagnosis of PMS at any time
between 1989 and 2001 to serve as potential controls; for these women, a randomly
chosen year between 1993 and 2001 was assigned as their reference year.
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To prevent the inclusion of women with menstrual symptoms attributed to causes
other than PMS, women with a diagnosis of cancer, endometriosis, usual irregular
menstrual cycles, or infertility before their reference year were excluded from the initial
selection of participants. Women who had a hysterectomy or who had reported
menopause were excluded to ensure participation of only premenopausal women.
Because the study was designed to focus on dietary factors and PMS, participants who
did not complete the food frequency questionnaires (FFQs) in 1991 and 1995 or who
reported an implausible total calorie intake (<500 and ≥ 3500 cal/day on their FFQ) were
also excluded from the study.

2.2.2

Exposure Assessment
To evaluate individual intake of selected nutrients, NHS2 participants completed

a semi quantitative food frequency questionnaire (FFQ) in 1991, 1995 and 1999.
The FFQs included 133 items, with a standard portion size for each, which aimed
to reflect natural portion sizes whenever possible (e.g. a slice of bread, an egg, a fruit).
Participants were asked how often they consume the specific food item, on average, with
9 response options: ">6 per day", "4 to 6 per day", "2 to 3 per day", "1 per day", "5 to 6
per week", "2 to 4 per week", "1 per week", "1 to 3 per month" and "never or less than
once per month".
The FFQ included additional questions about types of fat used, brand and type of
cold cereal consumed, and supplements used. For supplement use, participants were
asked to report whether they currently took multivitamins, how many they took per week
74

(<2, 3-5, 6-9, ≥10 tablets) and the specific brand used. Additional questions on regular
use of niacin, vitamin B6, folate, and B complex supplements (yes/no) were also
included. In addition, a specific question about vitamin B6 dosage (<50, 50 – 99, 100 –
149, ≥150 mg/day) was included on the 1991, 1995 and 1999 questionnaires. Niacin
supplement dosage (<50, 50-300, 400-800, ≥900 mg/day) was specifically included in the
1999 questionnaire, along with frequency of use.
For each B vitamin, total intake was calculated by multiplying the relative
frequency of consumption of each food item, converted to number of servings per day, by
the nutrient content of the specified portion size, according to the United States
Department of Agriculture database and manufacturers sources as needed. Finally,
adjustment for total calorie intake was performed using the residual method (80) .

Validity and Reproducibility of Exposure Assessment:
The validity and reproducibility of the FFQ has been widely studied before.(81, 82)
In 1985, Willett et al.(81) conducted a validation study among 194 women who
participated in the first Nurses’ Health Study. A 61-item semi quantitative FFQ was
administered twice with an interval of one year (1980 to 1981). During that period four 1week diet records were also collected to serve as a "gold" standard because they are
minimally dependent on memory and allow direct measurement of food quantities.
Participants were instructed by a trained dietitian on how to record detailed information
on food and beverages consumed for a one-week period, using a provided dietetic scale.
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Reproducibility was measured by comparing nutrient scores from both
questionnaires. Intraclass correlation coefficients ranged from 0.49 for vitamin A without
supplements to 0.79 for vitamin B6 with supplements. Validity was calculated by
comparing nutrient intake assessed by the FFQ to the nutrient intake assessed by the
average of the four one-week diet records. For vitamin B6 without supplements, the
correlation coefficient was 0.43 for the first questionnaire and 0.54 for the second
compared to mean nutrient scores from diet records (p < 0.05).
Additionally, participants’ nutrient scores from the questionnaire and the mean of
the four one-week diet records were categorized into quintiles and the joint classification
was compared. For vitamin B6, among the participants classified in the lowest quintile
according diet records, 47% were also in the lowest quintile and 88% were in the two
lowest quintiles for the questionnaire. Among the participants classified in the highest
quintiles according to diet records, 74% was in the highest quintile and 88% in the two
highest and 3% were misclassified in the lowest quintile according to the questionnaire.
In conclusion, the reproducibility and validity of nutrient scores for B vitamins calculated
from the food frequency questionnaire were found to be acceptable (81).

2.2.3

Outcome Assessment
Case and control status was ascertained using information from a supplementary

menstrual symptom questionnaire sent in 2002 to the 6000 selected sub-study participants
including 3430 women who reported a diagnosis of PMS made by a clinician between
1993 and 2001 and 2570 women who did not report a diagnosis of PMS. The
supplementary questionnaire was based on the Calendar of Premenstrual Experiences
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designed by Mortola et al.(83) Participants reported if they experienced any of 26 listed
symptoms ‘most months of the year for at least several days each month before their
menstrual period began’ during the specified 2 years prior to their reference year. For
example, if their reference year was 1995, the specified period was 1993 to 1995.
Symptoms queried included headaches, abdominal bloating, swelling of extremities, food
cravings, change in appetite, fatigue, insomnia, abdominal cramping, breast tenderness,
hot flashes, acne, palpitations, lower back pain, dizziness, nausea, diarrhea or
constipation, depression, irritability, mood swings, angry outbursts, confusion, anxiety or
nervousness, hypersensitivity, tendency to cry easily, desire to be alone, and
forgetfulness. Women experiencing any symptoms were asked to report the age at which
symptoms started, and the timing of symptom onset and cessation during an average
menstrual cycle, as well as overall symptom severity and whether symptoms interfered
with five specified life activities and interpersonal relationships. Completed
questionnaires were received from 2966 (86.5%) potential cases and 2504 (97.8%)
potential controls.
Validated PMS cases were self-reported cases who met the following criteria
based on those proposed by Mortola et al. in 1991 (83).
1) Occurrence of at least 1 physical and 1 affective menstrual symptom;
2) Overall symptom severity moderate or severe, or the effect of symptoms of
life and social relationships classified as moderate or severe;
3) Symptoms beginning within 14 days of the onset of menstruation;
4) Symptoms ending within 4 days of the onset of menstruation and;
5) Symptoms absent in the week after end of menses.
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From the 2966 potential cases who replied to the questionnaire, 1057 women (35.6%)
met these criteria.

Validated controls were women not reporting PMS during the follow-up who met
the following criteria:
1) Complete absence of symptoms or only mild symptoms
2) Mild overall symptom severity
3) No substantial effect on life activities and interpersonal relationships
4) Confirmed no diagnosis of PMS.
From the 2540 potential controls who replied to the questionnaire, 1968 women (78.6%)
met these criteria.

Validity of Outcome Assessment
The validity of this approach for assessing PMS symptoms was evaluated
previously by Bertone-Johnson et al (79). Participants from the PMS Sub-study who
reported a diagnosis of PMS for the first time in 2001 (n=138) and controls whose
reference year was 2001 (n=377) completed a retrospective questionnaire that inquired
about premenstrual symptoms and PMS diagnosis during the 2-years prior to
diagnosis/reference year. Potential cases were classified in four groups: 1) women who
met the Mortola criteria and kept prospective symptom charts as part of their diagnosis
(Chart/Mortola cases=36); 2) women who kept prospective charts for diagnosis but did
not met the Mortola criteria (Chart cases=31); 3) women who met the Mortola criteria but
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did not keep prospective symptom charts as part of their diagnosis (Mortola cases=30);
and 4) women who neither did met Mortola criteria, nor kept prospective charts (Selfreport-only cases=38). The first group was considered the most accurate diagnostic group
and was used as an “alloyed gold standard” for comparisons with the other groups.
Potential controls were classified in ‘confirmed controls’ if they met the control criteria
detailed before (absence or mild symptoms with no interference on normal life activities)
and ‘unconfirmed controls’ otherwise.
The authors found that both "Chart/Mortola cases" and "Mortola cases" were
similar with regard to symptom timing and severity, as well as to the presence of physical
symptoms. The groups only differed in the number of affective symptoms reported
(mean=5.3 for the "Chart/Mortola cases" vs. 4.3 for the "Mortola cases", p=0.04). In
contrast, the other 2 case groups ("Chart cases" and "Self-report-only" cases) differed in
multiple ways from the alloyed gold standard "Chart/Mortola cases". The authors
concluded that women who did not report prospective symptom charting as part of their
diagnosis but who met the Mortola criteria were essentially identical to those who
reported prospective charting and who met the modified Mortola criteria for PMS (79).

2.2.4 Covariate Assessment
Information on several factors potentially associated with PMS and B vitamin
intake, such as age, smoking status, weight, pregnancy history, tubal ligation, oral
contraceptive use, and other micronutrient intakes was collected on biennial
questionnaires throughout the study period.
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Some studies (84, 85) have found that PMS prevalence is inversely associated
with age. For our analysis, age was calculated using information on date of birth collected
at the baseline questionnaire. An elevated body mass index (BMI) has been found to be
associated with PMS in this population (86), as well as in other previous studies (84, 87).
BMI for all participants was calculated as the current weight in kilograms divided by the
square of the height in meters. Weight and height were self-reported in the baseline
questionnaire (1989), and current weight is queried on each follow up questionnaire.
Aspects of reproductive history such as parity, tubal ligation and use of oral
contraceptives have been assessed on the main NHS II questionnaires. These factors may
be potential confounders of the association between B vitamins and PMS. For example,
tubal ligation has been associated with premenstrual syndrome in some studies (88).
Parity is directly related to PMS via progesterone sensitization, and will be assessed as
the number of pregnancies that lasted more than 6 months. Oral contraceptives (OCs) are
recommended as treatment for PMS (89), but also may worsen some symptoms such as
depression and anxiety (90). In addition, oral contraceptive use has been associated with
lower levels of vitamin B6, which could be explained by an increased excretion of
tryptophan metabolites (91).
Smoking information was collected in the biannual NHS2 questionnaires and was
categorized into quintiles of pack-years of smoking. Alcohol information was collected in
the FFQs of 1991, 1995 and 1999, and was categorized into quintiles of intake. Cigarette
smoking and alcohol use may be associated with PMS through associations with levels of
sex steroids (92, 93) and neurotransmitters.(94, 95) Two recent studies using data from
the NHS II PMS-Sub study have evaluated the effects of cigarette smoking (96) and
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alcohol use (97) on incidence of PMS. In 2008, Bertone-Johnson et al.(96) found that
women who were current smokers had a two-fold increased risk for developing PMS
over the next 2 to 4 years (RR = 2.10, 95% CI = 1.56 - 2.83) as compared to never
smokers. There was a strong dose-response relationship with pack-years of smoking (p
trend = 0.03). With regard of alcohol intake, Bertone-Johnson et al.(97) found that among
leaner women (BMI < 25 kg/m2) there was a significant association between alcohol
intake and PMS. Lean women in the highest quintile of drinking-years of alcohol had a
RR of 1.74 (95% CI = 1.11 - 2.72) compared to never drinkers. Smoking and alcohol
may also be correlated with B vitamins. Smoking has been associated with lower plasma
levels of vitamin B6.(98, 99) Folate and B12 levels are lower among smokers(98, 100)
and alcohol users.(101) Therefore, we controlled for these potential confounders by
including them in the multivariate models.
Calcium intake and vitamin D have been also reported to be associated with
incidence of PMS in our study population (20). Information on these micronutrients, as
well as others potentially associated to PMS, has been collected FFQs and was
categorized by quintiles of total intake.

2.2.5

Data Analysis

Univariate Analysis:
We presented the number of self-reported cases and controls who were selected
from the NHS2 to participate in the PMS sub-study, the number and percentage of those
who replied to the ‘Menstrual Symptom Questionnaire’ and the number and percentages
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of women who fulfilled the validation criteria and were validated as cases and as controls
(Table 2.1).
For the six B vitamins, we presented the recommended dietary allowance (RDA)
among women of reproductive age as well as the mean, standard deviation (SD), median,
and interquartile range of their total intakes (Table 2.2), intakes from food sources only
(Table 2.3) and intakes from supplement sources only (Table 2.4).

Bivariate Analysis:
To evaluate the relationship between incident PMS or B vitamin intakes and
important covariates, we cross tabulated age-standardized covariate levels at baseline by
PMS status (Table 2.5) or by quintiles of total B vitamin intake (Tables 2.6a to 2.6f).
Continuous covariates included were age, BMI at baseline and at age 18, age at menarche
and at first birth, number of full-term pregnancies, and physical activity. Categorical
covariates were history of tubal ligation, use of oral contraceptives, smoking status, use
of antidepressants, and history of severe childhood trauma. We used t-tests and chisquare tests to compare continuous and categorical variables.
To examine the interrelationships among the individual B vitamins, we calculated
Spearman correlation coefficients for B vitamin total intake (Table 2.7), from food
sources (Table 2.8) and from supplemental sources (Table 2.9).
For each B vitamin total and from food sources only intakes 2 to 4 years before
reference year, we used logistic regression to calculate age-adjusted relative risks (RRs)
and 95% confidence intervals (CIs) for women in the highest quintiles using the lowest
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quintile as the reference (Tables 2.10 and 2.11). For supplemental intake of each B
vitamin, we selected non-users of supplements as the reference group and compared these
women with those who used supplements categorized by tertiles of intake (Table 2.12).
To assess dose-response relationships, we calculated the p for trend by including the
median of B vitamin intakes in each category as a continuous variable in the regression
model. For supplemental intakes, we calculated the p for trend among supplement users
only. Medians and case to control ratios are additionally reported in each category.

Multivariable analyses:
The multivariable models included those potential confounders whose addition to
the model changed the age-adjusted relative risks by more than 10%, as well as those
variables that have been identified as important predictors of PMS risk in previous
studies. The following covariates were included in the final models of total B vitamin
intake 2 to 4 years before reference year (Table 2.13): age (<30, 30-34, 35-39 or ≥ 40
years), year of diagnosis (1993, 1994-1995, 1996-1997, 1998-1999 or 2000-2001), BMI
(<20.0, 20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9 or ≥ 30.0 kg/m2), number of full term
pregnancies (pregnancies that lasted more than 6 months), tubal ligation (no vs. yes),
duration of oral contraceptive use (never, 1-23, 24-71, 72-119, or ≥120 months),
antidepressant use (never vs. ever), pack-years of smoking (quintiles), history of severe
childhood trauma score (5, 6-10, 11-15, or ≥16), and intake of alcohol, vitamin D,
calcium and potassium in quintiles during 2 to 4 years before reference year.
For B vitamin intakes from food sources, we additionally adjusted the RRs for
their respective intake from supplements (Model 1; Table 2.14). In addition, we evaluated
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a second model that included additional adjustment of each B vitamin for the effects of
the others (Model 2; Table 2.14).
B vitamin intakes from supplement sources were likewise adjusted for their
respective intake from food sources. P for trends were calculated among supplement
users only. Results of this analysis was included in table 2.16, summarized with
additional results on supplements.

Baseline and cross-sectional analysis
To evaluate the effects of a longer gap (2-10 years) between intakes of B vitamins
and PMS diagnosis, we calculated age and multivariable adjusted RRs and 95% CIs for
B vitamin intake from food (Table 2.15) and supplement sources (Table 2.16) at baseline
(1991).
To evaluate the potential of self-medication with B vitamin supplements, we
additionally calculated RRs and 95% CIs for B vitamin intakes from supplements 0 to 2
years before the reference year and for B vitamin intakes at baseline excluding cases who
reported presence of symptoms before 1991. Results of these analyses are presented in
table 2.16, in addition to those on B vitamin intake from supplements 2 to 4 years before
reference year and baseline analysis.

Effect modification
To evaluate effect modification, we stratified participants into two categories of
two categories of age ( < 40 years, n = 1289; and ≥ 40 years, n = 1735), two categories of
BMI ( < 25 kg/m2, n = 1890; and ≥ 25 kg/m2, n = 1048), ever smokers (n = 897) vs.
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never smokers (n = 2120), and alcohol intake (drinker, n = 1764; vs. non-drinkers, n =
1255). Then we assessed the B vitamin and PMS relationship within each stratum. We
created multiplicative interaction terms by multiplying these potential effect modifiers by
quintiles of the specific B vitamin intakes from food sources. We used the likelihood
ratio tests in multivariate models to test if the addition of the interaction term improves
the fitness of the model. Results from theses analysis for BMI, age, smoking, and alcohol
were reported in tables 2.17, 2.18, 2.19 and 2.20.
All analyses were conducted using the Statistical Analysis System (SAS Institute,
Cary, NC) for Unix, version 9.1

2.3 Results
The original study sample (Table 2.1) consisted of 3,430 women who reported a
PMS diagnosis between 1993 and 2001 and were considered potential cases, and 2,570
women who did not report a diagnosis of PMS between 1991 and 2001 and were
considered potential controls. Among the potential cases, 2,966 (86.5%) replied to the
Menstrual Symptom Questionnaire and 1057 (35.6%) met the Mortola criteria used for
case validation. Among the potential controls, 2,504 (97.4%) replied to the Menstrual
Symptom Questionnaire and 1968 (78.6%) were validated as controls according to
control criteria.
The mean total thiamin intake for the population for the period of 2 to 4 years
before reference year was 3.7 mg (SD = 8.5 mg) and the median total intake was 1.9 mg
(Table 2.2). Median intakes for total riboflavin, niacin, vitamin B6, folate and B12 were
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2.4 mg, 27.8 mg, 2.5 mg, 386 µg and 7 µg respectively. Except for folate, all median B
vitamin intakes were higher than their respective recommended dietary allowances
(RDAs). Mean total intakes were substantially higher than the medians, indicating a
positively skewed distribution.
Median intakes for thiamin, riboflavin, niacin, vitamin B6, folate and B12 from
food sources only were 1.6 mg, 1.9 mg, 23.3 mg, 2.0 mg, 305 µg and 5.4 µg respectively,
and except for folate they were higher than their respective RDAs (Table 2.3). Median
intakes for thiamin, riboflavin, niacin, vitamin B6, folate and B12 from supplement
sources only were 1.5 mg, 1.9 mg, 20 mg, 1.2 mg, 400 µg and 3.1 µg, respectively (Table
2.4).
We compared baseline age-standardized characteristics of cases and controls in
table 2.5. Compared with controls, cases were slightly younger and had a higher mean
BMI at baseline (p < 0.0001 for both). Cases were more likely than controls to report ever
use of oral contraceptives than controls (OC; 85.7% of users among cases vs. 77.7%
among controls, p < 0.001), to be current or past smokers ( 12.3% of current smokers and
26.5% of past smokers among cases vs. 6.5% and 18.2% among controls, p < 0.0001),
report ever use of antidepressants (12% among cases vs. 4.7% among controls, p <
0.0001), and to have a history of severe childhood trauma (14.8% among cases vs. 7.9
among controls, p < 0.0001). There were no significant differences in BMI at age 18, age
at menarche, age at first birth, physical activity, and history of tubal ligation between
cases and controls.
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In addition, we compared age-standardized characteristics of the population by
quintiles of intakes of thiamin, riboflavin, niacin, vitamin B6, folate, and vitamin B12
(Tables 2.6a to 2.6f). Overall, women in the highest quintiles of intake of any B vitamin
were younger (p < 0.0001) and were less likely to report tubal ligation (p = 0.05 - 0.001)
or to be current smokers (p= 0.08 - 0.002), compared to women in the lowest quintiles.
Among parous women, those in the highest quintiles of B vitamin intake were older when
they had their first child (p < 0.0001) and had fewer children compared to women in the
lowest quintiles (p < 0.0001). Except for niacin and vitamin B12, women in the highest
quintiles of B vitamin intakes were more active than those in the lowest quintiles (p <
0.0001). Women in the highest quintiles of vitamin B6 intakes were less likely to be
current users of OCs (p = 0.03) and more likely to report smoking in the past (p < 0.0001)
compared to women in the highest quintiles (Table 2.6d). Women in the highest quintiles
of folate intake were less likely to report current use of oral contraceptives (p=0.02)
compared to women in the lowest quintile (Table 2.6f).
There were strong correlations between total intakes of vitamins B6, riboflavin,
niacin and thiamin (range of Spearman correlation coefficients: 0.68 – 0.91; all p <
0.0001; Table 2.7). The correlation between thiamin and riboflavin was the highest (r =
0.91). Total niacin intake was also strongly correlated with thiamin and vitamin B6 (r =
0.86 for both). Correlations between dietary intakes of vitamins B6, riboflavin, niacin and
thiamin from food sources were smaller but still significant (range of Spearman
correlation coefficients: 0.16 – 0.64; all p < 0.0001; Table 2.8). Intakes of niacin and
vitamin B6 (r = 0.64) and thiamin and riboflavin (r = 0.57) from foods were the most
strongly correlated. Intake of vitamin B12 was modestly correlated with intake of other
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B vitamins. In contrast, intakes of B vitamins from supplement sources were very highly
correlated (range of Spearman correlation coefficients: 0.81 – 0.99; all p < 0.0001; Table
2.9). The correlation between thiamin and riboflavin intakes from supplement sources
was very high (r=0.99). The lowest correlation was found between vitamin B6 and
vitamin B12 (r=0.81).
Adjusting only for age, we observed no significant association between total
intakes of thiamin, riboflavin, folate, and vitamin B12 2 to 4 years before reference year
and premenstrual syndrome (Table 2.10). For example, women in the highest quintile of
thiamin intake had an age-adjusted relative risk (RR) of 1.10 (95% confidence interval
(CI) = 0.86 - 1.40) compared to women in the lowest quintile. In contrast, there was an
increased risk of premenstrual syndrome among women in the highest quintiles of niacin
and vitamin B6 intake (RR=1.45, 95% CI=1.14-1.85 for niacin and RR=1.48,
95%CI=1.16-1.90 for vitamin B6) compared to women in the lowest quintile.
For B vitamins from food sources only, there was an inverse association between
thiamin and riboflavin and risk of PMS in age-adjusted analyses (Table 2.11). Women in
the highest quintiles of thiamin intake from foods had an age-adjusted RR of 0.76 (95%
CI = 0.60 - 0.97, p trend = 0.01) compared to women in the lowest quintile. Women in
the highest quintile of riboflavin intake had 32% lower risk of developing PMS (RR =
0.68, 95%CI = 0.53 - 0.87, p trend = 0.004) compared to women in the lowest quintile.
There was no significant association between intakes of niacin, vitamin B6, folate, and
vitamin B12 from foods and risk of PMS.
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We presented age-adjusted relative risks for B vitamin intakes from supplement
sources and PMS 2 to 4 years before reference year and risk of PMS in table 2.12.
Women in the highest tertile of thiamin, niacin and vitamin B6 intakes had age-adjusted
relative risks of 1.28 (95 % CI = 1.03 - 1.59), 1.32 (1.05 - 1.66) and 1.48 (1.21 - 1.82)
respectively, compared to women who did not use supplements. There was no
association between supplemental intake of riboflavin, folate and vitamin B12 and
incidence of PMS.
We adjusted relative risks of total B vitamin intake and PMS for age in 1989, year
of diagnosis, number of fulltime pregnancies, BMI, pack-years of smoking, tubal ligation,
duration of oral contraceptive use, antidepressant use, history of childhood trauma and
total intakes of alcohol, potassium, calcium and vitamin D intake 2 to 4 years before
reference year (Table 2.13). There was no significant association between total intakes of
thiamin, riboflavin, folate, and vitamin B12 and incident PMS. However, niacin and
vitamin B6 were associated with an increased risk of PMS. For example, women in the
highest quintile of total niacin intake had a multivariate adjusted RR of 1.71 (95% CI =
1.23 - 2.39, p trend = 0.002) compared to women in the lowest quintile. Women in the
highest quintile of total vitamin B6 intake had a multivariate adjusted RR of 1.77 (95%
CI = 1.26 - 2.48, p trend < 0.001) compared to women in the lowest quintile.
B vitamin from food sources were additionally adjusted for intakes of each
vitamin from respective supplemental sources (Model 1; Table 2.14). In a subsequent
analysis, we adjusted each vitamin for the effect of the other B-vitamins (Model 2; Table
2.14). In model 1, thiamin and riboflavin from food sources were inversely associated
with risk of PMS. Women in the highest quintile of thiamin intakes from foods had a RR
89

of 0.75 (95%CI = 0.56-1.00, p trend = 0.04) compared to women in the lowest quintile.
Women in the highest quintile of riboflavin intakes from foods had a RR of 0.65 (95%CI
= 0.46 - 0.93, p trend = 0.03) compared to women in the lowest quintile. After adjustment
for other B vitamins, these results were no longer significant, although relative risks did
not change substantially. For example, in model 2, women in the highest quintile of
riboflavin intakes from foods had a RR of 0.67 (95%CI = 0.43-1.05, p trend = 0.09)
compared to women in the lowest quintile. There was no association between intakes of
niacin, vitamin B6, folate and vitamin B12 from foods and incident PMS.
We further evaluated intakes of B vitamins from food sources at baseline and risk
of PMS, after adjustment for all covariates selected at baseline and for supplement use of
each vitamin (Table 2.15). Results were similar compared to those for intake 2 to 4 years
before reference, but slightly attenuated. Women in the highest quintile of thiamin intake
from foods at baseline had a multivariate adjusted RR of 0.76 (95%CI=0.57-1.01, p trend
0.02) compared to women in the lowest quintile. Women in the highest quintile of
riboflavin intake from foods at baseline had a multivariate adjusted RR of 0.84
(95%CI=0.58-1.20, p trend 0.28) compared to women in the lowest quintile.
B vitamin intakes from supplements were additionally adjusted for intake of each
vitamin from food sources. Results for the association of B vitamins supplemental intakes
at 2-4 years before reference year, at baseline and at 0-2 years before reference year are
presented in table 2.16. In general, women with supplemental intake of B vitamins had a
higher risk of PMS as compared to non-users. For example, compared to women with no
intake of thiamin from supplements during the 2 to 4 years before reference, relative risks
in tertiles one through three were 1.41, 1.54, and 1.66, respectively (P for trend among
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users of thiamin supplements=0.22). Relative risks were attenuated when we evaluated
supplement intake measured at baseline, and higher when we assessed supplement intake
0 to 2 years before reference year. For example, for thiamin, relative risks for tertiles 1-3
vs. non-users were 1.44, 1.45 and 1.50, respectively (P for trend =0.68) for supplemental
intake at baseline, and 1.35, 1.44 and 1.77 (P for trend = 0.07) for supplement use 0-2
years before reference year. In the sub-analysis excluding women reporting that their
symptoms began before the start of follow-up in 1991, use of B vitamin supplements was
not associated with increased risk of PMS. For example, relative risks in tertiles 1-3 of
thiamin use vs. non-use were 1.16, 1.00, and 0.91, respectively (P for trend = 0.62).
Finally, after stratification of relative risks by quintiles of total intake, and testing
of multiplicative interaction terms, we found no evidence that the relationships between
B vitamin intake and incidence of PMS were modified by age (Table 2.17), BMI (Table
2.18), ever smoking (Table 2.19) or alcohol intake (Table 2.20), though our power for
this analysis was relatively low.

2.4 Discussion
In this subset of women from a large cohort of nurses, we found an inverse
association between thiamin and riboflavin intakes from food sources and the
development of PMS. There was no significant association between niacin, vitamin B6,
folate, and vitamin B12 from food sources and incident PMS. We found that use of B
vitamin supplements during the 2 to 4 years before the reference year was associated with
an increased risk of PMS, but there was no association between B vitamin supplement
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use at baseline and PMS when we excluded all cases with PMS symptoms before 1991.
In contrast, relative risks were higher when we compared B vitamin supplemental intake
closer to the reference year. The relationship between B vitamin intakes and PMS was
not modified by age, BMI, smoking and alcohol. To our knowledge, this is the first
prospective study on dietary B vitamin intake and PMS.
For both thiamin and riboflavin, the level of intake at which we observed a benefit
was considerably above current recommendations. For thiamin (RDA = 1.1 mg.day),(54)
we found that women consuming approximately 1.9 mg per day had a 25% lower risk of
PMS than those consuming approximately 1.2 mg/day. This level of intake can be
achieved by consuming 2-3 servings per day of thiamin rich foods such as fortified
cereals, legumes, nuts, and red meats such as pork. For riboflavin (RDA = 1.1 mg/day)
(54) women consuming approximately 2.5 mg/day had a 35% lower risk compared to
those consuming approximately 1.4 mg/day. This level of intake can be achieved with 12 servings/day of fortified cereal, or 6-7 servings of riboflavin rich foods such as cow’s
milk or soy milk, spinach, and red meats.
Previous randomized clinical trials have found a beneficial effect of vitamin B6
supplementation on PMS symptoms using doses up to 100 mg/day (13, 14, 17). For
example, in 2007, Sharma et al.(14) conducted a randomized clinical trial among 60
women who reported premenstrual symptoms, and found that women who received a
supplement of 100 mg/day of pyridoxine for 3 months showed a significant reduction of
premenstrual symptoms as compared to placebo or bromocriptine (P < 0.01). In the same
year, Kashanian et al.(13) conducted a randomized clinical trial among 94 college
students who received either 80 mg of pyridoxine or placebo for 2 months. The authors
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observed a greater reduction of PMS psychological symptom scores in the group
receiving pyridoxine compared to those receiving placebo. In our population, the doses of
vitamin B6 from supplements consumed were very low compared to those used in
intervention studies; the median B6 intake from supplements in the highest tertile was
4.98 mg/day. Hence, because of the low intakes in our population, we were unable to
evaluate association with "therapeutic" doses of vitamin B6 in incident cases of PMS, and
could have missed the potential beneficial effects.
No other studies have evaluated the effects of individual supplements of thiamin
or riboflavin and PMS supplementation, but few clinical trials have evaluated the effects
of supplements containing riboflavin, folate, and vitamin B12, among other
micronutrients in PMS symptoms (64, 65). In 1991, London et al.(64) conducted a
randomized clinical trial among 44 women with premenstrual tension, divided into three
treatment groups receiving different doses of a multivitamin containing thiamin,
riboflavin, niacin, vitamin B6, folate and vitamin B12 among others and a placebo group,
which received riboflavin only. The authors observed that all groups significantly
improved PMS symptoms after three months compared to baseline (p<0.0003). Although
there was no proper comparison for B vitamin supplementation, this study suggests that B
vitamin supplements, including riboflavin only supplements, may relieve PMS symptoms
after three months of intake.
The pathophysiology of PMS may include an interaction of ovarian hormones
with brain neurotransmitters, such as serotonin and GABA (8, 9). The B vitamins
evaluated in this analysis are involved in the metabolism of neurotransmitters through
different mechanisms, and their dietary intakes may affect neurotransmitter levels in the
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brain (11). Thiamin is required for the metabolism of glucose and precursors of GABA.
Riboflavin is needed to activate vitamin B6, which is a cofactor in the generation of
serotonin from the amino acid tryptophan. Niacin deficiency may lead to depletion of
tryptophan, thereby reducing its availability to form serotonin (12). Vitamins B12, B6,
and folate are associated with the formation of s-adenosyl-methionine and
tetrahydrobiopterin, both of which are required for the metabolism of serotonin and
dopamine (22, 57).

Study limitations
We observed an increased risk of PMS associated with any supplemental intake of
B vitamins. These results likely reflect of the use of B vitamins to treat menstrual
symptoms developing before diagnosis. Despite the lack of consistent evidence,
deficiencies in B vitamins have been believed to be associated with menstrual symptom
occurrence and severity, and supplements may be recommended by physicians for
treatment of mild symptoms (1, 6, 102, 103). To evaluate the likelihood that the observed
increased risks were due to this type of confounding by indication, we conducted separate
analyses of the association of intake of B vitamin supplements at three time periods,
hypothesizing that risks would be higher when supplement use was assessed closer in
time to diagnosis. We did in fact find that associations were strongest for riboflavin and
folate when supplement use was assessed 0 to 2 years before diagnosis and attenuated
when use was assessed at baseline (i.e., 2 to 10 years before diagnosis). Moreover, when
we conducted a separate analysis excluding women who reported that their symptoms
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had already begun before the start of our follow-up period (1991), intake of B vitamins
from supplements was not associated with PMS risk.
To evaluate B vitamin intakes from foods and supplement sources, we used
information collected on self-reported FFQs of the NHS II. These questionnaires have
been validated before in similar populations (80, 81). Nevertheless, it may be difficult to
accurately recall dietary intake over the past year, therefore some misclassification is
likely. To minimize within person variability in reporting, specific portion sizes were
included for each item. Additionally, we excluded from the analysis women who reported
intakes below 500 or above 3500 calories per day, because of such small and large
intakes are likely to be due to misreport. Misclassification is more likely between
adjacent quintiles than distant quintiles, thus we focused our analysis on comparisons
between the highest versus the lowest quintile (reference) and the trend over quintiles.
Dietary assessment was conducted independently from the outcome assessment, therefore
any misclassification would be non-differential and could have attenuated our results.
Participants prospectively reported new PMS diagnosis over the follow-up period
and completed a retrospective menstrual symptom questionnaire in 2002. From this group
of women, cases were selected using specific criteria for PMS based on those proposed
by Mortola in 1991 and accepted by the ACOG (1, 83). For the selection of controls, we
identified a sub-set of women who did not report PMS diagnosis during follow-up years,
and selected only those with complete absence of symptoms or only mild symptoms with
no impact on functioning. Thus our aim was to compare women at the ends of the
spectrum of premenstrual symptoms, and therefore to minimize misclassification
occurring in the middle of the spectrum. Because of the prospective design of our study
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and the large number of participants, we were unable to use prospective charting (i.e.
recording of daily symptoms for at least two cycles) for identification of PMS cases, as is
the gold standard for PMS assessment in clinical studies and recommended by the ACOG
(1). The lack of prospective charting of symptoms could have contributed to some
misclassification of the outcome, leading to exclusion of potential cases from our sample
or inclusion of women without PMS among the cases. Nevertheless, in the validation
study of our method (79), the authors found that women who reported prospective
charting and who met PMS criteria based on those defined by Mortola et al.(83) were
essentially identical to those who did not report prospective charting but who met the
Mortola criteria assessed in the retrospective questionnaire. Because PMS assessment
was conducted independently of diet assessment, any misclassification of PMS status
would be non-differential and could have attenuated our results.
Throughout the follow-up period, the NHS II questionnaires collected information
on a large number of variables, many of which may be associated with B vitamin intake
and PMS. Although we tried to minimize confounding by including all known risk
factors for PMS as potential confounders, it is possible that there are potential
confounders yet unknown as risk factors for PMS and associated with B vitamin intakes,
thus leading to residual confounding.
Participants in this study arise from the population of the a cohort of mostly white
women and generally more educated than the general population. It is possible that they
have a better diet quality than the general population, and therefore a different range of
intake of B vitamins. Nevertheless, we have no reason to believe that B vitamin intake
physiologically affects PMS in women from this cohort in a different manner as other
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women. Therefore, we can generalize these results to other premenopausal women with
the same range of intakes of B vitamins.

Conclusion
The results of this study suggest a possible benefit of high intakes of riboflavin
and thiamin from food sources on the incidence of PMS. No significant associations
between niacin, vitamin B6, folate, and vitamin B12 dietary intake and incident PMS
were observed. Intakes of B vitamins from supplements were not associated with lower
risk of PMS, but were likely to be influenced by self-medication. Because this is the first
prospective study to evaluate the effects of these vitamins, additional studies of these
relationships are warranted, including randomized clinical trials of thiamin and riboflavin
for the prevention and possibly the treatment of PMS.

2.5 Significance
Premenstrual syndrome affects approximately 15% of women of reproductive age
and is associated with substantial impact on quality of life and high economical burden.
Proposed treatments for PMS have significant side effects and have limited efficacy.
Although prevention of PMS through identification of modifiable risk factors is of
primary importance, few studies to date have studied PMS development. This is the first
study to evaluate the association between intakes of thiamin, riboflavin, niacin, vitamin
B6, folate, and vitamin B12 and development of PMS. The potential benefit of thiamin
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and riboflavin in PMS development should be further studied before suggesting specific
dietary changes to prevent PMS.

2.6 Human Subject Protection
This study has been approved by the University of Massachusetts, Amherst and
the Brigham and Women’s Hospital (BWH) institutional review boards.
Participants in the NHS2 are identified through a confidential identification
number only. Documents containing the names corresponding to each ID as well as the
questionnaires are kept separately in the Channing Laboratory in locked fire-proof
cabinets.
There are no invasive procedures involved in this sub-study. There are no known
risks involved in filling in questionnaires, except for the consequences of potential
disclosure of confidential data. Women will not benefit directly from participating in this
study.
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2.7 Permission to Access Data
I give Patricia Chocano-Bedoya permission to access relevant data from my grant
funded research for her dissertation on "Micronutrients and Premenstrual Syndrome".

Elizabeth Bertone-Johnson, Sc.D.
Associate Professor of Epidemiology
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Table 2.1 Number of cases and controls before and after validation, and
response rates: NHS2 PMS Sub-study, 1991-2001.
Potential Cases
Potential Controls
Original study sample

3430

2570

Replied to Menstrual Symptom
Questionnaire

2966 (86.5%)

2504 (97.4%)

Validated as cases or controls

1057 (35.6%)

1968 (78.6%)

Table 2.2 Distribution of total intake of B vitamins 2 to 4 years before reference
year: NHS2 PMS Sub-study, 1991-2001.
Interquartile
Recommended
Standard
Median
1 Mean
Dietary Allowance
Deviation
Range
Thiamin (mg/d)
1.1
3.7
8.5
1.9
1.5 - 3.0
Riboflavin (mg/d)
1.1
4.1
8.3
2.4
1.8 - 3.6
Niacin (mg/d)
14
35.9
27.6
27.8
22.6 - 40.0
Vitamin B6 (mg/d)
1.3
7.3
21.8
2.5
2.0 - 4.2
Folate (µg/d)
400
487
285
386
284 - 635
Vitamin B12 (µg/d)
2.4
9.9
13.4
7.0
5.0 - 11.0
1

Recommended dietary allowance for women aged 20 to 40 years.
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Table 2.3 Distribution of intakes of B vitamins from food sources 2 to 4 years
before reference year: NHS2 PMS Sub-study, 1991-2001.
Standard
Interquartile
Mean
Deviation
Median
Range
Thiamin (mg/d)
1.6
0.4
1.6
1.4 - 1.8
Riboflavin (mg/d)
2.0
0.6
1.9
1.6 - 2.2
Niacin (mg/d)
23.9
5.4
23.3
20.5 - 26.4
Vitamin B6 (mg/d)
2.1
0.5
2.0
1.8 - 2.3
Folate (µg/d)
321
108
305
251 - 370
Vitamin B12 (µg/d)
6.1
3.6
5.4
4.3 - 6.9

Table 2.4 Distribution of intakes of B vitamins from supplement sources1 2 to
4 years before reference year: NHS2 PMS Sub-study, 1991-2001.
Standard
Interquartile
Mean
Deviation
Median
Range
Thiamin (mg/d)
4.3
11.4
1.5
0.9 - 3.0
Riboflavin (mg/d)
4.4
11.3
1.7
1.0 - 3.4
Niacin (mg/d)
25.0
32.3
20.0
11.4 - 20.0
Vitamin B6 (mg/d)
7.0
23.1
1.2
0.04 - 2.6
Folate (µg/d)
364
261
400
228 - 400
Vitamin B12 (µg/d)
5.4
13.3
3.1
0.4 - 6.1
1

Includes multivitamin and individual supplement users.
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Table 2.5 Age-standardized characteristics of premenstrual syndrome cases
and controls at baseline: NHS2 PMS Sub-study, 1991-2001.
Cases
Controls
(n=1057)
(n=1968)
Characteristics1
Age in years2
BMI (kg/m2)
At baseline (1991)
At the age of 18 years
Age at menarche, years
Age at first birth, years3
Number of full-term pregnancies
MET of physical activity per week

History of tubal ligation
Oral contraceptive use
Ever
Current
Duration > 4years
Smoking status
Current smoker
Past smoker
Ever used antidepressant
History of childhood trauma

Mean (SE)
34.4 (4.3)

Mean (SE)
35.0 (3.9)

p-value4
<0.0001

24.6 (0.2)
21.4 (0.1)
12.4 (0.1)
25.9 (0.1)
1.7 (0.04)
23.0 (1.8)

23.7 (0.1)
21.1 (0.1)
12.5 (0.03)
26.1 (0.1)
1.7 (0.03)
23.3 (1.3)

<0.0001
0.03
0.08
0.22
0.52
0.88

%
16.8

%
18.2

p-value5
0.34

85.7
10.7
42.0

77.0
9.9
36.6

<0.0001
0.51
0.04

12.3
26.5
12.1
18.0

6.5
18.2
4.7
9.0

<0.0001
<0.0001
<0.0001
<0.0001

1

All characteristics, except for age, standardized to the age distribution of participants in 1991.

2

For age, the value in parentheses is the standard deviation instead of the standard error.

3

Limited to parous women.

4

Calculated using the t statistic.

5

Calculated using the chi-square statistics.
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Table 2.6a Age-standardized characteristics of the population by total thiamin
intake at baseline: NHS2 PMS Sub-study, 1991-2001.
Total thiamin intake in 1991, mg/d

Characteristics1
Age in years2

Q1
(n=531)

Q2
(n=603)

Q3
(n=671)

Q4
(n=643)

Q5
(n=577)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

35.0 (4.2) 35.2 (4.0) 35.1 (4.0) 34.2 (4.0) 34.3 (4.0)

Pvalue4
<0.0001

2

BMI (kg/m )
At baseline (1991) 24.6 (0.2) 24.2 (0.2) 23.7 (0.2) 23.8 (0.2) 24.0 (0.2)
At the age of 18 yrs 21.3 (0.1) 21.5 (0.1) 21.1 (0.1) 21.0 (0.1) 21.1 (0.1)
Age at menarche, years 12.5 (0.1) 12.5 (0.1) 12.5 (0.1) 12.4 (0.1) 12.5 (0.1)
Age at first birth, years3 25.6 (0.2) 25.6 (0.2) 25.5 (0.2) 26.9 (0.2) 26.4 (0.2)
Number of full-term
1.5 (1.2) 1.8 (1.2) 1.9 (1.2) 1.6 (1.2) 1.5 (1.3)
pregnancies
MET of physical
17.5 (4.0) 24.4 (4.0) 19.4 (4.0) 30.1 (4.0) 23.0 (4.0)
activity per week

0.01
0.06
0.80
<0.0001
<0.0001
0.001

History of tubal ligation

%
19

%
19

%
20

%
16

%
14

Pvalue5
0.04

Oral contraceptive use
Current user
Ever user

13
82

11
83

9
81

9
77

9
81

0.18
0.06

12
18

10
22

7
22

8
21

7
22

0.002
0.46

8

8

6

7

8

0.35

11

11

10

11

10

0.68

Smoking Status
Current smoker
Past smoker
Ever used
antidepressants
History of severe
childhood trauma
1

All characteristics, except for age, standardized to the age distribution of participants in 1991.
2
For age, the value in parentheses is the standard deviation instead of the standard error.
3
Limited to parous women.
4
Calculated using the t statistic.
5
Calculated using the F statistic.
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Table 2.6b Age-standardized characteristics of the population by total riboflavin
intake at baseline: NHS2 PMS Sub-study, 1991-2001.
Total riboflavin intake in 1991, mg/d

Characteristics1
Age in years2

Q1
(n=535)

Q2
(n=591)

Q3
(n=659)

Q4
(n=646)

Q5
(n=594)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

35.4 (4.1)

Pvalue4

35.0 (4.0) 35.0 (4.1) 34.3 (4.1) 34.1 (4.0) <0.0001

2

BMI (kg/m )
At baseline (1991) 24.6 (0.2)
At the age of 18 yrs 21.3 (0.1)
Age at menarche, years 12.5 (0.1)
Age at first birth, years3 25.5 (0.2)
Number of full-term
1.6 (0.1)
pregnancies
MET of physical
17.0 (2.5)
activity per week

History of tubal ligation

23.8 (0.2) 23.9 (0.2) 23.9 (0.2) 24.0 (0.2)
21.2 (0.1) 21.3 (0.1) 21.1 (0.1) 21.1 (0.1)
12.5 (0.1) 12.4 (0.1) 12.4 (0.1) 12.5 (0.1)

0.11
0.83
0.43

25.4 (0.2) 25.6 (0.2) 26.6 (0.2) 26.9 (0.2) <0.0001
1.8 (0.05) 1.8 (0.05) 1.7 (0.05) 1.5 (0.05) <0.0001
21.1 (2.4) 23.7 (2.3) 28.4 (2.3) 24.2 (2.4)

0.01

%

%

%

%

%

Pvalue5

20

18

21

16

13

0.001

11
80

14
85

9
79

10
78

9
81

0.18
0.06

12
18

11
23

6
21

8
22

7
22

0.002
0.46

8

9

6

7

8

0.35

11

11

9

12

10

0.68

Oral contraceptive use
Current user
Ever user
Smoking Status
Current smoker
Past smoker
Ever used
antidepressants
History of severe
childhood trauma
1

All characteristics, except for age, standardized to the age distribution of participants in 1991.
2
For age, the value in parentheses is the standard deviation instead of the standard error.
3
Limited to parous women.
4
Calculated using the t statistic.
5
Calculated using the F statistic.
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Table 2.6c Age-standardized characteristics of the population by total niacin
intake at baseline: NHS2 PMS Sub-study, 1991-2001.
Total niacin intake in 1991, mg/d
Q1
(n=579)

Q2
(n=589)

Q3
(n=662)

Q4
(n=609)

Q5
(n=594)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

35.2 (4.1)

34.7 (4.1)

35.1 (3.9) 34.1 (4.0) 34.7 (4.0) <0.0001

BMI (kg/m )
At baseline (1991) 23.8 (0.2)
At the age of 18 yrs 20.9 (0.1)
Age at menarche, years 12.6 (0.1)

24.3 (0.2)
21.4 (0.1)
12.4 (0.1)

24.2 (0.2) 23.9 (0.2) 24.0 (0.2)
21.4 (0.1) 20.9 (0.1) 21.3 (0.1)
12.4 (0.1) 12.5 (0.1) 12.4 (0.1)

25.4 (0.2)

25.6 (0.2) 26.8 (0.2) 26.4 (0.2) <0.0001

1.8 (0.05)

1.8 (0.05) 1.6 (0.05) 1.4 (0.05) <0.0001

21.3 (2.3)

20.5 (2.4) 25.6 (2.3) 27.1 (2.4)

1

Characteristics
Age in years2

Pvalue4

2

Age at first birth, years3 25.8 (0.2)
Number of full-term
1.7 (0.05)
pregnancies
MET of physical
20.5 (2.4)
activity per week

0.33
0.01
0.32

0.14

History of tubal ligation

%
20

%
20

%
20

%
14

%
15

Pvalue5
0.005

Oral contraceptive use
Current user
Ever user

13
82

11
81

8
82

8
76

10
82

0.03
0.04

9
15

11
19

8
26

7
22

8
24

0.082
<0.0001

6

8

7

6

9

0.22

10

9

11

11

12

0.72

Smoking Status
Current smoker
Past smoker
Ever used
antidepressants
History of severe
childhood trauma
1

All characteristics, except for age, standardized to the age distribution of participants in 1991.
For age, the value in parentheses is the standard deviation instead of the standard error.
3
Limited to parous women.
4
Calculated using the t statistic.
5
Calculated using the F statistic.
2
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Table 2.6d Age-standardized characteristics of the population by total vitamin B6
intake at baseline: NHS2 PMS Sub-study, 1991-2001.
Total vitamin B6 intake in 1991, mg/d

Characteristics1
Age in years2

Q1
(n=537)

Q2
(n=697)

Q3
(n=592)

Q4
(n=595)

Q5
(n=604)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Pvalue4

35.1 (4.1) 35.2 (4.1) 35.0 (3.9) 34.2 (4.2) 34.3 (3.9) <0.0001

2

BMI (kg/m )
At baseline (1991) 24.3 (0.2) 24.3 (0.2) 23.7 (0.2) 23.7 (0.2) 24.1 (0.2)
At the age of 18 yrs 21.1 (0.1) 21.5 (0.1) 21.0 (0.1) 21.1 (0.1) 21.2 (0.1)
Age at menarche, years 12.6 (0.1) 12.4 (0.1) 12.5 (0.1) 12.4 (0.1) 12.5 (0.1)

0.06
0.04
0.15

Age at first birth, years3 25.6 (0.2) 25.6 (0.2) 25.6 (0.2) 26.4 (0.2) 26.8 (0.2) <0.0001
Number of full-term
1.7 (0.05) 1.8 (0.05) 1.8 (0.05) 1.6 (0.05) 1.5 (0.05) <0.0001
pregnancies
MET of physical
17.5 (2.5) 21.8 (2.2) 22.7 (2.4) 25.9 (2.4) 27.3 (2.4) 0.04
activity per week
History of tubal ligation

%
20

%
19

%
20

%
17

%
13

Pvalue5
0.003

Oral contraceptive use
Current user
Ever user

12
83

12
80

10
82

10
77

8
82

0.03
0.14

12
16

10
20

6
26

7
21

8
22

0.002
<0.0001

9

6

8

7

7

0.24

11

9

11

11

10

0.67

Smoking Status
Current smoker
Past smoker
Ever used
antidepressants
History of severe
childhood trauma
1

All characteristics, except for age, standardized to the age distribution of participants in 1991.
2
For age, the value in parentheses is the standard deviation instead of the standard error.
3
Limited to parous women.
4
Calculated using the t statistic.
5
Calculated using the F statistic.
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Table 2.6e Age-standardized characteristics of the population by total folate intake
at baseline: NHS2 PMS Sub-study, 1991-2001.
Total folate intake in 1991, µg/d

Characteristics1
Age in years2

Q1
(n=556)

Q2
(n=621)

Q3
(n=585)

Q4
(n=604)

Q5
(n=659)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Pvalue4

34.8 (4.1) 35.3 (4.0) 35.2 (4.0) 34.6 (4.1) 34.0 (4.0) <0.0001

2

BMI (kg/m )
At baseline (1991) 24.7 (0.2) 24.1 (0.2) 23.8 (0.2) 23.5 (0.2) 24.1 (0.2)
At the age of 18 yrs 21.4 (0.1) 21.3 (0.1) 21.2 (0.1) 20.9 (0.1) 21.3 (0.1)
Age at menarche, years 12.5 (0.1) 12.5 (0.1) 12.5 (0.1) 12.5 (0.1) 12.4 (0.1)

0.002
0.13
0.53

Age at first birth, years3 25.6 (0.2) 25.5 (0.2) 25.4 (0.2) 26.2 (0.2) 27.2 (0.2) <0.0001
Number of full-term
1.7 (0.05) 1.8 (0.05) 1.8 (0.05) 1.6 (0.05) 1.5 (0.05) <0.0001
pregnancies
MET of physical
16.9 (2.5) 24.1 (2.3) 22.7 (2.4) 23.9 (2.4) 27.4 (2.3) 0.04
activity per week
History of tubal ligation

%
20

%
20

%
18

%
18

%
13

Pvalue5
0.003

Oral contraceptive use
Current user
Ever user

11
82

12
84

10
80

12
78

8
79

0.02
0.11

12
19

10
19

7
23

7
21

7
23

0.007
0.20

8

8

7

8

6

0.85

10

8

13

10

11

0.15

Smoking Status
Current smoker
Past smoker
Ever used
antidepressants
History of severe
childhood trauma
1

All characteristics, except for age, standardized to the age distribution of participants in 1991.
2
For age, the value in parentheses is the standard deviation instead of the standard error.
3
Limited to parous women.
4
Calculated using the t statistic.
5
Calculated using the F statistic.
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Table 2.6f Age-standardized characteristics of the population by total vitamin B12
intake at baseline: NHS2 PMS Sub-study, 1991-2001.
Total vitamin B12 intake in 1991, µg/d
Q1
(n=508)

Q2
(n=775)

Q3
(n=550)

Q4
(n=616)

Q5
(n=576)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

35.2(4.1)

35.0(4.0)

34.7(3.9)

34.5(4.0)

34.3(4.2) <0.0001

BMI (kg/m )
At baseline (1991) 24.2(0.2)
At the age of 18 yrs 21.5(0.1)
Age at menarche, years 12.5(0.1)

24.0(0.2)
21.3(0.1)
12.5(0.1)

23.9(0.2)
21.0(0.1)
12.4(0.1)

23.7(0.2)
21.0(3.0)
12.5(0.1)

24.3(0.2)
21.2(3.0)
12.4(0.1)

25.6(0.2)

25.8(0.2)

26.4(0.2)

26.7(0.2) <0.0001

1.8(0.04)

1.7(0.05)

1.7(0.05)

1.6(0.05)

0.01

21.6(2.1)

24.7(2.5)

26.1(2.3)

22.8(2.4)

0.49

History of tubal ligation

%
18

%
19

%
17

%
20

%
14

Pvalue5
0.05

Oral contraceptive use
Current user
Ever user

11
80

11
82

11
79

11
81

9
80

0.50
0.70

12
20

9
21

6
23

8
22

8
20

0.03
0.76

7

8

7

8

7

0.83

12

10

10

11

10

0.89

Characteristics1
Age in years2

Pvalue4

2

Age at first birth, years3 25.7(0.2)
Number of full-term
1.7(0.05)
pregnancies
MET of physical
20.8(2.6)
activity per week

Smoking Status
Current smoker
Past smoker
Ever used
antidepressants
History of severe
childhood trauma
1

All characteristics, except for age, standardized to the age distribution of participants in 1991.
2
For age, the value in parentheses is the standard deviation instead of the standard error.
3
Limited to parous women.
4
Calculated using the t statistic.
5
Calculated using the F statistic.
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0.24
0.15
0.16

Table 2.7 Spearman correlation coefficients1 for total intake of B vitamins:
NHS2 PMS Sub-study, 1991-2001.
Thiamin
Riboflavin
Niacin
B6
Folate
B12
Thiamin
1.00
Riboflavin
0.91
1.00
Niacin
0.86
0.81
1.00
B6
0.85
0.84
0.86
1.00
Folate
0.82
0.79
0.76
0.80
1.00
B12
0.70
0.80
0.69
0.70
0.68
1.00
1

All correlations are statistically significant at <0.0001

Table 2.8 Spearman Correlation Coefficients1 for intake of B vitamins from
food sources: NHS2 PMS Sub-study, 1991-2001.
Thiamin
Riboflavin
Niacin
B6
Folate
B12
Thiamin
1.00
Riboflavin
0.57
1.00
Niacin
0.46
0.26
1.00
B6
0.54
0.49
0.64
1.00
Folate
0.61
0.48
0.36
0.60
1.00
B12
0.20
0.54
0.23
0.30
0.16
1.00
1

All correlations are statistically significant at <0.0001

Table 2.9 Spearman Correlation Coefficients1 for intake of B vitamins from
supplement sources: NHS2 PMS Sub-study, 1991-2001.
Thiamin
Riboflavin
Niacin
B6
Folate
B12
Thiamin
1.00
Riboflavin
0.99
1.00
Niacin
0.98
0.98
1.00
B6
0.89
0.89
0.88
1.00
Folate
0.90
0.90
0.90
0.83
1.00
B12
0.90
0.90
0.89
0.81
0.88
1.00
1

All correlations are statistically significant at <0.0001
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Table 2.10 Age-adjusted relative risks (RR) and 95% confidence intervals (CI) for
total intake of B vitamins 2 to 4 years before reference year and risk of
premenstrual syndrome: NHS2 PMS Sub-study, 1991-2001.
Q1
Thiamin (mg/d)
Median
Case:Control Ratio
RR
95% CI
Riboflavin (mg/d)
Median
Case:Control Ratio
RR
95% CI
Niacin (mg/d)
Median
Case:Control Ratio
RR
95% CI
Vitamin B6 (mg/d)
Median
Case:Control Ratio
RR
95% CI
Folate (µg/d)
Median
Case:Control Ratio
RR
95% CI
Vitamin B12 (µg/d)
Median
Case:Control Ratio
RR
95% CI

Q2

Q3

Q4

Q5

1.27
186:342
1.00

1.53
1.84
2.73
5.06
218:395
204:462
226:405
221:360
1.01
0.81
1.00
1.10
(0.80-1.29) (0.64-1.04) (0.79-1.28) (0.86-1.40)

1.45
195:356
1.00

1.83
2.33
3.28
6.09
197:390
226:440
218:424
219:354
0.90
0.92
0.90
1.08
(0.70-1.15) (0.73-1.17) (0.71-1.14) (0.84-1.37)

19.4
180:356
1.00

23.6
28.0
37.7
56.4
234:422
194:377
221:396
226:354
1.27
1.19
1.24
1.45
(1.00-1.61) (0.93-1.53) (0.98-1.58) (1.14-1.85)

1.63
173:369
1.00

2.00
2.54
3.90
9.10
227:464
218:402
197:392
240:337
1.04
1.16
1.05
1.48
(0.82-1.33) (0.91-1.48) (0.82-1.34) (1.16-1.90)

219.9
180:382
1.00

293.0
371.0
551.0
846.5
208:403
213:380
243:380
211:419
1.11
1.21
1.36
1.03
(0.87-1.41) (0.95-1.54) (1.07-1.72) (0.81-1.31)

4.0
194:358
1.00

5.0
7.0
10.0
17.0
251:533
172:335
238:411
200:327
0.87
0.94
1.05
1.10
(0.69-1.10) (0.73-1.21) (0.83-1.33) (0.85-1.40)
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Ptrend

0.16

0.24

0.01

0.001

0.92

0.10

Table 2.11 Age-adjusted relative risks (RR) and 95% confidence intervals (CI) for
intake of B vitamins from food sources 2 to 4 years before reference year and risk
of premenstrual syndrome: NHS2 PMS Sub-study, 1991-2001.
Q1
Thiamin (mg/d)
Median
Case:Control Ratio
RR
95% CI
Riboflavin (mg/d)
Median
Case:Control Ratio
RR
95% CI
Niacin (mg/d)
Median
Case:Control Ratio
RR
95% CI
Vitamin B6 (mg/d)
Median
Case:Control Ratio
RR
95% CI
Folate (µg/d)
Median
Case:Control Ratio
RR
95% CI
Vitamin B12 (µg/d)
Median
Case:Control Ratio
RR
95% CI

Q2

Q3

Q4

Q5

Ptrend

1.20
185:314
1.00

1.39
1.53
1.67
1.93
214:364
227:400
218:417
211:469
1.01
0.97
0.89
0.76
(0.79-1.29) (0.76-1.23) (0.70-1.14) (0.60-0.97)

1.38
195:318
1.00

1.63
1.86
2.12
2.52
198:382
241:396
220:405
201:463
0.84
0.97
0.87
0.68
0.004
(0.66-1.08) (0.76-1.23) (0.69-1.11) (0.53-0.87)

18.1
203:397
1.00

21.2
23.5
25.8
29.9
212:425
239:382
188:406
213:354
0.99
1.23
0.91
1.20
(0.78-1.25) (0.97-1.55) (0.72-1.16) (0.95-1.53)

1.56
178:380
1.00

1.83
2.05
2.28
2.71
245:414
217:426
231:372
184:372
1.27
1.09
1.33
1.07
(1.00-1.61) (0.86-1.39) (1.04-1.69) (0.83-1.38)

206.0
198:348
1.00

256.0
299.1
347.0
434.4
207:403
223:399
231:398
196:416
0.90
1.01
1.04
0.85
(0.71-1.15) (0.79-1.28) (0.82-1.32) (0.66-1.08)

3.3
224:384
1.00

4.6
5.5
6.6
9.0
225:396
202:454
213:370
191:357
0.97
0.77
0.98
0.92
(0.77-1.23) (0.61-0.97) (0.78-1.25) (0.72-1.17)
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0.01

0.23

0.69

0.34

0.60

Table 2.12 Age-adjusted relative risks (RR) and 95% confidence intervals
(CI) of B vitamins from supplements 2 to 4 years before reference year and
risk of premenstrual syndrome: NHS2 PMS Sub-study, 1991-2001.

Thiamin (mg/d)
Median
Case:Control Ratio
RR
95% CI
Riboflavin (mg/d)
Median
Case:Control Ratio
RR
95% CI
Niacin (mg/d)
Median
Case:Control Ratio
RR
95% CI
Vitamin B6 (mg/d)
Median
Case:Control Ratio
RR
95% CI
Folate (µg/d)
Median
Case:Control Ratio
RR
95% CI
Vitamin B12
(µg/d)
Median
Case:Control Ratio
RR
95% CI
1

Supplement Users
T2
T3

Non-Users

T1

538:1080
1.00

0.9
163:287
1.12
(0.90-1.39)

1.5
178:328
1.05
(0.85-1.30)

5.7
178:273
1.28
(1.03-1.59)

540:1081
1.00

1.0
179:310
1.14
(0.93-1.41)

1.7
158:290
1.04
(0.84-1.30)

5.7
180:287
1.22
(0.99-1.52)

535:1077
1.00

6
154:294
1.04
(0.83-1.30)

20
220:372
1.13
(0.93-1.38)

50
148:225
1.32
(1.05-1.66)

288:626
1.00

0.03
242:460
1.16
(0.94-1.43)

1.2
234:463
1.08
(0.88-1.34)

5.0
293:419
1.48
(1.21-1.82)

553:1115
1.00

228
220:359
1.22
(1.00-1.49)

400
196:317
1.22
(0.99-1.50)

800
88:177
0.90
(0.68-1.19)

295:647
1.00

0.3
260:462
1.25
(1.02-1.53)

3.2
258:411
1.35
(1.10-1.67)

6.5
244:448
1.16
(0.94-1.43)

Test for trend was conducted among users of supplements only.
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Ptrend1

0.16

0.38

0.09

0.01

0.05

0.41

Table 2.13 Multivariable adjusted RR1 and 95% CI for total B vitamin intake
2 to 4 years before reference year and PMS: NHS2 PMS Sub-study 1991-2001.
Thiamin
RR
95% CI
Riboflavin
RR

Q1

Q2

Q3

Q4

Q5

Ptrend

1.00

0.91
(0.69-1.21)

0.76
(0.57-1.01)

1.08
(0.78-1.51)

1.30
(0.92-1.84)

0.02

1.00

0.97

0.94

0.93

1.23

0.06

(0.71-1.32)

(0.66-1.34)

(0.62-1.39)

(0.82-1.86)

1.17

1.03

1.42

1.71

(0.90-1.53)

(0.78-1.37)

(1.04-1.95)

(1.23-2.39)

0.99

1.09

1.25

1.77

(0.75-1.30)

(0.81-1.47)

(0.88-1.75)

(1.26-2.48)

1.24

1.24

1.48

1.32

(0.93-1.63)

(0.92-1.66)

(1.07-2.04)

(0.90-1.95)

0.81

0.90

1.16

1.29

(0.62-1.06)

(0.66-1.24)

(0.83-1.63)

(0.90-1.86)

95% CI
Niacin
RR

1.00

95% CI
Vitamin B6
RR

1.00

95% CI
Folate
RR

1.00

95% CI
Vitamin B12
RR
95% CI

1.00

1

0.002

<0.001

0.23

0.02

Adjusted for age (<30, 30-34, 35-39 or ≥40 years), year of diagnosis (1993, 1994-1995, 1996-1997, 1998-1999 or 20002001), number of full-term pregnancies (0. 1-2, 3-4 or ≥5 pregnancies lasting at least 6 months), body mass index (<20.0,
20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9 or ≥30.0 kg/m2), pack-years of smoking (quintiles), tubal ligation (no vs. yes),
duration or oral contraceptive use (never, 1-23, 24-71, 72-119 or ≥120 months), antidepressant use (never vs. ever), history of
childhood trauma score (5, 6-10, 11-15, ≥16), intake of alcohol, potassium, calcium and vitamin D (quintiles) at 2 to 4 years
before reference year.
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Table 2.14 Multivariable adjusted RR1 and 95% CI for B vitamin intake from
food sources 2 to 4 years before reference year and risk of PMS: NHS2 PMS Substudy, 1991-2001.
Q1

Q2

Q3

Q4

Q5

Ptrend

1.00

0.94
(0.71-1.25)
0.90
(0.67-1.21)

0.91
(0.68-1.21)
0.87
(0.64-1.19)

0.89
(0.67-1.19)
0.87
(0.62-1.21)

0.75
(0.56-1.00)
0.78
(0.53-1.14)

0.04

0.81

1.00

0.99

0.65

0.02

(0.60-1.09)

(0.74-1.37)

(0.64-1.25)

(0.46-0.93)

0.85

1.04

0.94

0.67

(0.62-1.16)

(0.74-1.47)

(0.64-1.39)

(0.43-1.05)

1.00

1.01

1.18

0.84

1.10

0.87

1.00

(0.77-1.31)
1.02

(0.91-1.54)
1.21

(0.64-1.10)
0.89

(0.83-1.45)
1.27

0.28

(0.77-1.34)

(0.91-1.62)

(0.65-1.23)

(0.90-1.80)

1.20

1.04

1.16

0.97

(0.91-1.58)

(0.78-1.38)

(0.86-1.57)

(0.70-1.33)

1.23

1.08

1.18

1.05

(0.92-1.65)

(0.77-1.49)

(0.82-1.70)

(0.70-1.61)

0.87

1.00

0.99

0.75

(0.66-1.14)

(0.76-1.33)

(0.69-1.26)

(0.55-1.03)

0.92

1.11

1.09

0.98

95% CI
Vitamin B12
Model 1
1.00

(0.69-1.24)

(0.81-1.53)

(0.77-1.54)

(0.66-1.45)

0.97

0.79

0.93

0.89

95% CI

(0.74-1.26)

(0.60-1.03)

(0.70-1.23)

(0.67-1.19)

0.93

0.77

0.92

0.98

(0.71-1.22)

(0.58-1.02)

(0.69-1.24)

(0.71-1.35)

Thiamin
Model 1
95% CI
Model 2
95% CI
Riboflavin
Model 1

1.00

1.00

95% CI
Model 2
95% CI
Niacin
Model 1
95% CI
Model 2
95% CI
Vitamin B6
Model 1

1.00

1.00

95% CI
Model 2
95% CI
Folate
Model 1

1.00

1.00

95% CI
Model 2

Model 2
95% CI

1.00

1.00

0.22

0.09

0.57
0.97

0.25
0.91

0.50
0.93

Model 1. Adjusted for age (<30, 30-34, 35-39 or ≥40 years), year of diagnosis (1993, 1994-1995, 1996-1997, 1998-1999 or
2000-2001), number of full-term pregnancies (0. 1-2, 3-4 or ≥5 pregnancies lasting at least 6 months), body mass index (<20.0,
20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9 or ≥30.0 kg/m2), pack-years of smoking (quintiles), tubal ligation, duration or oral
contraceptive use, antidepressant use (never vs. ever), history of childhood trauma score (5, 6-10, 11-15, >=16), intake of alcohol,
potassium, calcium and vitamin D (quintiles) at 2 to 4 years before reference year and respective intake from supplemental
sources.
Model 2. Model 1 additionally adjusted for food intake of other B vitamins in table.
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Table 2.15 Multivariable adjusted RR1 and 95% CI of intake of B vitamins from
food sources at baseline and PMS: NHS2 PMS Sub-study, 1991-2001.
Thiamin (mg/d)
Median
Case:Control Ratio
RR
95% CI
Riboflavin (mg/d)
Median
Case:Control Ratio
RR
95% CI
Niacin (mg/d)
Median
Case:Control Ratio
RR
95% CI
Vitamin B6 (mg/d)
Median
Case:Control Ratio
RR
95% CI
Folate (µg/d)
Median
Case:Control Ratio
RR
95% CI
Vitamin B12 (µg/d)
Median
Case:Control Ratio
RR
95% CI

Q1

Q2

Q3

Q4

Q5

1.2
203:308
1.00

1.4
221:356
0.98
(0.74-1.30)

1.5
222:415
0.83
(0.63-1.10)

1.7
192:420
0.73
(0.54-0.97)

1.9
219:469
0.76
(0.57-1.01)

1.4
201:315
1.00

1.6
202:370
0.92
(0.68-1.24)

1.9
222:365
0.99
(0.72-1.36)

2.1
212:454
0.85
(0.61-1.19)

2.5
220:464
0.84
(0.58-1.20)

17.9
199:422
1.00

21.2
219:429
1.19
(0.92-1.55)

23.4
240:378
1.35
(1.04-1.76)

25.9
196:376
1.14
(0.87-1.51)

30.4
203:363
1.18
(0.89-1.57)

1.6
183:381
1.00

1.8
238:395
1.18
(0.89-1.56)

2.1
218:428
1.02
(0.76-1.37)

2.3
234:367
1.28
(0.94-1.73)

2.8
184:397
0.94
(0.68-1.30)

210
207:373
1.00

261
235:404
0.84
(0.64-1.11)

303
209:414
1.12
(0.84-1.49)

350
209:399
1.04
(0.77-1.41)

438
196:378
0.75
(0.55-1.04)

3.5
208:373
1.00

4.7
235:404
1.00
(0.76-1.29)

5.6
209:414
0.97
(0.73-1.27)

6.8
209:399
0.99
(0.74-1.31)

9.2
196:378
1.01
(0.76-1.35)

1

Ptrend

0.02

0.28

0.39

0.56

0.16

0.89

Adjusted for age (<30, 30-34, 35-39 or ≥40 years), year of diagnosis (1993, 1994-1995, 1996-1997, 1998-1999 or 2000-2001),
number of full-term pregnancies (0. 1-2, 3-4 or ≥5 pregnancies lasting at least 6 months), body mass index (<20.0, 20.0-22.4, 22.524.9, 25.0-27.4, 27.5-29.9 or ≥30.0 kg/m2), pack-years of smoking (quintiles), tubal ligation (no vs. yes), duration or oral contraceptive
use, antidepressant use (never vs. ever), history of childhood trauma score (5, 6-10, 11-15, >=16), intake of alcohol, potassium,
calcium and vitamin D (quintiles) at baseline (1991) and respective intake from supplemental sources.

115

Table 2.16 Multivariate relative risks (RR)1 of B vitamin intakes from
supplemental sources at different times and risk of PMS: NHS2 PMS Sub-study,
1991-2001.
Supplement Users
Non-Users
RR
Thiamin (mg/d)
Median3
Case:Control Ratio3
Baseline (1991)

0
538:1080
1.00

Baseline excluding cases with
symptoms before 19914

1

2-4 years before reference

1

0-2 years before reference

1

Riboflavin (mg/d)
Median3
Case:Control Ratio3

0
540:1081

Baseline (1991)

1

Baseline excluding cases with
symptoms before 19914

1

2-4 years before reference

1

0-2 years before reference

1

Niacin (mg/d)
Median3
Case:Control Ratio3

0
535:1077

Baseline (1991)

1

Baseline excluding cases with
symptoms before 19914

1

2-4 years before reference

1

0-2 years before reference

1

T1
RR
(95% CI)

T2
RR
(95% CI)

T3
RR
(95% CI)

0.85
163:287
1.44
(1.09,1.88)
1.16
(0.76,1.77)
1.41
(1.08,1.85)
1.35
(1.04,1.75)

1.5
178:328
1.45
(1.03,2.04)
1.00
(0.58,1.70)
1.54
(1.11,2.14)
1.44
(1.05,1.97)

5.7
178:273
1.50
(1.10,2.06)
0.91
(0.55,1.51)
1.66
(1.23,2.26)
1.77
(1.33,2.36)

0.96
179:310
1.42
(1.07,1.86)
1.17
(0.76,1.80)
1.38
(1.05,1.81)
1.24
(0.95,1.62)

1.7
158:290
1.51
(1.06,2.14)
1.14
(0.65,1.98)
1.42
(1.00,2.01)
1.39
(1.01,1.91)

5.7
180:287
1.43
(1.03,1.98)
0.98
(0.58,1.65)
1.44
(1.05,1.97)
1.71
(1.28,2.30)

5.7
154:294
1.34
(1.02,1.76)
1.06
(0.69,1.62)
1.33
(1.01,1.74)
1.29
(1.00,1.67)

20
220:372
1.69
(1.23,2.33)
1.14
(0.69,1.87)
1.81
(1.32,2.47)
1.44
(1.05,1.94)

50
148:225
1.77
(1.26,2.48)
1.02
(0.59,1.78)
2.07
(1.49,2.87)
2.11
(1.56,2.85)
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Ptrend1

0.68
0.62
0.22
0.07

0.98
0.82
0.65
0.05

0.22
0.99
0.01
0.002

Table 2.16, continued.
Vitamin B6 (mg/day)
Median3
Case:Control Ratio3

0
288:626

Baseline (1991)

1

Baseline excluding cases with
symptoms before 19914

1

2-4 years before reference

1

0-2 years before reference

1

Folate (ug/day)
Median3
Case:Control Ratio3

0
553:1115

Baseline (1991)

1

Baseline excluding cases with
symptoms before 19914

1

2-4 years before reference

1

0-2 years before reference

1

Vitamin B12 (ug/day)
Median3
Case:Control Ratio3

0
295:647

Baseline (1991)

1

Baseline excluding cases with
symptoms before 19914

1

2-4 years before reference

1

0-2 years before reference

1

0.03
242:460
0.93
(0.74,1.17)
0.74
(0.51,1.07)
1.09
(0.86,1.37)
1.05
(0.83,1.33)

1.15
234:463
1.37
(1.04,1.79)
1.03
(0.68,1.55)
1.45
(1.00,1.92)
1.43
(1.08,1.90)

4.98
293:419
1.79
0.0004
(1.34,2.41)
1.12
0.35
(0.70,1.77)
2.08
<0.0001
(1.56,2.78)
2.10
<0.0001
(1.58,2.79)

228
220:359
1.53
(1.19,1.98)
1.15
(0.76,1.72)
1.57
(1.22,2.03)
1.29
(0.99,1.67)

400
196:317
1.69
(1.19,2.41)
1.30
(0.74,2.26)
2.05
(1.46,2.87)
1.90
(1.40,2.58)

800
88:177
1.11
(0.74,1.66)
0.92
(0.51,1.66)
1.43
(0.96,2.13)
1.61
(1.15,2.25)

0.3
260:462
1.00
(0.79,1.26)
1.25
(0.88,1.78)
1.25
(1.00,1.58)
1.25
(0.91,1.71)

3.2
258:411
1.41
(1.09,1.83)
1.17
(0.77,1.78)
1.65
(1.25,2.16)
1.75
(1.20,2.55)

6.5
244:448
1.59
(1.13,2.23)
1.20
(0.71,2.04)
1.68
(1.19,2.35)
1.45
(0.97,2.17)

1

0.05
0.68
0.25
0.15

0.02
0.72
0.13
0.26

Adjusted for age (<30, 30-34, 35-39 or ≥40 years), year of diagnosis (1993, 1994-1995, 1996-1997, 1998-1999 or 2000-2001),
number of full-term pregnancies (0. 1-2, 3-4 or ≥5 pregnancies lasting at least 6 months), body mass index (<20.0, 20.0-22.4,
22.5-24.9, 25.0-27.4, 27.5-29.9 or ≥30.0 kg/m2), pack-years of smoking (quintiles), tubal ligation (no vs. yes), duration or oral
contraceptive use (never, 1-23, 24-71, 72-119 or ≥120 months), antidepressant use (never vs. ever), history of childhood trauma
score (5, 6-10, 11-15, ≥16), intake of alcohol, potassium, calcium and vitamin D (quintiles) at 2 to 4 years before reference time.
Intake of each vitamin from supplement sources is also adjusted for intake of that vitamin from food sources.
2
Test for trend among users of supplements only.
3
Medians and case-control ratios from 2-4 years before reference data.
4
Analysis includes 329 cases and 1968 controls.

/
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Table 2.17 Stratified RR1 and 95% CI for total B vitamin intake 2 to 4 years before
reference year and PMS by age at diagnosis: NHS2 PMS Sub-study, 1991-2001.
Q1
Case:Control 90:112
RR
1.00
95% CI
Case:Control 96:230
RR
1.00
95% CI
Riboflavin Case:Control 90:111
Age < 40
RR
1.00
95% CI

Q2

Q3

Q4

Q5

Pvalue2

Thiamin
Age < 40
(n=1289)
Age ≥ 40
(n=1735)

103:151
85:180
115:182
114:157 0.16
0.77
0.55
0.89
1.03
(0.49-1.20) (0.35-0.87) (0.54-1.50) (0.59-1.79)
115:244
119:282
111:223
107:203
1.00
1.01
1.17
1.40
(0.69-1.44) (0.70-1.45) (0.74-1.82) (0.88-2.22)
96:156
98:170
108:188
115:157 0.29
0.93
0.77
0.81
1.13
(0.56-1.54) (0.43-1.37) (0.43-1.54) (0.58-2.21)

Age ≥ 40

Case:Control 105:245 101:234
128:270
110:236
104:197
RR
1.00
1.03
1.12
1.02
1.26
95% CI
(0.68-1.53) (0.71-1.77) (0.60-1.75) (0.74-2.14)
Case:Control 85:160
121:153
78:143
111:185
112:141 0.32
RR
1.00
1.50
1.03
1.34
1.82
95% CI
(1.00-2.26) (0.66-1.60) (0.82-2.19) (1.08-3.07)
Case:Control 95:255
113:269
116:234
110:211
114:213
RR
1.00
0.04
0.13
1.44
1.66
95% CI
(0.73-1.49) (0.79-1.63) (0.95-2.19) (1.06-2.59)

Niacin
Age < 40
Age ≥ 40

Vitamin B6 Case:Control 91:143
Age < 40
RR
1.00
95%CI

102:168
96:147
97:181
121:143 0.25
0.90
1.00
1.13
1.65
(0.59-1.38) (0.63-1.58) (0.68-1.89) (0.99-2.76)

Age ≥ 40

125:296
122:255
100:211
119:194
1.09
1.21
0.14
1.89
(0.75-1.59) (0.81-1.81) (0.87-2.23) (1.19-3.00)

Case:Control 82:226
RR
1.00
95%CI

Case:Control
RR
95%CI
Age ≥ 40
Case:Control
RR
95%CI
VitaminB12 Case:Control
Age < 40
RR
95%CI
Age ≥ 40
Case:Control
RR
95%CI
Folate
Age < 40

100:135
1.00
80:247
1.00
96:123
1.00
98:235
1.00

85:151
0.86
(0.56-1.33)
123:252
1.55
(1.07-2.25)
114:195
0.65
(0.43-1.00)
137:338
0.96
(0.67-1.36)

1

90:138
0.87
(0.55-1.37)
123:242
1.54
(1.03-2.30)
77:142
0.61
(0.37-1.00)
95:193
1.18
(0.77-1.80)

117:159
1.14
(0.71-1.85)
126:221
1.64
(1.05-2.57)
115:179
0.85
(0.50-1.43)
123:232
1.43
(0.90-2.27)

115:199 0.08
0.91
(0.51-1.60)
96:220
1.53
(0.89-2.61)
105:143 0.13
0.99
(0.57-1.72)
95:184
1.45
(0.88-2.39)

Adjusted for age (continuous), year of diagnosis, number of full-term pregnancies, BMI, pack-years of smoking, tubal ligation,
duration of oral contraceptive use, antidepressant use, history of childhood trauma score, intake of alcohol, potassium, calcium
and vitamin D at 2 to 4 years before reference year.
2
P-value for likelihood ratio test of the interaction terms of age (<40 or ≥40 years) by quintiles of each mineral.
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Table 2.18 Stratified RR1 and 95% CI for total B vitamin intake 2 to 4 years before
reference year and PMS by BMI: NHS2 PMS Sub-study, 1991-2001.
Q1
Case:Control 107:209
Thiamin
BMI<25
RR
1.00
(n=1890)
95% CI
BMI≥25
Case:Control 75:117
(n=1048)
RR
1.00
95% CI
Riboflavin Case:Control 111:213
BMI<25
1.00
RR
95% CI
BMI≥25
Case:Control 77:131
1.00
RR
95% CI
Niacin
Case:Control 108:283
BMI<25
1.00
RR
95% CI
BMI≥25
Case:Control 60:115
1.00
RR
95% CI
Vitamin B6 Case:Control 104:230
BMI<25
1.00
RR
95% CI
BMI≥25
Case:Control 64:125
1.00
RR
95% CI
Folate
Case:Control 99:233
BMI<25
1.00
RR
95% CI
BMI≥25
Case:Control 75:139
1.00
RR
95% CI
Vitamin B12 Case:Control 117:227
BMI<25
BMI≥25

RR
95% CI
Case:Control
RR
95% CI

Q2
122:238
0.84
(0.58-1.20)
82:142
0.82
(0.51-1.32)
113:255
0.80
(0.54-1.20)
75:121
1.27
(0.74-2.18)
133:246
1.37
(0.98-1.93)
93:163
1.08
(0.68-1.73)
121:284
0.89
(0.62-1.26)
93:165
1.10
(0.69-1.76)
116:241
1.37
(0.95-1.98)
80:148
1.00
(0.63-1.60)

Q3
114:302
0.65
(0.45-0.94)
81:151
0.81
(0.50-1.32)
127:287
0.79
(0.50-1.24)
89:141
1.26
(0.68-2.33)
112:236
1.15
(0.81-1.63)
75:130
1.05
(0.64-1.72)
125:267
0.96
(0.66-1.39)
85:124
1.29
(0.77-2.17)
130:247
1.34
(0.92-1.97)
75:119
1.08
(0.65-1.79)

Q4
138:283
0.94
(0.62-1.42)
84:115
1.18
(0.67-2.09)
128:278
0.83
(0.50-1.39)
85:135
1.04
(0.52-2.10)
129:280
1.25
(0.84-1.87)
89:108
1.89
(1.09-3.27)
116:263
1.18
(0.77-1.82)
76:119
1.20
(0.65-2.20)
142:268
1.34
(0.88-2.03)
96:101
1.81
(1.04-3.15)

Q5
141:233
1.27
(0.82-1.97)
79:119
1.26
(0.69-2.30)
143:232
1.23
(0.74-2.06)
75:116
1.28
(0.62-2.62)
140:220
1.93
(1.27-2.93)
84:128
1.66
(0.92-3.01)
156:221
1.75
(1.16-2.65)
83:111
1.74
(0.95-3.20)
135:276
1.53
(0.94-2.48)
75:137
0.96
(0.48-1.90)

Pvalue2
0.35

154:335

98:225

131:285

122:193

0.41

1.00

0.79
0.68
0.82
(0.56-1.11) (0.45-1.03) (0.53-1.27)
72:114
88:180
65:105
103:115
1.00
0.74
1.09
1.68
(0.47-1.18) (0.64-1.87) (0.94-3.01)

1

0.65

0.29

0.59

0.42

1.20
(0.76-1.90)
73:130
1.09
(0.58-2.05)

Adjusted for age, year of diagnosis, number of full-term pregnancies, BMI (continuous), pack-years of smoking, tubal ligation,
duration of oral contraceptive use, antidepressant use, history of childhood trauma score, intake of alcohol, potassium, calcium and
vitamin D at 2 to 4 years before reference year.
2
P-value for likelihood ratio test of the interaction terms of BMI (<25 or ≥25 years) by quintiles of each mineral.
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Table 2.19 Stratified RR1 and 95% CI for total B vitamin intake 2 to 4 years
before reference year and PMS by smoking: NHS2 PMS Sub-study, 1991-2001.
Q1
Thiamin
Ever smoker
(n=897)
Never smoker
(n=2120)
Riboflavin
Ever smoker
Never smoker

Niacin
Ever smoker
Never smoker

Vitamin B6
Ever smoker
Never smoker

Folate
Ever smoker
Never smoker

Vitamin B12
Ever smoker
Never smoker

Case:Control
75:85
RR
1.00
95%CI
Case:Control 111:256
RR
1.00
95%CI
Case:Control
76:91
RR
1.00
95%CI
Case:Control 119:263
RR
1.00
95%CI
Case:Control
59:79
RR
1.00
95%CI
Case:Control 121:335
RR
1.00
95%CI
Case:Control
67:87
RR
1.00
95%CI
Case:Control 106:282
RR
1.00
95%CI
Case:Control
69:99
RR
1.00
95%CI
Case:Control 111:282
RR
1.00
95%CI
Case:Control 70:103
RR
1.00
95%CI
Case:Control 123:253
RR
1.00
95%CI

Q2

Q3

Q4

Q5

Pvalue2

82:107
84:105
85:91
80:103
0.59
0.68
0.66
0.77
0.85
(0.41-1.12) (0.39-1.12) (0.41-1.44) (0.45-1.62)
134:287
120:355
141:314
141:255
1.03
0.79
1.24
1.63
(0.73-1.46) (0.55-1.12) (0.83-1.85) (1.06-2.49)
77:101
84:107
92:89
77:103
0.76
0.85
0.60
0.75
0.68
(0.48-1.49) (0.32-1.15) (0.35-1.60) (0.32-1.44)
119:289
141:331
126:335
142:249
1.01
1.12
1.00
1.67
(0.69-1.48) (0.73-1.73) (0.62-1.64) (1.01-2.73)
91:107
85:115
83:88
88:102
0.44
1.18
0.83
1.22
1.30
(0.71-1.97) (0.49-1.40) (0.65-2.30) (0.68-2.47)
142:314
108:260
138:308
138:250
1.13
1.09
1.50
2.01
(0.82-1.55) (0.77-1.52) (1.03-2.18) (1.34-3.00)
92:105
88:109
79:89
80:101
0.11
0.94
0.67
0.80
0.89
(0.57-1.57) (0.39-1.17) (0.42-1.53) (0.47-1.69)
134:358
129:290
118:303
160:234
0.93
1.24
1.40
2.31
(0.67-1.31) (0.86-1.78) (0.92-2.13) (1.54-3.47)
81:96
1.32
(0.79-2.19)
127:307
1.13
(0.80-1.59)
104:126
1.10
(0.67-1.80)
147:405
0.70
(0.51-0.97)

1

88:100
1.17
(0.69-1.98)
123:278
1.18
(0.82-1.71)
60:78
0.87
(0.48-1.59)
111:257
0.87
(0.60-1.28)

85:92
1.07
(0.58-1.98)
158:287
1.57
(1.06-2.32)
101:89
1.55
(0.83-2.90)
137:322
1.00
(0.66-1.51)

83:104
0.87
1.10
(0.53-2.27)
128:313
1.38
(0.87-2.20)
71:95
0.84
1.10
(0.56-2.15)
129:230
1.40
(0.90-2.17)

Adjusted for age, year of diagnosis, number of full-term pregnancies, BMI, tubal ligation, duration of oral contraceptive use,
antidepressant use, history of childhood trauma score, intake of alcohol, potassium, calcium and vitamin D at 2 to 4 years before
reference year.
2
P-value for likelihood ratio test of the interaction terms of smoking (ever vs. never) by quintiles of each mineral.
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Table 2.20 Stratified RR1 and 95% CI for total B vitamin intake 2 to 4 years before
reference year and PMS by alcohol intake: NHS2 PMS Sub-study, 1991-2001.
Q1
Case:Control 117:190
Thiamin
Drinker
RR
1.00
(n=1764)
95% CI
Non-drinker Case:Control 69:152
(n=1255)
RR
1.00
95% CI
Riboflavin Case:Control 119:210
Drinker
RR
1.00
95% CI

Q4
Q2
Q3
Q5
Pvalue2
132:240
110:254
143:256
125:197
0.52
0.74
0.61
0.83
1.00
(0.51-1.06) (0.41-0.90) (0.54-1.28) (0.64-1.59)
86:155
94:208
83:149
96:163
1.24
0.99
1.48
1.79
(0.79-1.95) (0.63-1.55) (0.86-2.54) (1.02-3.15)
112:232
141:243
131:254
124:198 0.44
0.83
0.90
0.75
0.97
(0.55-1.25) (0.57-1.42) (0.45-1.26) (0.57-1.65)

Non-drinker Case:Control
RR
95% CI
Case:Control
Niacin
Drinker
RR
95% CI
Non-drinker Case:Control
RR
95% CI

85:158
85:197
87:170
95:156
1.24
1.03
1.24
1.70
(0.76-2.05) (0.58-1.85) (0.64-2.41) (0.87-3.32)
103:213 129:242
121:232
143:245
131:205
0.67
1.00
1.07
0.98
1.31
1.47
(0.75-1.52) (0.68-1.41) (0.86-1.98) (0.95-2.29)
77:202
105:180
73:145
78:151
95:149
1.00
1.30
1.06
1.56
2.05
(0.86-1.95) (0.68-1.66) (0.94-2.58) (1.20-3.50)

Vitamin B6 Case:Control
Drinker
RR
95%CI

109:203
1.00

Non-drinker Case:Control
RR
95%CI
Folate
Case:Control
Drinker
RR

64:166
1.00

95%CI
Non-drinker Case:Control
RR
95%CI
VitaminB12 Case:Control
Drinker
RR
95%CI
Non-drinker Case:Control
RR
95%CI

76:146
1.00

123:265
137:239
119:234
139:196
0.45
0.71
0.97
0.97
1.33
(0.49-1.02) (0.66-1.44) (0.62-1.52) (0.86-2.06)
104:199
81:163
1.55
1.28
(1.00-2.41) (0.79-2.08)

100:207
1.00

126:235
1.25
(0.86-1.83)
80:175
82:168
1.00
1.22
(0.79-1.88)
112:216 157:309
1.00
0.87
(0.61-1.24)
82:142
94:224
1.00
0.74
(0.48-1.14)

1

78:158
101:141
1.80
2.84
(1.03-3.15) (1.64-4.92)

133:226
151:229
117:240 0.63
1.23
1.37
1.03
(0.83-1.82) (0.89-2.11) (0.62-1.72)
80:154
92:151
94:179
1.22
1.55
1.77
(0.76-1.96) (0.93-2.58) (0.96-3.29)
102:181
143:246
113:185
0.97
0.97
1.09
1.13
(0.63-1.47) (0.69-1.70) (0.70-1.82)
70:154
95:165
87:142
0.85
1.30
1.51
(0.52-1.40) (0.76-2.24) (0.85-2.68)

Adjusted for age, year of diagnosis, number of full-term pregnancies, BMI, pack-years of smoking, tubal ligation, duration of oral
contraceptive use, antidepressant use, history of childhood trauma score, intake of potassium, calcium and vitamin D at 2 to 4
years before reference year.
2
P-value for likelihood ratio test of the interaction terms of drinking (yes vs. no) by quintiles of each mineral.
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CHAPTER 3
DIETARY INTAKE OF SELECTED MINERALS
AND PREMENSTRUAL SYDROME

3.1 Background

3.1.1 Introduction
Premenstrual syndrome (PMS) affects 8 to 15% of women of reproductive age in
the US (1). Most frequently reported PMS symptoms are irritability, depression, fatigue,
bloating, breast tenderness and headaches (2). Presence of these symptoms is restricted to
the luteal phase of the menstrual cycle, and has effects on social life, interpersonal
relationships and work activities (1).
Because of the wide variety of symptoms and timing during the menstrual cycle,
the pathophysiology of PMS likely involves multiple systems affected by hormonal
variations during the menstrual cycle. The neurotransmitters gamma-amino butyric acid
(GABA) and serotonin are the most widely studied (3, 4). However, other
neurotransmitters like melatonin (5) and systems like the renin-angiotensin-aldosterone
system(6, 7) may be involved. Moreover, potential cyclic variations in serum mineral
levels may reflect an interaction between ovarian hormones and mineral metabolism that
contributes to symptom occurrence and severity.
Although overt micronutrient deficiencies are not common in the US, it has been
suggested that women with affective disorders have low levels of magnesium (8), zinc
(9), and iron (10, 11). Increased intake of minerals and vitamins has been recommended
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for prevention and treatment of affective disorders such as PMS (1, 12). The
identification of a modifiable risk factor, such as dietary mineral intake, could contribute
to the prevention of PMS.
To date, only supplemental magnesium, manganese and potassium have been
studied in relation to PMS. Zinc has been studied as a potential treatment for depression
and as an adjunct treatment in cases of treatment resistant depression (13). No previous
studies have evaluated the effect of dietary intake of these minerals on the development
of PMS. Therefore, we propose to study the effects of magnesium, zinc, copper,
manganese, potassium, sodium, and iron in the development of incident PMS among a
sub-group of women participating in the Nurses’ Health Study II.

3.1.2 Physiologic Mechanisms
a) Magnesium
Magnesium (chemical symbol: Mg) is the fourth most abundant cation in the
body, and it acts as a cofactor for enzymatic reactions involved in muscle contraction,
neurotransmitter release and regulation of ion channels (14). The recommended dietary
allowance (RDA) is 320 mg/day for adult women (15). However, deficiency is relatively
common. Although there are many food sources of magnesium, according to the 19992000 U.S. National Health and Nutrition Examination Survey (NHANES) the median
magnesium dietary intake in Caucasian women was 237 mg/day (16), which was
substantially lower than the RDA. In addition, many other dietary factors interfere with
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Mg absorption and elimination, such as coffee, ethanol, phosphoric acid, and selenium
(17).
Magnesium may be associated with PMS through its association with melatonin
deficiency, which may contribute to PMS. Additionally, magnesium is an antagonist to
glutamate, which has been associated with depression, and like serotonin and GABA,
may also be associated with PMS.
• Magnesium and melatonin
Melatonin is synthesized in the pineal gland from serotonin (18). Magnesium is a
cofactor for N-acetyl-transferase, the enzyme responsible for the conversion of serotonin
into melatonin(18). Premenstrual syndrome, as well as other affective disorders, might be
associated with abnormal melatonin secretion. In 1990, Parry et al.(19) conducted a study
among 8 women with a diagnosis of PMS and 8 women without PMS, matched
according to cycle phase. Participants provided plasma samples every 30 minutes from 6
pm to 9 am during the early follicular (day 8 ± 2), late follicular (day 12 ± 2), mid-luteal
(day 7 ± 2 after luteinizing hormone (LH) surge) and late-luteal phases (day 12 ± 2 after
LH surge) of the menstrual cycle. Throughout the menstrual cycle, women with PMS had
an overall lower secretion of melatonin, with a lower area under the curve (Mean area
under the curve, 10,000 nmol/L melatonin among PMS cases, compared to 22,000
nmol/L melatonin among controls, during the late luteal phase, p< 0.001), lower
melatonin half life (1 hour average in PMS cases vs. 8 hours average in controls, during
late luteal phase, p = 0.03) and an earlier cessation of melatonin secretion (5 am among
PMS cases vs. 7 am among controls, during late luteal phase; p = 0.03) as compared to
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controls. Although the sample size for this study is small, it suggests that women with
PMS have an abnormal melatonin secretion compared to women without PMS (19).
Magnesium may play a role in the abnormal secretion of melatonin. In 2006,
Billyard et al. (20) conducted studied young male rats to evaluate the effects of a Mgdeficient (150 ppm, n=20) or a Mg-adequate (1000 ppm, n=19) diet on plasma melatonin
levels. After four weeks, the authors found that mean plasma melatonin levels decreased
significantly among animals with the Mg deficient diet (mean=50 pg/mL) as compared to
those with the Mg-adequate diet (mean=75 pg/mL, p=0.01). Although this was a pilot
study, the results show that magnesium can negatively influence plasma melatonin levels
in rats. If this is the case in humans, magnesium could be associated to PMS through its
interaction with melatonin (20).
• Magnesium and glutamate receptor NMDA
Glutamate is an excitatory neurotransmitter inhibited by GABA and also
associated with fast pain conduction. The glutamate receptor N-methyl-d-aspartate
(NMDA) binds to membrane sodium–calcium channels, leading to an influx of
extracellular calcium after activation by glutamate. The actions of the NMDA receptor
are associated with learning, memory and depression (21, 22). Magnesium is a natural
antagonist of the NMDA receptor and blocks the entrance of glutamate to the postsynaptic cells (22).
Several lines of evidence support a relationship between glutamate and PMS, in
which magnesium may play a role. Batra et al.(23) used proton magnetic resonance
spectroscopy to evaluate glutamate levels in the prefrontal cortex during the follicular and
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luteal phases of 12 women with a diagnosis of PMDD and 13 women without PMD, and
found that glutamate levels were lower during the luteal phase as compared to the
follicular phase in both cases and controls (Mean (±SD) glutamate/creatinine levels
during follicular phase were 5.86 (2.3) in controls and 6.14 (1.5) in cases, compared to
levels during luteal phase of 4.85 (1.3) and 4.51 (1.2), respectively, p=0.014). Even
though the differences in glutamate levels were the same in cases vs. controls, this study
suggests that there is an association of glutamate levels with hormonal fluctuations of the
menstrual cycle. Other studies (24, 25) have suggested that glutamate levels in the brain
are associated with major depression, a disorder that could have a similar underlying
mechanisms to PMS. Finally, PMS has been successfully treated with selective serotonin
reuptake inhibitors (1, 26, 27) which, in addition to inhibiting serotonin reuptake, may
act as antagonists of the glutamate NMDA receptor (28). Other NMDA antagonists such
as ketamine may have antidepressant effects (29). Magnesium may play a role in PMS by
blocking the NMDA receptor and thereby acting as an antidepressant.

b) Zinc
Zinc (chemical symbol: Zn) is highly concentrated in the brain, particularly in the
hippocampus and the amygdala, and it is believed to be involved in neuronal growth and
function (14). The RDA for zinc in adult women is 8mg/day, and best food sources of
zinc are red meats, liver and shellfish (14, 15). Because zinc transport between the
plasma and the brain is strictly regulated by the blood-brain barrier, brain zinc
homeostasis is not easily disrupted by dietary zinc deficiency. However, chronic zinc
deficiency may reduce zinc concentrations in the hippocampus, induce abnormal
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glucocorticoid secretion, and elicit neuropsychological symptoms such as isolation and
depression. Zinc deficiency can also aggravate glutamate excitotoxicity in the presence of
neurological diseases (30).
In presynaptic neurons in the brain, free zinc is translocated to glutamate vesicles,
and co-released with glutamate after depolarization of the membrane. Free zinc and
glutamate bind to allosteric sites on the subunits of the NMDA receptor. Zinc binding to
the NMDA receptor inhibits its activity (31, 32). Like magnesium, zinc may have an
antidepressant effect by blocking the NMDA receptor. Certain subtypes of NMDA
receptors (NR1/NR2A) have a higher affinity for zinc than others (NR1/NR2B) which
suggests that the role of zinc is specific to some neurons (33).

c) Manganese
Manganese (chemical symbol: Mn) is an essential trace element required for
many enzymatic and redox reactions. It is involved in a variety of cellular functions
including brain energy metabolism, cartilage formation and reproduction. Food sources
include unrefined cereals, nuts, tea and leafy vegetables (14). After ingestion, dietary
manganese is transported to the liver, and then crosses the blood-cerebrospinal fluid
barrier bound with transferrin. Brain permeability to manganese is higher than to iron and
zinc (30). Though uncommon in humans, manganese deficiency in animals is associated
with poor growth, impaired glucose tolerance, reduced reproduction and malformation of
offspring.(34) Low levels of manganese in humans may be associated with epilepsy.(35)
There is no recommended dietary intake (RDA) for manganese but the adequate intake
(AI) is 2.3 mg/day for adult women. The upper tolerable level (UL) for manganese is 11
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mg/day.(15) This level may be reached by individuals consuming western vegetarian
diets.(34) High manganese exposure through parenteral nutrition and toxic pollutants is
associated with neurotoxicity (36). Manganese toxicity is called manganism, and
symptoms include fatigue, headaches, sleep disturbances, reduced coordination,
hallucinations and mental irritability (36).
Manganese is present in the substantia nigra and striatum in the brain, where most
GABAergic neurons are also present. The vast majority of brain manganese is present in
astrocytes associated to glutamine synthetase. This enzyme catalyzes the conversion of
glutamate into glutamine, thereby removing the excitatory neurotransmitter from the
extracellular space. In addition, manganese is present in presynaptic cells inside the
glutamate vesicules. Manganese possibly activates the voltage dependent calcium
channels, leading to release of glutamate and GABA from the presynaptic cells (30). As
mentioned before, the GABA system may be associated with PMS, as neurosteroids
generated by the corpus luteum interact with GABA receptors and women with PMS may
have a lower sensibility to them (37).

d) Potassium and sodium
Potassium (chemical symbol: K) is a mineral widely distributed in fruits and
vegetables. It is a mainly intracellular cation, and it is required for many cellular
functions, such as protein synthesis and the control of intracellular fluid volume (14). The
adequate intake (AI) is 4700 mg/day for adults (15). To date, there is no evidence that
high levels of potassium from foods have adverse effects.
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Sodium (chemical symbol: Na) is mainly consumed as sodium chloride (table
salt). Sodium is the main determinant of extracellular fluid volume (14). The AI for adult
women is 1.5 g/day (65 mmol/day), equivalent to 3.8 g of table salt per day (15).
Potassium and sodium may play a role in PMS symptoms like swelling and
bloating though their interaction with aldosterone, a mineralocorticoid shown to fluctuate
across the menstrual cycle (6, 38, 39). A potassium channel called TREK-1 has been
identified as a potential target for antidepressant drugs (40), which are recommended for
PMS treatment. To date, the effects of dietary intake of potassium and sodium on PMS
are still unclear.

• Potassium and TREK-1 in depression
TREK-1 is a potassium two-pore channel that acts as an outward rectifier of the
membrane potential contributing to repolarization of the cell by moving potassium
cations from the intracellular space to the extracellular space (41). TREK-1 is abundant in
GABA neurons in the caudate nucleus and putamen and in serotoneric neurons of the
dorsal raphe nuclei.(41, 42) TREK-1 regulation is still under study but it may be blocked
after phosphorilation by protein kinase A (PKA). In the raphe nuclei cells, activation of
the serotonin receptor 5-HTA1 leads to decreased activity of PKA and increased activity
of TREK-1. In consequence, there is hyperpolarization of the cell and decreased
serotonin release. SSRIs may inhibit TREK-1, and therefore not only reduce serotonin
reuptake but also increase serotonin release (41). In 2006, Hearteaux (42) conducted a
study in TREK-1 -/- knockout mice and normal mice (wild type). Using the forced swim
test to measure depression, the authors found that the TREK-1 -/- mice demonstrated less
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depressive behavior than the wild type mice. The authors concluded that deletion of the
TREK-1 gene led to increased efficiency of serotonin transmission and resistance to
depression (42).
Serotonin levels may be lower during the luteal phase of women with PMS (43), and
SSRIs have shown to be efficient in reducing PMS symptoms (1, 26, 27). Although the
potassium channel TREK-1 in the brain may play a role in the metabolism of serotonin
and in the pharmacologic mechanisms of SSRIs, the effects of dietary potassium on this
receptor have not been studied to date.

• Potassium, sodium and aldosterone
Potassium and sodium balance is regulated by the renin-angiotensin-aldosterone
system (RAAS). Renin is secreted and released by the kidneys in response to low arterial
pressure. In the liver, renin stimulates the conversion of angiotensinogen into angiotensin
I and angiotensin II. Release of these hormones leads to vasoconstriction and increased
blood pressure. In the adrenal glands, angiotensin II stimulates the secretion of
aldosterone, a mineralocorticoid that increases sodium and water reabsorption and
stimulates potassium secretion in the kidneys. Excess potassium intake leads to higher
levels of aldosterone and therefore to a higher urinary potassium excretion (14, 18).
Some studies have found that aldosterone levels are higher during the luteal than
during the follicular phases of normal premenopausal women.(6, 38, 39) For example, in
a study by Fommei et al.(2009) (39), 26 women aged 21 to 55 years with mild
hypertension and low renin levels provided plasma samples on the 7th, 14th, 21st, and 28th
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day of their cycles. The authors found that aldosterone levels increased from 11.2 ng/100
ml at day 7 (follicular phase) to 17.8 ng/100 ml at day 21 (luteal phase, p=0.004).
Because aldosterone is associated with water and sodium retention, high secretion of
aldosterone during the luteal phase has been postulated as a contributor for symptoms of
PMS such as swelling of extremities and abdominal bloating (3).
High dietary intake of potassium, and to a lesser extent sodium, increases the
levels of aldosterone secretion (18) but the effect of these minerals may vary by
menstrual cycle phase. For example, Szmuilowicz et al.(6) conducted a randomized
clinical trial among 60 women aged 25 to 41 years receiving either a high sodium (200
mEq) or a low sodium diet (10 mEq) for 7 days. The authors found that among women
with the high sodium diet, urinary and serum aldosterone were significantly greater
among those who were in the luteal than to those who were in the follicular phases (Mean
urinary aldosterone, 16.5 µg/24 hr during the luteal phase and 8.5 µg/24 hr during the
follicular phase, p<0.05), and that progesterone levels were positively correlated with
aldosterone levels (r=0.65, p <0.001). No differences were shown among those with a
low sodium diet (Mean urinary aldosterone, 78 µg/24 hr during the luteal phase and 76
µg/24 hr during the follicular phase, p<0.05).
Spironolactone, an aldosterone agonist, has been shown to reduce PMS symptoms
in some studies(44, 45), but not in all (46). In 1995, Wang et al.(44) conducted a crosssectional study among 35 women aged 25 to 45 years with a diagnosis of “late luteal
phase dysphoric disorder” .(47) Participants received 100 mg spironolactone (n=17) or
placebo (n-16) from day 14 of the cycle for 3 cycles, and then crossed over to the other
group for another 3 cycles. At the end of the first 3 cycles, women randomized with
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spironolactone had a significant decrease in all premenstrual symptoms as compared to
women assigned to placebo (Mean (SE) negative affective and somatic symptom scores
were 11.1 (0.3) and 4.7 (0.2) for spironolactone group, while mean (SE) respective scores
were 12.1 (0.4) and 6.2 (0.2) for the placebo group, p<0.001), and their symptoms did not
worsen after changing to placebo. Women who crossed over from placebo to
spironolactone reported a significant decrease in negative mood and somatic symptoms
(F (5, 1526) = 7.12 and F (5,1514) = 4.97, for summarized negative and somatic
symptom scores, p < 0.001) after three months.
In conclusion, potassium and sodium may play a role on PMS through their
interactions with the TREK-1 receptor and the RAAS system. The potassium TREK-1
channel has been associated with depression, and TREK-1 agonists have been used as
antidepressants but the effects of dietary potassium on this receptor are unknown.
Aldosterone may be increased during the luteal phase, which leads to water and sodium
retention and potassium secretion. Aldosterone antagonists, such as spironolactone, may
reduce PMS symptoms. Potassium and sodium from the diet may act as aldosterone
agonists, but their particular role in PMS remains unknown.

e) Copper
Copper (chemical symbol: Cu) is a transition metal that is a cofactor in a variety
of reactions. It is the third most abundant metal in the body after iron and zinc. Copper is
required for immune cell differentiation, iron metabolism, collagen formation, and the
synthesis of dopamine and melanin.(11) The RDA for copper is 0.9 mg/day for adult
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women, and the UL is 10 mg/day.(12) Food sources of copper include shellfish, nuts,
legumes and the bran portions of grains. Copper interacts with the absorption of iron and
manganese.(11)
Patients with Wilson’s disease, a genetic disorder where copper is accumulated in
the liver, cornea and brain, have symptoms of depression, anxiety and personality
changes, which suggest a disruption of the serotonergic system. In a study by Jones et
al.(2007),(48) rat pheochromocytoma cells (PC12) were used as model neuronal cells to
evaluate the interactions between copper and serotonin in vitro. The authors found that
copper addition caused a 32% reduction in the survival of serotonin-cultured
undifferentiated cells, possibly due to oxidation of serotonin molecules. In differentiated
cells, there was no reduction in the survival of cells by the interaction of copper with
serotonin.

f) Iron
Iron (chemical symbol: Fe) is required for oxygen transport and metabolism, and
is a cofactor for the enzyme tryptophan hydroxylase, required in the synthesis of
serotonin from tryptophan.(49) Many areas in the brain are rich in iron, but particularly in
the cells that receive input from the GABA system, suggesting a functional association
(50). Rodents fed with iron deficient diets have shown altered GABA metabolism (51,
52). Nevertheless, the role of iron deficiency in serotonin and GABA metabolism in
humans is still under study (49).
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In 2008, Anderson et al.(52) evaluated the effects of dietary iron (Fe) and
manganese (Mn) on the GABA system. Fourty-one male rats were treated with one of
four diets: 1) Iron deficient diet ( 6 mg Fe/kg), 2) Iron adequate diet (35 mg Fe/kg), 3)
Iron deficient diet + manganese (1g Mn/l of drinking water), and 4) Iron adequate diet +
manganese. The authors found that animals in the ‘iron deficient diet + manganese diet’
exhibited increased concentrations of extracellular GABA and a decrease in GABA-B
receptor expression as compared to those on the other diets. This study shows that there is
an interaction between manganese intake, iron and the neurotransmitter GABA, which
has been previously associated with the pathophysiology of PMS.
Iron deficiency is the most common single-nutrient deficiencies, and as many as
50% of women of reproductive age in the entire world may suffer from it (50). The RDA
for iron among women aged 18 to 50 years is 18 mg/day, but the median intake of
women of reproductive age in the U.S from 1999 to 2000 was 11.6 mg/day (53).
Symptoms of iron deficiency include impaired physical work performance, depressed
immune function and cognitive impairment (49, 54).

g) Summary
Because PMS is characterized by a variety of symptoms, many systems may be
involved in its pathophysiology. Magnesium, zinc, copper, manganese, iron and
potassium are important cofactors in many reactions associated to neurotransmitter
metabolism involved in PMS pathophysiology such as GABA, melatonin and serotonin.
Additionally magnesium and zinc interact with the glutamate receptor NMDA, associated
with depression. Potassium and sodium are involved in the regulation of extracellular and
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intracellular fluid balance and may therefore be associated with symptoms related to
water retention. Nevertheless, the pathophysiology of PMS is still under study, and the
role of these minerals on PMS development is unclear.

3.1.3 Epidemiologic Research
To date, only magnesium(55-59), manganese (60), and potassium(61) have been
studied as potential treatments for PMS. Zinc has been studied in relation to depression
and affective symptoms (9, 13, 32, 62). Copper and iron have been studied in relation to
post-partum depression (PPD) (11, 63), which is characterized by the presence of
depression symptoms such as sleep disturbances, lack of appetite, lack of energy,
depressed mood, during most of the day every days for two weeks or more beginning
within 4 weeks of delivery (64). The underlying causes of PPD are under study, but onset
is likely triggered by the rapid decline in reproductive hormones levels after delivery
(65). As premenstrual syndrome is also associated to changes in reproductive hormones,
these two disorders may share the same underlying risk factors. Moreover, some studies
(66) have found that premenstrual dysphoric disorder is a risk factor for PPD .
a) Magnesium
To date, there are no prospective studies on the effects of magnesium on
prevention of incident PMS. One cross-sectional study (8) but not another one (56) found
that magnesium levels are lower in women with PMS compared to those without PMS.
Other clinical trials have evaluated the effects of magnesium supplementation on PMS
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symptoms, with beneficial (55, 59) or null results (56, 58), though one study found that
placebo is better than magnesium in relieving PMS symptoms (57).
The most recent clinical trial of magnesium supplementation in PMS was
conducted by Quaranta et al.(55) among 40 Italian women aged 18 to 45 years. All
participants had PMS, defined by a score higher or equal to 25 on the Moos’ Modified
Menstrual Distress Questionnaire (MMDQ). After 3 months of observation, participants
were instructed to take 250 mg of magnesium beginning 20 days after the start of the last
menstruation and continuing until the start of the next menstrual period for the next 3
months. During the observation and treatment periods participants completed a daily
symptom diary, and at the end of each treatment period, participants compared their
symptoms to the MMDQ rating scale (self-assessed MMDQ). Participants also completed
interviewer-administered MMDQ questionnaires at screening visits before and after the
treatment period. At the end of the treatment period, there was a 35% reduction in the
mean total interviewer-assessed MMDQ score (mean ± standard deviation (SD) = 19.7 ±
7.6) compared to baseline (mean ± SD = 30.5 ±4.5, p<0.0001). In addition, there was a
43.5% decrease in mean total self-assessed MMDQ score (mean ± SD = 17.9 ± 7.3)
compared to baseline (mean ± SD= 31.8 ± 6.4 respectively, p <0.0001). Side effects were
low, though one patient reported vertigo as a side effect for treatment. Although the
authors found that magnesium decreased the number and severity of PMS symptoms, this
study has several limitations. The study had no control group, as all women received
magnesium. Neither participants nor interviewers were blinded to treatment status.
In 2005, Khine et al.(56) studied the relationship of magnesium and PMS in three
ways. First, the authors conducted a cross-sectional study of magnesium levels in serum,
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red blood cells (RBC) and mononuclear cells (MBC) of women with and without PMDD.
Participants were 17 women aged 27 to 43 years prospectively diagnosed with
premenstrual dysphoric disorder (PMDD) and 14 women aged 20 to 37 years without
PMDD. PMDD was assessed with a completion of a daily visual analogue symptom
rating scale for at least 3 months before entering the study and DSM-IV diagnostic
criteria. Women met criteria for PMDD if they reported an increase of more than 30% in
mean negative mood symptoms in the week before menses compared to the week
following cessation of menses during at least 2 menstrual cycles. The authors measured
serum, RBC and MBC magnesium content at baseline. Both cases and controls had
normal serum total magnesium levels (0.79 mmol/L among cases, 0.75 mmol/L among
controls) and there was no statistically significant difference between serum, RBC or
MBC total magnesium levels between both groups.
The authors then conducted a magnesium loading test to further assess
magnesium status. After the 3 months of the screening period, women of both groups
received magnesium sulfate at a dose of 0.1mmol/kg body infused over 4 hours in 5%
dextrose during the luteal phase of the menstrual cycle. Participants collected 24hour
urine samples before and after each infusion for measurements of total Mg, calcium and
creatinine. Deficiency was assessed by calculating how much of the administered Mg
load was retained, based on the criteria that people in Mg balance should excrete 100% of
the Mg load. Mg deficiency was defined as the retention of more than 30% of the Mg
load. After the Mg infusion, the authors found no statistically significant difference in %
urinary Mg retention between cases (mean± SD =31.5± 25) and controls (mean± SD
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=27.5± 19). These results did not provide evidence of Mg deficiency among PMDD
cases compared to controls (56).
Finally, the authors conducted a cross-over study to assess changes in mood and
behavioral ratings among a sub-group of 10 women with PMDD after magnesium
infusion. Participants were randomized to receive a 4-hour infusion of magnesium sulfate
(dose of 0.1 mmol/kg body in 5% dextrose) or placebo (5% dextrose) during the 8 to 12
days following LH surge and crossed over the other treatment (placebo or magnesium)
for the next cycle. Before and immediately following each infusion, as well as the
morning after, participants completed a variety of mood and behavior questionnaires
including a Premenstrual Tension Scale-Self Rated (PMTS-S) and Premenstrual Tension
Scale-Objective Rated. There was no statistically significant effect of magnesium
treatment on any of the mood symptom measures compared to placebo. For example, for
the PMTS-S questionnaire, participants reported a mean (SD) score of 21.6 (5.4) before
treatment and 13.5 (7.6) after treatment vs. 21.0 (5.5) before placebo and 15.3 (7.5) after
placebo. Overall, in this study the authors found no evidence of magnesium deficiency in
women with PMDD compared to controls, and no beneficial effect of magnesium
infusion on premenstrual symptoms compared to placebo. However, this study has
several limitations. Power in this study was limited for finding differences between
placebo and magnesium infusions given the small sample size. Additionally, magnesium
and placebo supplementation was provided without a washout period in between. The
effects of magnesium acutely infused may be different to long term oral magnesium
intake (56).
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In contrast to these studies, Walker et al. (57) conducted a crossover trial to
evaluate the effect of different doses of daily Mg supplementation on premenstrual
symptoms and had unexpected results. Participants were 85 women with a mean age of
35 years who reported premenstrual symptoms. After one month of observation,
participants were randomized into four groups: three treatment groups receiving different
doses of magnesium (200, 350 or 500 mg of Mg per day, containing 1050, 830 and 717
mg of sorbitol as excipients respectively) and a placebo group (sorbitol 1305 mg).
Participants received one of four potential treatments for two cycles, followed by a
washout period of one cycle without treatment. Then, participants were randomized again
into one of the other treatment or placebo groups for another 2 months. Throughout the
study period, women completed a daily 20-item menstrual diary where they scored daily
symptoms on a 5-point scale (0=none to 4=very severe). Symptoms were classified into
four categories: anxiety, craving, depression and hydration. For each category, symptom
scores during the luteal phase (7 days before menstruation) were compared to scores
during the postmenstrual phase (days 8-14 of the cycle). The authors found that after two
months of supplementation, participants who took placebo had a significant reduction in
anxiety-related and total symptoms as compared to women taking any dose of
magnesium after adjustment for baseline scores. Total scores after the second month were
6.9 for placebo and 10.8, 9.8 and 10.8 for those receiving magnesium a different doses
(p=0.0006). Anxiety scores were 1.7 for placebo and 3.6, 2.8 and 3.2 for magnesium
treatment (p=0.006). The authors suggest that this counterintuitive result may be related
to an influence of sorbitol on magnesium homeostasis in women suffering from
premenstrual symptoms.
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Overall, these three studies reported different effects of magnesium on PMS.
Although Quaranta et al. observed a beneficial effect of magnesium on PMS symptoms,
there was no placebo group and participants were thus unblinded. As suggested by the
results observed by Walker et al., the placebo effect can be substantial. In the crossover
study by Khine et al. magnesium infusion was no better than placebo in ameliorating
mood and behavioral symptoms in women with PMDD. However, this study had a very
small sample size (10 women). Therefore, the effects of magnesium supplementation on
premenstrual symptoms remain unclear.

b) Manganese
To date, only one study has evaluated the effects of manganese on PMS. In this
study conducted by Penland et al. in 1992.(60) ten women who reported the presence of
premenstrual and menstrual symptoms were randomly assigned to one of four diets: 1)
587 mg of calcium and 1.0 mg of manganese/day, 2) 587 mg of calcium and 5.6 mg of
manganese/day, 3) 1336 mg of calcium and 1.0 mg of manganese/day, and 4) 1336 mg of
calcium and 5.6 mg of manganese/day. The duration of the intervention was 39 days.
After the menstrual phase of each cycle, participants completed a ‘Menstrual Distress
Questionnaire’ (MDQ) assessing the presence of 47 symptoms during the premenstrual (7
days before menses), inter-menstrual, and menstrual phases of the most recent cycle.
Symptoms were grouped into eight categories: autonomic reactions, behavior change,
concentration, negative affect, pain, water retention, arousal, and a control group of
symptoms not associated with PMS but found in perimenopausal women. During the
premenstrual phase, women assigned to the low calcium diets reported significant
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worsening of behavior, concentration, negative affect, and water retention symptom
scores, as compared to when they were treated with high calcium diets. There was no
significant difference based on manganese intake, but women consuming the high
calcium low manganese diets had worsening in negative affect scores during the
premenstrual phase (mean MDQ score = 17.6, standard error (SE) = 1.9) compared to
when they consumed the high calcium-high manganese diet (mean MDQ score = 11.5,
SE = 1.8, p < 0.05). There was significant interaction of calcium and manganese for
negative affect symptoms (p = 0.04). Although the authors observed a role of calcium
and manganese on premenstrual affective symptoms, they did not find a beneficial effect
of manganese alone. However, as the authors report, absorption of manganese may have
been blunted due to high iron intakes of the diets (32 mg iron/day) and poor solubility of
the form of manganese selected for the study. Moreover, the intervention periods were of
longer duration than menstrual cycles, with no supplementation-free diet period in
between, which could have led to a carry-over effect from one diet to the others.
Although it is possible that manganese plays a role in PMS, potentially due to its
interaction with other micronutrients, its effects on PMS development remain unstudied.

c) Potassium and sodium
The only study of potassium supplementation and premenstrual symptoms dates
from 1971. In this cross-over study conducted by Reeves et al.(61), 10 women with a
diagnosis of premenstrual tension and 10 women with only mild menstrual ‘complaints’
or no symptoms received 1 mg of potassium chloride or placebo (glucose) for 2
consecutive cycles, and then crossed over to the other treatment. Each day throughout the
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study period, participants recorded their weight and symptoms common in PMS such as
swollen ankles, breast tenderness, bloating, headache, and irritability. Overall, study
participants had an average weight gain of 0.22 lb (standard error (SE) = 0.06) during the
last 5 days of the cycle (p < 0.001). Treatment with potassium produced no substantial
difference in weight gain (mean = 0.21, SE = 0.09) as compared to placebo (mean = 0.19,
SE = 0.09) although no statistical test was conducted to evaluate the differences between
these groups. Furthermore, potassium treatment was not associated with fewer symptoms
after treatment (mean number of symptoms = 12.6) vs. before treatment (mean = 12.3).
Participants receiving placebo reported fewer symptoms (mean = 9.5), but no statistical
test was conducted to evaluate the differences between these groups. The results of this
study are unclear because of the lack of appropriate statistical testing. Therefore, it is
necessary to further evaluate the role of potassium in premenstrual symptoms.
One additional study has tested the effects of potassium along with sodium and
calcium in overall mood. Torres et al.(67) conducted a crossover study among 38 women
and 56 men with average age 56.3 years. The authors tested the effects of four diets: 1) a
high-potassium, high-calcium, moderate-sodium diet based on the Dietary Approaches to
Stop Hypertension diet (OD); 2) a high-potassium diet with lower sodium and potassium
than the OD diet (LNAHK); and 3) a high calcium diet (HC). At baseline all participants
received a control diet (CD) low in potassium, magnesium and calcium for 2 weeks.
Then, participants were randomized to one of the three diets for four weeks, followed by
a washout period of 2 weeks with the CD diet. After this period, participants were
randomized again into one of the remaining test diets. Mood was assessed weekly using
the ‘Profile of Mood States’ (POMS) questionnaire, which rated 37 items on a 5 point
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scale (0 = not at all, 4 = extremely). Every two weeks, 24-hr urinary samples were
collected to assess diet compliance and electrolyte balance. Compared to the control diet,
there was a significant reduction of POMS global scores for the LNAHK diet (POMS
score difference = -3.9, p = 0.02) and for the HC diet (POMS score difference = -2.5, p =
0.04), but no significant difference with the OD diet. Compared to the OD diet, there was
a significant reduction of the POMS global score for participants taking the LNAHK diet
(POMS score difference = -5.4 p < 0.05), but no significant differences with the HC diet.
Additionally, the authors found that urinary sodium excretion was positively associated
with anger and vigor symptoms (r = 0.13 and 0.16 respectively, p < 0.01). Higher urinary
potassium excretion was associated with lower fatigue symptoms (r = -0.17, p < 0.0001).
Overall, the results suggest that a diet high in potassium (LNAHK) improves mood
symptoms as compared to a diet low in potassium (CD), and high potassium intake
reflected in high urinary potassium excretion may lead to lower fatigue. With regard to
sodium, a diet low in sodium (LNAHK) improves mood symptoms as compared to diets
with moderate sodium (OC and CD), and high sodium intake, reflected in high sodium
urinary excretion, is positively correlated with anger and vigor. Overall this study
supports the hypothesis of a beneficial role of potassium and an adverse effect of sodium
on symptoms associated to PMS such as depression, vigor and fatigue.

d) Zinc
Few studies have suggested that women with PMS may have lower levels of zinc
(68) and that zinc serum levels fluctuate during the menstrual cycle (69). However,
several studies have found that people with major depression have lower zinc levels as
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compared to people without depression (9, 70). The effects of zinc supplementation on
mood have been studied recently (62). In addition, zinc has also been considered for
treatment augmentation in treatment resistant depression (13).
One of the most complete studies of zinc status and PMS throughout the
menstrual cycle was conducted by Chuong et al.(68). Cases were 10 women diagnosed
with PMS using prospective charting of presence and severity of 18 symptoms. Controls
were 10 women as controls who reported absence of significant symptoms. Participants
were required to not consume vitamin, mineral or herbal supplements two months before
the study period. Since the day 1 of the cycle, and every 2 to 3 days, blood samples were
collected from all participants for 3 menstrual cycles. Luteinizing hormone (LH) was
measured to estimate timing of the luteal and follicular phases. Samples from 14 to 3
days before the surge of LH were considered as follicular phase samples, and their
average values for the 3 cycles were calculated for each woman. Luteal phase values
were an average between days 3 to 14 after the LH surge. In cases, serum zinc levels
during the luteal phase were significantly lower than during the follicular phase (mean ±
SE = 90.3 ± 4.1 µg/dL vs. 100.2 ± 3.6 µg/dL, p < 0.05), and significantly lower than
serum zinc luteal phase levels in controls (mean ± SE = 107.8 ± 7.8 µg/dL, p < 0.05).
Follicular zinc levels in controls were not significantly different from the luteal phase
levels (mean ± SE = 102.6 ± 7.1 µg/dL). Additionally during the luteal phase, copper
levels were significantly higher in cases compared to controls (mean ± SE = 106.3 ± 3.3
µg/dL vs. 96.2 ± 2.1 µg/dL, p < 0.05), but there was no significant difference with the
respective follicular phases. Although this study had a very small sample size, it suggests
that zinc levels are lower in women with PMS during the luteal phase. Moreover, serum
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copper levels are elevated during the luteal phase (68) and may have affected zinc status,
as copper is known to interfere with zinc absorption.(14) Nevertheless, it is possible that
during the luteal phase women with PMS may have different dietary intakes of certain
foods because of their symptoms, which include cravings.
A most recent cross-sectional study was conducted by Amani et al. (2009)(9)
among Iranian female university students aged 20 to 25 years to the correlation of serum
zinc concentrations and dietary zinc intake with depression scores. First, 308 students
were screened for major depressive disorder (MDD) using Beck’s Depression Inventory
(BDI). From this group, 23 students were identified as having moderate to severe
depression (BDI score > 19) and were selected as cases. Controls were 23 students
matched by age, who reported no history of depressed mood. All participants completed
a 12-item FFQ and a 24 hr diet recall to assess daily and weekly consumption of zinc
from food sources. Additionally, participants provided blood samples for measurement of
serum zinc concentrations. The authors found that women with MDD had significantly
lower serum zinc concentrations (mean ± SD = 79.6 ± 30.7 µg/dL) as compared to
controls (mean ± SD = 111.6 ± 21.9 µg/dL, p < 0.001). There was a statistically
significant inverse linear correlation between BDI scores and zinc serum levels among all
participants (r = -0.65, p < 0.001), which was stronger among cases (r = -0.71, p < 0.001).
Moreover, 23% of cases but no controls had serum zinc concentrations < 70 µg/dL and
were classified as having zinc deficiency. Dietary zinc intake was also substantially
lower among cases (mean ± SD=1.97 ±0.5 mg/day) as compared to controls (mean ± SD
= 2.93 ± 0.9 mg/day, p < 0.001). Specific zinc-rich foods that were less commonly
consumed by cases as compared to controls were red meat and chicken (p < 0.0001).
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However, because of the cross-sectional nature of this study, it is not possible to
determine whether zinc deficiency contributed to the development of depression, or
whether it was a consequence of decreased appetite, a common symptom of depression.
Recently, Sawada et al. (2010) (62) conducted a small clinical trial of Zn
supplementation among healthy Japanese women aged 18-21 years old. Participants were
randomized to receive multivitamin capsules alone (n=16) or multivitamins and 7 mg of
zinc (n=15) for 10 weeks. The multivitamins contained vitamins A, D, B6, B12, thiamin,
riboflavin, niacin and folic acid in concentrations that were 50% of the Japanese
recommended dietary allowance. Psychological tests included the Japanese versions of
the Cornell Medical Index (CMI) and the Profile of Moods State (POMS). After the
intervention, serum Zn levels were significantly increased among those who received
zinc and multivitamins (0.92 µg/ml compared to 0.84 µg/ml at baseline, p = 0.01),
whereas those who received only multivitamins did not change their serum zinc levels
significantly. Among women who received zinc and multivitamins, the CMI assessment
suggested an improvement of somatic symptoms (19.1 post-intervention compared to
25.5 at baseline, p = 0.07), but no improvement of psychological symptoms. Using the
POMS assessment, there was a significant improvement of depression-dejection
symptoms (15.1 post-intervention compared to 19.6 at baseline, p < 0.01) and an
improvement of anger-hostility symptoms (8.4 post-intervention compared to 11.7 at
baseline, p = 0.01) but no improvement of vigor, fatigue, confusion, and tension-anxiety
symptoms. Using Mann-Whitney tests to compare changes from baseline among both
groups, the authors found no statistically significant difference between scores in both
groups. To our knowledge, this is the first study to evaluate the effects of zinc
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supplementation on mood of healthy premenopausal women. Although the authors did
not report a statistically significant improvement of mood symptoms as compared to
placebo, they found a significant effect of zinc supplementation on somatic, depression
and anger symptoms as compared to baseline (62). The use of multivitamins containing
vitamin B6, folate and vitamin B12 as a placebo could explain the lack of statistically
significant differences between both groups.
Siwek et al.(13) conducted a randomized clinical trial among 60 men and women
aged 18 to 55 years diagnosed as having unipolar major depression according to the
DSM-IV criteria. Participants were randomized to receive either placebo (n = 30) or
supplements with 25 mg of Zinc (n = 30) daily for 12 weeks. During the study period,
both groups were treated with 100-200 mg of imipramine, a tricyclic antidepressant.
Depression status was evaluated before treatment and at weeks 2, 6 and 12 of treatment
using the ‘Hamilton Depression Rating Scale’ (HDRS), Beck Depression Inventory
(BDI), Clinical Global Impression (CGI) and Montogomery-Asberg Depression Rating
Scale (MADRS). Based on reaction to prior depression treatments, participants in both
groups were sub-classified as ‘treatment resistant’ and ‘non-resistant’. The authors found
that treatment with imipramine and zinc resulted in improvements HDRS, BDI, CGI and
MADRS scores as compared to imipramine and placebo. All groups had a significant
improvement in scores by week 2. Treatment-resistant patients who received imipramine
and zinc (n = 12) had lower depression scores (mean BDI for weeks 2, 6 and 12 were 25,
17 and 10) than those who received imipramine and placebo (n = 10, mean BDI scores
were 31, 30 and 18, for respective weeks, p < 0.05 at any given point). Furthermore,
treatment-resistant patients receiving imipramine and zinc had scores similar to those
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who were not treatment resistant. Among non treatment-resistant patients, there were no
significant differences in any scores between zinc- or placebo- supplemented therapy.
Overall, this study suggests that zinc supplementation in addition to imipramine improves
depression symptoms among treatment-resistant patients.
These studies show that there is a potential role of zinc in mood and affective
symptoms, though the effects of zinc supplementation in PMS remains unknown.

e) Copper
Copper levels may be higher in women with PMS as detailed previously in the
study by Chuong et al. (68). Copper levels have also been studied in women with
PPD,(54) which likely has a similar pathophysiology to PMS, as both disorders are
related to changes in reproductive hormone levels (65, 66).
In 2007, Crayton et al. (63) conducted a cross-sectional study among patients of
the Pfeiffer Treatment Center. Cases were 226 women diagnosed with depression. Of this
group, 78 had history of PPD and 148 had no history of PPD. Controls were 28 women
without history of psychiatric problems who were participating in a wellness program at
the clinic. Blood samples were collected from all study participants to assess copper and
zinc levels. The authors found that women with a prior history of PPD had higher serum
copper levels (mean = 131 µg/dL) than non depressed women (mean = 106 µg/dL, p <
0.001) and higher levels than depressed women without history of PPD (mean = 111
µg/dL, p < 0.001). There was no significant difference between zinc levels in any group.
A particular limitation of this study is that women participating in this study may have
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had PPD months or years prior to the collection of blood samples. The time range
between PPD and sample collection was not taken into account for the analyses. Because
samples were collected after PPD diagnosis, copper elevation could be a result of
treatment instead of cause of disease. Another limitation is that free copper measured in
this group may not reflect copper status (71).
Although copper levels have a potential correlation with PMS and PPD, the role
of copper in PMS development remains unknown.

f) Iron
To date, there are no studies of dietary iron intake and PMS. In a study by
Shamberger et al.(1996) (10) among 46 women with PMS diagnosis and 50 women
without PMS as controls, iron levels in hair were significantly lower in PMS patients than
in controls (mean ± SD = 5.5 ± 3.8 ppm among cases and 8.4 ± 5.7 ppm among controls,
p-value < 0.03), but no statistically significant differences were observed in red blood cell
levels (mean ± SD = 692 ± 134 ppm among cases and 696 ± 107 ppm among controls).
However, this was a cross-sectional study and iron measurements in hair are not as
representative of iron levels in the body as ferritin.
Some studies have evaluated the association between ferritin levels and postpartum depression (11, 72). In a recent study conducted by Alcabar et al. (11) in Spain,
729 women were followed from childbirth for two years. Several iron status markers
were measured 40 hours after delivery, and participants replied to depressive
questionnaires 48 hours, 8 weeks and 32 weeks after delivery. From this sample, 9% of
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women developed PPD during the 32 week postpartum period, and had lower serum
ferritin concentrations (mean (SD) = 15.4 (12.7) µg/L) compared to the rest of the
participants (mean (SD) = 21.6 (13.5) µg/L, p=0.002) . This study shows that iron
deficiency may play a role in depressive disorders associated with hormonal changes.
Nevertheless, the role of iron in PMS remains unstudied.

g) Summary
To date, the effects of dietary intake of manganese, magnesium, potassium,
sodium, zinc and copper on incident PMS are unknown. Magnesium is the mineral most
studied with regards of PMS. Although it has been suggested that magnesium levels are
lower in women with PMS, a magnesium load test found no differences in magnesium
levels between women with PMDD and women without PMDD (56). Several randomized
clinical trials (55-59) have evaluated magnesium as a treatment for symptoms with mixed
results. One study evaluated the effects of manganese and calcium supplementation on
PMS symptoms, and although it did not find significant improvement of symptoms with
manganese, it found a significant interaction between manganese and calcium (60). A
study evaluating the effects of potassium on PMS symptoms and weight gain did not
observe a significant benefit (61). A study of dietary intakes of different combination of
electrolyte levels found that diets high in potassium and low in sodium resulted in
improved depression symptoms, less fatigue and higher vigor compared to diets low in
potassium and moderate in sodium (67). Women with PMS may have higher copper and
lower zinc serum levels during the luteal phase as compared to women without PMS
(68). One study found that copper levels were elevated in women with PPD, and in
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consequence may be associated as well with PMS symptoms (63). The roles of these
minerals in incident PMS remain to be studied.

3.1.4 Summary
Although PMS affects a substantial number of women of reproductive age, there
is no clear understanding of its pathophysiology and effective treatments are still under
study. Current recommended pharmaceutical treatments are associated with substantial
side effects, and certain micronutrient supplements have been studied as alternative
treatments. Moreover, because mineral deficiency has been associated with PMS,
minerals from dietary and supplementary sources could prevent PMS in some women.
Magnesium and zinc are antagonists of the NMDA receptor of glutamate.
Glutamate is an excitatory amino acid, but its receptor activity has been associated with
depression (33). Magnesium and zinc may have the same mechanism of action as many
antidepressants, through inhibition of the NMDA (31, 73). Additionally, magnesium is
required for the formation of melatonin from serotonin. Women with PMS may have
altered melatonin metabolism leading to an earlier ‘phase’ secretion and overall lower
serotonin levels (19). Manganese and iron deficiency has been associated with lower
GABA levels and decreased expression of the GABA-B receptor (52). Copper has been
associated with serotonin oxidation (48).
Potassium and sodium are associated with PMS through their interaction with the
renin-angiotensin-aldosterone system. Women with PMS may have higher levels of
aldosterone during the luteal phase than women without PMS (6). High potassium intakes
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from diet are controlled by increased aldosterone levels, which lead to increased sodium
reabsorption and potassium secretion in urine. Sodium reabsorption leads to extracellular
water retention, and is associated with edema and bloating, which are common PMS
symptoms (18). Additionally, the action of potassium channels influences serotoninergic
function, but the role of dietary potassium on these is unknown (42).
To date, there are no prospective studies of the effects of these minerals in the
development of PMS. Some studies(8, 56, 68, 69) have found that magnesium, zinc, and
copper blood levels vary throughout the menstrual cycle in women with PMS.
Magnesium supplements have been studied as potential treatments, with mixed results
(55-57, 59). Manganese has shown no direct effect on PMS but potentially an interaction
with calcium to reduce symptoms (60). Only one study evaluated the effects of potassium
chloride in PMS, with no significant difference in PMS symptoms compared to placebo
(61). Copper and iron have been studied in post-partum depression (PPD), a disorder also
associated with increased sensitivity to gonadal hormones changes, suggesting an
association with copper levels(63) and an inverse association with ferritin levels (11). In
normal women, zinc supplements did not show improvement of mood compared to
multivitamins only. However, zinc supplementation has shown beneficial effects in
patients with treatment resistant-depression when given in conjunction with imipramine,
a tricyclic antidepressant (13).
Overall, the role of minerals in PMS is still unknown but because of all the
potential role of magnesium, zinc, copper, manganese, potassium, sodium, and iron in
PMS, it is important to evaluate whether intake of these minerals affect PMS
development in the following years.
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3.1.5 Specific Aims and Hypotheses
Specific Aim:
To examine the relationship between magnesium, zinc, copper, manganese, potassium,
sodium, and iron intake and the development of premenstrual syndrome among a subset
of women participating in the Nurses’ Health Study II.

Secondary Aims:
1) To evaluate the effects of magnesium, zinc, copper, manganese, potassium,
sodium and iron intake from food sources 2 to 4 years before reference time on
the development of PMS.
2) To evaluate the effects of magnesium, zinc, copper, manganese, potassium,
sodium and iron intake from supplement sources 2 to 4 years before reference
time on the development of PMS.
3) To evaluate effect modification of the association between these minerals and
PMS by age, body mass index (BMI), alcohol and smoking.

Hypotheses:
There is an inverse relationship between dietary intake of magnesium, manganese,
potassium and zinc and the risk of developing premenstrual syndrome. High intakes of
sodium and copper are associated with increased risk of developing premenstrual
syndrome.
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Age, BMI, alcohol and smoking status do not modify the relationship between
magnesium, manganese, potassium and zinc and the risk of developing premenstrual
syndrome.

3.2 Methods

3.2.1 Study Design and Population
The Nurses’ Health Study II (NHS II) is a prospective cohort of 116,678 female
US registered nurses, who replied to a mailed questionnaire in 1989 when they were 25 to
42 years old. Information regarding various lifestyle factors and medical conditions has
been collected by mailed questionnaire every 2 years. The response rate for each
questionnaire cycle has been ≥89%.
The establishment of the NHS II PMS Sub-study has been described in detail in
chapter 2. From among all NHS II participants who had not reported a diagnosis of PMS
in 1989 or 1991, 3,430 women reported a new clinician-made diagnosis of PMS on an
NHSII questionnaire between 1993 and 2001. The diagnosis year was assigned as the
‘reference year’ and it was used to determine eligibility for the study, as well as to assess
menstrual symptom experience and diet. The authors then identified 2,570 women who
did not report a diagnosis of PMS at any time between 1989 and 2001 to serve as
potential controls. For these women, a randomly chosen year between 1993 and 2001 was
assigned as their reference year.
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To prevent the inclusion of women with menstrual symptoms attributed to causes
other than PMS, women with a diagnosis of cancer, endometriosis, usual irregular
menstrual cycles or infertility before their reference year were excluded from the initial
selection of participants. Women who had a hysterectomy or who had reported
menopause were excluded to ensure participation of only premenopausal women.
Because the study was designed to focus on dietary factors and PMS, participants who
did not complete the food frequency questionnaires (FFQs) in 1991 and 1995 or who
reported an implausible total calorie intake (<500 and ≥ 3500 cal/day on their FFQ) were
also excluded from the study.

3.2.2 Exposure Assessment
To evaluate individual intake of selected nutrients, NHS2 participants completed
a semi quantitative food frequency questionnaire (FFQ) in 1991, 1995 and 1999.
The FFQs included 133 items, with a standard portion size for each, which aimed
to reflect natural portion sizes whenever possible (e.g. a slice of bread, an egg, a fruit).
Participants were asked how often they consume the specific food item, on average, with
9 response options: ">6 per day", "4 to 6 per day", "2 to 3 per day", "1 per day", "5 to 6
per week", "2 to 4 per week", "1 per week", "1 to 3 per month" and "never or less than
once per month".
Additionally, the FFQ included questions about types of fat used, brand and type
of cold cereal consumed, and supplements used. For supplement use, participants were
asked to report whether they currently took multivitamins, how many they took per week
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(<2, 3-5, 6-9, ≥10 tablets) and the specific brand used. Additional questions on regular
use of supplements or multivitamins (yes/no) were also included. Specific use of
magnesium and potassium supplements was measured on all questionnaires. A question
about zinc use and dosage (<25, 25–74, 75-100, ≥101 mg/day) was included on the
questionnaires of 1991, 1995 and 1999. Iron use and dosage was included on
questionnaires in 1991 (<51, 51–200, 201-400, ≥401 mg/day) and in 1995 (<41, 41–80,
81–150, ≥151 mg/day).
The total intake of each mineral was calculated multiplying the relative frequency
of consumption of each food item (converted to number of servings per day) by the
nutrient content of the specified portion size, according to the United States Department
of Agriculture database and manufacturers sources as needed. Finally, adjustment for
total calorie intake was performed using the residual method (74).

Validity and Reproducibility of Exposure Assessment:
The validity and reproducibility of the FFQ designed by Willett et al. has been
widely studied before (75, 76). In 1992, Rimm et al.(75) conducted a validation study of
this FFQ among 127 men, members of the Health Professionals Follow-up study cohort.
Participants completed two FFQS between 1996 and 1988, separated by one year. Two
one-week diet records were collected between those years, separated by 6 to 7 months to
capture seasonal variability. Participants were given a dietetic scale and trained by a
dietitian for weighing and recording all foods consumed during 7 days. Diet records
were used as a "gold" standard because they are minimally dependent on memory and
allow direct measurement of food quantities. Nutrient scores were calculated for each
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questionnaire and for the diet records and were adjusted for total calorie intake based on
the residual method.
Reproducibility was measured by comparing nutrient scores from both
questionnaires. Intraclass correlation coefficients were 0.72 for magnesium, 0.53 for
sodium, 0.60 for potassium, and 0.64 for zinc. Validity was measured by comparing
nutrient intake assessed by the FFQ to the nutrient intake assessed by the average nutrient
score of the one-week diet records. Correlation coefficients for the second FFQ corrected
for within-person variability assessed by the diet records were 0.71 for magnesium, 0.60
for sodium, 0.73 for potassium and 0.71 for zinc.
Participants’ nutrient scores from the questionnaire and the mean of the two oneweek diet records were categorized into quintiles to evaluate the degree of
misclassification. Among participants classified in the lowest quintile of magnesium
according diet records, 48% of them were also in the lowest quintile according to the
questionnaire, and 72% were in the two lowest quintiles. Among the participants
classified in the highest quintile of magnesium intake according to diet records, 44%
were in the highest quintile and 68% in the two highest quintiles according to the
questionnaire. Results were similar for sodium, potassium and magnesium.
In conclusion, the reproducibility and validity of nutrient scores for
micronutrients calculated from the food frequency questionnaire were found to be
acceptable (75). The validity and reproducibility of this questionnaire is likely to be
similar in our population of U.S. female nurses.
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3.2.3 Outcome Assessment
Case and control status was ascertained in 2002 using information from a
supplementary menstrual symptom questionnaire based on the Calendar of Premenstrual
Experiences designed by Mortola et al.(77) as detailed in the previous chapter. Briefly,
sub-study participants (i.e., 3430 women who reported a diagnosis of PMS made by a
clinician between 1993 and 2001 and 2570 women who did not report a diagnosis of
PMS) reported the presence of any of 26 specific symptoms for at least several days each
month, most months of the year in the specific 2 years before their individual reference
year. The questionnaire included questions about the age at which symptoms started,
timing of symptom onset and cessation during an average menstrual cycle, as well as the
severity of the symptoms and their interference on personal relationships, social
functioning and work-related activities. This questionnaire was completed by 86.5% of
the potential cases (n=2966) and 97.4% of the potential controls (n=2504).
Validated PMS cases were self-reported cases who met the following criteria
based on those proposed by Mortola in 1990 (77).
1) Occurrence of at least 1 physical and 1 affective menstrual symptom;
2) Overall symptom severity moderate or severe, or the effect of symptoms of life
and social relationships classified as moderate or severe;
3) Symptoms beginning within 14 days of the onset of menstruation;
4) Symptoms ending within 4 days of the onset of menstruation; and
5) Symptoms absent in the week after end of menses.

166

From the 2966 potential cases who replied to the questionnaire, 1057 women (35.6%)
met these criteria.

Validated controls were women not reporting PMS during the follow-up who met the
following criteria:
1) Complete absence of symptoms or only mild symptoms
2) Mild overall symptom severity
3) No substantial effect on life activities and interpersonal relationships
4) Confirmed no diagnosis of PMS.

From the 2540 potential controls who replied to the questionnaire, 1968 women (78.6%)
met these criteria.

Validity of outcome assessment
The validity of this approach for assessing PMS symptoms was evaluated
previously by Bertone-Johnson et al.(78) and detailed in the previous chapter. Briefly, the
validation study included only those participants from the PMS Sub-study who reported a
diagnosis of PMS for the first time in 2001 (n=138) and controls whose reference year
was 2001 (n=377). They concluded that women who did not report prospective symptom
charting as part of their diagnosis but who met the Mortola criteria for PMS (77) were
essentially identical to those who both reported prospective charting and who met the
Mortola criteria (78).
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3.2.4 Covariate assessment
We collected information on several factors potentially associated with PMS and
mineral intake, such as age, smoking status, body weight, pregnancy history, tubal
ligation, oral contraceptive use, and other micronutrient intakes on biennial
questionnaires throughout the study period.
Age may be inversely associated with PMS prevalence (79). For this study, age
was calculated using information on date of birth collected at the baseline questionnaire.
High BMI has been associated with PMS (79, 80). BMI for all participants will be
calculated as the weight reported in the reference year questionnaire in kilograms divided
by the square of the height in meters reported in the baseline questionnaire (1989).
Some reproductive factors may be potential confounders of the association
between minerals and PMS. For instance, tubal ligation has been associated with
premenstrual syndrome (3, 81). Oral contraceptives (OCs) are recommended as
treatment for PMS (82), but also may be associated to symptoms such as depression and
anxiety (83). Oral contraceptive use has been associated with lower levels of zinc (84),
potassium (85), magnesium (86), and higher levels of sodium (85). Parity is directly
related to PMS via progesterone sensitization, and will be assessed as the number of
pregnancies that lasted more than 6 months. These variables have been assessed on the
main NHS II questionnaires.
Cigarette smoking and alcohol use may be associated with PMS through an
association with levels of sex steroids (87, 88) and neurotransmitters (89, 90). In this
population, Bertone-Johnson et al.(91) found that there was a dose-response relationship
168

for pack-years of smoking and PMS (p trend = 0.03). Current smokers had relative risk of
2.10 (95% CI = 1.56 - 2.83) of developing PMS over the next 2 to 4 years as compared to
never smokers. There was no overall association between alcohol intake and PMS in this
population (92), but among leaner women (BMI <25 kg/m2), those in the highest quintile
of drinking-years of alcohol had a RR of 1.74 (95% CI = 1.11 - 2.72) compared to never
drinkers. Additionally, smoking and alcohol are related with mineral intake. Smokers
may have less healthful diets than non smokers (93). Alcohol interferes with zinc and
magnesium absorption (94). Smoking information was collected in the biannual NHS2
questionnaires and alcohol information was collected in the FFQs of 1991, 1995 and
1999.
Other micronutrients such as calcium, vitamin D, and iron are known to interact
with magnesium and zinc absorption, and excretion. Intakes of calcium and vitamin D
have been associated with incidence of PMS in this population (95) and thus will be
evaluated as confounders.

3.2.5 Data Analysis
Univariate Analysis:
The number and percentages of women who fulfilled the validation criteria and
who were validated as cases and controls was already presented in chapter 2 (Table 2.1).
For magnesium, zinc, copper, manganese, and iron, we presented the recommended
dietary allowance (RDA) for women aged 20 to 40 years. Because there is no RDA
information available on potassium and sodium intakes, the adequate intake (AI) was
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presented instead (15). Using the Statistical Analysis System (SAS Institute, Cary, NC)
for Unix, version 9.1, we calculated means, standard deviations (SD), medians and
interquartile ranges (IQR) of total intakes (Table 3.1), intakes from food sources only
(Table 3.2) and intakes from supplement sources only (Table 3.3).
Bivariate Analysis:
We examined the relationship between mineral intake and potential confounders
by cross-tabulation of age-standardized covariates at baseline by quintiles of mineral
intake (Tables 3.4a to 3.4g). We used t-tests to compare the distribution of continuous
covariates: age, BMI at baseline and at age 18, age at menarche, physical activity, and
age at first birth and number of full term pregnancies among parous women. For
dichotomous covariates, which included history of tubal ligation, use of oral
contraceptives, smoking, use of antidepressants and history of severe childhood trauma,
we used chi-square tests. Covariates were cross-tabulated with PMS in chapter 2 (Table
2.5).
To examine the interrelationships among minerals, we calculated Spearman
correlation coefficients for mineral total intake (Table 3.5), for food sources (Table 3.6)
and for supplement sources (Table 3.7).
For each selected mineral, we used logistic regression to calculate age-adjusted
relative risks (RR) and 95% confidence intervals (CIs) for women in the highest quintiles
of total and foods only intakes using the lowest quintile as the reference. For
supplemental intakes, supplement-users were categorized in tertiles and we selected nonusers of supplements as the reference group. To assess dose-response relationships, we
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calculated p-values for trend by including the median of mineral intakes in each category
as a continuous variable in the regression model. For supplemental intakes we calculated
the p for trend among supplement users only. Medians, case to control ratios, ageadjusted RRs, 95% CIs and p for trends were reported in tables 3.8, 3.9 and 3.10 for total,
food and supplement intakes respectively.
Multivariable Analysis:
Using logistic regression, we calculated multivariable-adjusted RRs by including
covariates whose addition to the model changed the relative risks by more than 10%, as
well as those covariates identified as important predictors of PMS risk. The final models
were adjusted for age (<30, 30-34, 35-39 or ≥ 40 years), year of diagnosis (1993, 19941995, 1996-1997, 1998-1999 or 2000-2001), BMI (<20.0, 20.0-22.4, 22.5-24.9, 25.027.4, 27.5-29.9 or ≥ 30.0 kg/m2), number of full term pregnancies (pregnancies that
lasted more than 6 months), tubal ligation (no vs. yes), duration of oral contraceptive use
(never, 1-23, 24-71, 72-119, or ≥ 120 months), antidepressant use (never vs. ever), packyears of smoking (quintiles), history of severe childhood trauma score (5, 6-10, 11-15, or
≥ 16), and intake of alcohol, vitamin D, calcium and vitamin B6 in quintiles.
Additionally, for each mineral from food sources, we adjusted relative risks for the same
specific mineral intake from supplements and vice versa. For food mineral intake, we
estimated a second model that included additional adjustment of each mineral for the
effects of the others. P for trends for all models were calculated using the medians of
each category as a continuous variable. Relative risks, 95% CIs and p-values are reported
in tables 3.11, 3.12 and 3.13 for total, food, and supplemental intake respectively.
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Post-hoc Analysis:
After our initial analyses, we decided to evaluate the effects of potassium in
symptoms of PMS. We used logistic regression to calculate relative risks and 95% CIs of
physical and emotional symptoms, presented in tables 3.14a and 3.14b.
Additionally, we evaluated the effects of zinc to copper and calcium to
magnesium ratios in PMS. First, we divided total and food intakes of zinc, copper,
calcium and magnesium by their molecular weight (65.41, 63.55, 40.10, and 24.31
respectively). Then we divided the results of zinc by copper and calcium by magnesium
intake. After categorization by quintiles, we used logistic regression to calculate relative
risks and 95% CIs using the lowest category as the reference. P for trends were calculated
in the same manner as detailed above. We summarized the results in table 3.15.
Effect Modification:
We stratified mineral intakes from food sources into two categories of age ( < 40
years, n= 1289; and ≥ 40 years, n = 1735), two categories of BMI ( < 25 kg/m2, n = 1890;
and ≥ 25 kg/m2, n = 1048), ever smokers (n = 897) vs. never smokers (n = 2120), and
alcohol intake (drinker, n = 1764; vs. non-drinkers, n = 1255). Using logistic regression,
we calculated stratified RRs and 95% CIs for each mineral. We created interaction terms
by multiplying mineral intakes in quintiles by the potential effect modifiers, and used
likelihood ratio tests to test multiplicative interaction. Results for the potential effect
modifiers: age, BMI, smoking and alcohol are reported in tables 3.16, 3.17, 3.18, and
3.19.
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3.3 Results
The NHS2 PMS Sub-study had a total of 3025 participants. The distribution of
their total intakes of minerals, as well as intakes from food and supplement sources
separately are summarized in tables 2.1, 2.2 and 2.3. Mean total dietary intake of
minerals was in general higher than the recommended dietary intakes (RDA, Table 3.1).
For example, the mean (SD) dietary intake of zinc was 16.2 (0.8) mg/day, twice the
RDA for women aged 20 to 40 years (RDA=8 mg/day), and the mean intake of
magnesium was 320 (72) mg/day, slightly higher than the RDA of 310 mg/day. Mean
dietary intakes of zinc and magnesium from food sources were 11.9 (3.2) and 305 (59)
mg/day respectively (Table 3.2). For iron, the mean (mean=14.4 mg/day, SD=5.4
mg/day) and median (median=13.4 mg/day) intakes from food sources were not as high
as the RDA (RDA=18 mg/d, Table 2.2). Among multivitamin and individual supplement
users, intakes of zinc and magnesium from supplemental sources were 16.1 (14.3) and 70
(52) mg/day (Table 3.3).
We evaluated the characteristics of the population by quintiles of mineral intake
(Tables 3.4a to 3.4g). Overall, women with higher mineral intakes were older, except for
women with high iron and zinc intakes who were younger (p<0.0001 for all). Women
with high intakes of zinc and sodium had higher BMI at baseline and at age 18
(p<0.0001) than those with low intakes. Among parous women, those with higher intakes
of zinc, magnesium, copper, manganese and iron had a higher age at first birth and lower
number of pregnancies (p=0.04 to <0.0001). The opposite was observed for women with
high sodium intakes (p=0.01). With the exception of zinc and sodium, women with high
intakes of minerals had higher physical activity (p=0.04 to <0.0001). Women with high
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intakes of zinc, magnesium, manganese, and iron were less likely to report tubal ligation
(p=0.05 to 0.002). Overall, dietary intakes of minerals were not associated with ever use
of oral contraceptives (OCs), but women in the highest quintiles of zinc, copper,
potassium and iron were more likely to be current users of OCs (p=0.05 to 0.01). High
zinc, manganese and iron intakes were inversely associated with current smoking (p =
0.0003, 0.01 and p <0.0001 respectively). On the other hand, high potassium intake was
positively associated with current smoking (p= 0.01). Except for zinc, women with high
mineral intakes were more likely to be past smokers (p=0.03 to <0.0001). There was no
association between use of antidepressants and mineral intakes.
We evaluated the correlations between total mineral intake (Table 3.5), mineral
intakes from food sources only (Table 3.6), and mineral intakes from supplement sources
only (Table 3.7). Magnesium and potassium had the highest correlation for total and
foods only intakes (Spearman correlation coefficient, r=0.72 and 0.80, respectively,
p<0.0001 for both,). There were high correlations between intakes of magnesium and
copper, magnesium and manganese, and manganese and copper (range of Spearman
coefficients: 0.62 to 0.65 for total intakes, and 0.61 to 0.56 for foods only intakes).
Sodium had the lowest correlation coefficients with other minerals. Among intakes from
supplements, the highest correlation was observed between manganese and potassium
(r=0.86) but overall correlation coefficients were high and significant for all minerals
(range: 0.86 to 0.49) except for calcium, which had the lowest correlation coefficients.
In age-adjusted analysis, we observed no significant association between total
intakes of zinc, magnesium, and iron and PMS (Table 3.8). Women in the highest
quintiles of copper, potassium and manganese intakes had higher significant risks of PMS
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(RR=1.43, 1.37, and 1.32 respectively), with a significant linear trend across quintiles (p
trend=0.004, 0.009, and 0,03 respectively). Women with high sodium intake had a
significant trend of increased risk (p=0.04), but the relative risks for the highest quintiles
were not significant (RR for the highest quintile=1.18, 95% CI=0.93-1.49).
When we studied the association between mineral intakes only from food sources
and PMS, adjusting only for age, we found no significant associations between potassium
and manganese and PMS (Table 3.9). Copper was associated with increased risk of PMS;
women in the highest quintiles of copper intake from foods only had 47% higher risk of
developing PMS as compared to women in the lowest quintile (95%CI=1.51-1.87, p
trend=0.002). Food intakes from other minerals were not associated with PMS.
When we evaluated mineral intake from supplements and PMS, adjusting only for
age, we observed a significant inverse trend between supplemental intake of zinc and
PMS (p trend=0.03, Table 3.10). There was no significant association between intakes of
magnesium, zinc, copper, potassium, manganese, and iron, and PMS.
In the multivariable analysis of total intakes of minerals, we adjusted relative risks
for age, year of diagnosis, number of full-term pregnancies, body mass index, smoking,
tubal ligation, duration of oral contraceptive use, antidepressant use, childhood trauma
score, antidepressant use and intakes of alcohol, vitamin B6, calcium and vitamin D
(Table 3.11). After adjustment, we no longer observed an increased risk of PMS among
women with high intakes of copper, manganese, and sodium. However, women in the
highest quintile of potassium intake had a higher risk of developing PMS as compared to
women in the lowest quintile (RR = 1.53, 95% CI = 1.14 - 2.04, p trend = 0.004). In
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contrast, we observed an inverse association with iron intake; women in the highest
quintile of total iron intake had a 31% lower risk of developing PMS as compared to
women in the lowest quintile (95% CI=0.50-0.95, p trend=0.03). There was no
association between total intakes of zinc, and magnesium and PMS.
In table 3.12, we presented the results for the multivariable analysis of mineral
intakes from foods and PMS. After adjustment for the selected covariates, including
respective supplement use (model 1) as well as further adjustment for the effect of the
other minerals (model 2), there was no association between zinc, magnesium, copper,
manganese and iron intakes from food sources and PMS. We observed that women in the
highest quintile of potassium intake from food sources had a higher risk of PMS as
compared to women with the lowest intake (RR=1.42, 95%CI=1.05-1.92). After further
adjustment of each mineral for the effect of the others, the association between potassium
and PMS was no longer significant. In the multivariable analysis of mineral intakes from
supplement sources only, we found no association between any of the selected minerals
and PMS (Table 3.13).
To further investigate the observed positive association of PMS risk with
potassium, we evaluated potassium intake from foods and risk of specific physical (Table
3.14a) and emotional (Table 3.14b) symptoms. High potassium intake was associated
with a significant increased risk of all symptoms except diarrhea, acne, anger, confusion
and anxiety.
Additionally, we evaluated the association between the zinc to copper and
calcium to magnesium molar ratios and PMS (Table 3.15). For mineral intake from food
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sources only, we observed that women with the highest zinc to copper and calcium to
magnesium ratios had lower risks of PMS. For example, women in the highest quintile of
calcium to magnesium ratio of intakes from food sources had a multivariable adjusted RR
of 0.74 compared to women in the lowest quintile (95%CI=0.54-1.00, p trend=0.02).
Women in the highest quintile of zinc to copper ratios of intakes from food sources had
an adjusted RR of 0.69 compared to women in the lowest quintile (95%CI=0.52-0.90, p
trend=0.02). For total intakes, the association between zinc to copper ratio and PMS was
marginally significant (RR for the highest quintile vs. the lowest = 0.76, 95% CI = 0.58 1.00, p trend = 0.05).
Finally, we tested whether the association between minerals and PMS was
modified by age (<40 vs. ≥40, Table 3.16), BMI (<25 vs. ≥25 kg/m2, Table 3.17),
smoking (ever vs. never, Table 2.18) and alcohol (drinker vs. non-drinker, Table 2.19).
We found no significant interaction of the mineral-PMS relationship by any of these
factors.
3.4 Discussion
This is the first study to evaluate the association between dietary intakes of zinc,
magnesium, copper, potassium, manganese, iron, and sodium and PMS incidence. We
observed that total iron intake was associated with a lower risk of PMS. However there
was no association between iron intake from foods and from supplements separately and
PMS. In addition, we found that total potassium intake and potassium intake from food
sources only was associated with higher risk of PMS, as well as with risk of most
physical and emotional risk factors. There was no association between other mineral
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intakes from foods or supplements and PMS. When we evaluated the zinc to copper and
calcium to magnesium ratios, we found that women with higher zinc to copper ratios had
lower risks of developing PMS as compared to women with lower zinc to copper ratios.
The same was observed for the calcium to magnesium ratio. The relationship between
mineral intakes and PMS was not modified by age, BMI, smoking and alcohol.
There have been few previous studies of minerals and PMS, some of which have
found significant associations. Women with PMS may have lower blood levels of
magnesium,(8) zinc,(68) and higher levels of copper(68) during the luteal phase as
compared to women without PMS. Some randomized clinical trials(55)but not all(56, 57)
have found that magnesium supplementation could effectively reduce PMS symptoms.
In a randomized clinical trial conducted by Khine (2005) among ten women aged 27 to
43 years old diagnosed with PMDD, 1 hour infusion with 0.1 mmol/kg of magnesium
was not different than infusion of 5% dextrose alone for one cycle.(56) Only one
previous study has evaluated the effect of dietary manganese on PMS, in combination
with calcium.(60) In the study by Penland, ten women with reported PMS were assigned
to one of four diets combining high and low levels of manganese and calcium for 39
days. The authors observed that women with diets high in calcium but low in manganese
had worsening of premenstrual affective symptoms (interaction test for calcium and
manganese=0.04). (60)
Contrary to our main hypothesis that potassium could exert a protective effect on
PMS, we found that higher total potassium intakes and potassium intakes from foods only
was associated with increased risk of PMS. A study more than 30 years old evaluated the
effects of a very low potassium supplementation (1 mg/day for two cycles) among 10
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women with PMS symptoms and did not observe a significant difference with placebo on
symptom occurrence and weight gain.(61) However, a study of dietary intakes of a
different combination of electrolytes found that diets high in potassium and low in
sodium resulted in improvement of affective symptoms and higher vigor compared to
diets low in potassium and with moderate sodium levels.(67)
Potassium levels are regulated by aldosterone, and high potassium intakes lead to
higher levels of aldosterone secretion.(18) In normal premenopausal women, aldosterone
levels may be higher during the luteal phase than during the follicular phase.(6, 38, 39)
High aldosterone levels have been proposed as contributors to PMS symptoms of
bloating and edema. In fact, an aldosterone agonist and diuretic, spironolactone, has been
shown to reduce PMS symptoms.(44, 45) The association of potassium with increased
risk of PMS in our study could be related to induction of higher levels of aldosterone. We
observed that high potassium intakes were associated with increased risk of not only
bloating and edema symptoms, but of several other symptoms of PMS including mood
and behavioral symptoms. Nevertheless, mood and behavioral symptoms may be highly
correlated with physical symptoms. The role of potassium in PMS is still unclear and
needs to be further studied.
Iron is a cofactor for the enzyme tryptophan hydroxylase which catalyzes the
conversion of tryptophan into 5-hydroxytryptophan, a precursor of serotonin; yet it is
unclear whether iron deficiency affects this enzyme.(49) Dietary iron intakes and PMS
have not been studied before. However, some studies have evaluated the association
between ferritin levels and post-partum depression,(11, 72) which may have a similar
pathophysiology and shares some of the same risk factors as premenstrual syndrome. In
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the study conducted by Alcabar in Spain,(11) 729 women were followed from childbirth
for two years. During the postpartum period, 9% of participants developed PPD, and had
lower serum ferritin concentrations (mean (SD) = 15.4 (12.7) µg/L) compared to the rest
of the participants (mean (SD) = 21.6 (13.5) µg/L, p=0.002) . Although in our study we
did not have information on ferritin status, participants in the lowest three quintiles of
iron intake had medians below the RDA of 18 mg/day for women aged 30-40 years of
age.
Although there are no previous studies of zinc to copper ratios in PMS, we
hypothesized a possible association given the potential protective effect of zinc in PMS
and the potential increased risk of PMS in women with high intakes of copper (observed
in age-adjusted analysis only). Zinc and copper can compete with each other for binding
sites at the intestine,(96) but the interaction of their dietary intakes in their absorption
levels remains unclear.(97) Average zinc to copper molar ratios are 5 to 14 in the U.S.,
(98) and a ratio of no more than 15 has been suggested due to risk of decreasing copper
absorption.(99). In our population, ratios of zinc to copper intakes from foods only, as
well as total intakes were between 6.6 to 13.9. The observed protective effects of high
zinc low copper ratios on PMS observed in this population should be further studied.
Calcium and magnesium have been both associated with PMS(12, 100) A
previous study in our population observed an inverse association between calcium intakes
from food sources and PMS risk.(95) Some studies have evaluated the effects of calcium
to magnesium ratios in serum(101) and in cerebral spinal fluid(25) and their association
with depressive syndromes with inconsistent results. We decided to further evaluated the
role of calcium to magnesium ratios and PMS risk. We observed that high intakes of
180

calcium from food sources were associated with lower PMS risk, possibly regardless of
magnesium status as the RR is very similar as for calcium alone (RR = 0.74, 95% CI 0.54 - 1.00, and p trend =0.02 for highest quintile of calcium to magnesium ratio, vs. RR
= 0.70, 95% CI = 0.50 - 0.97, p trend = 0.02 for the highest quintile of calcium intake
from food sources as reported by Bertone-Johnson in 2005 (95) ).

Study limitations
We used self-reported FFQs to estimate mineral intake from foods and from
supplemental sources. Specific portion sizes were included for each item, in order to
minimize within person variability in reporting. Nevertheless, it may be difficult to
accurately recall dietary intake over the past year, therefore some misclassification is
likely. We excluded from the analysis women who reported intakes below 500 or above
3500 calories per day, because of such small and large intakes are likely to be due to
misreport. Misclassification is more likely between adjacent quintiles than distant
quintiles, thus we focused our analysis on comparisons between the highest versus the
lowest quintile (reference) and the trend over quintiles. Additionally, because the dietary
assessment was conducted independently from the outcome assessment, misclassification
would be non-differential with respect of PMS status. This type of misclassification could
have attenuated relative risks observed in this study.
The gold standard for PMS assessment in clinical studies requires prospective
recording of daily symptoms for two to three menstrual cycles, which was not feasible
with our study size. However, we used validated established criteria to retrospectively
identify PMS cases and symptom-free controls and thus to compare women at the two
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extremes of the spectrum of menstrual symptom experience, thereby decreasing the
likelihood of misclassification of PMS cases or controls. In the validation study of our
method,(78) the authors found that women who reported prospective charting and who
met PMS criteria based on those defined by Mortola et al.(77) were essentially identical
to those who did not report prospective charting but who met the Mortola criteria
assessed in the retrospective questionnaire. Because PMS assessment was conducted
independently of diet assessment, any misclassification of PMS status would be nondifferential and could have attenuated our results.
Information on many lifestyle and dietary variables that are potential confounders
of the association between minerals and PMS was collected by questionnaires throughout
the follow-up. However, because risk factors for PMS are still under study, and the
pathophysiology of the disorder is still unclear, it is possible that there are confounders of
the association of minerals and PMS yet unknown. Although we tried to minimize
confounding by including all known risk factors for PMS as potential confounders, some
residual confounding it is still possible.
Clinical indication could also be confounder with regard to use of mineral
supplements. Although use of specific mineral supplements in the treatment of menstrual
symptoms is less common than specific vitamin supplement use, minerals are part of
multivitamin/mineral supplements sold over the counter and used commonly. Some
physicians may recommend magnesium supplements or multivitamins to women
complaining of premenstrual symptoms, and this could bias the relative risk from an
inverse association to a positive association as we observed in Chapter 2 for B vitamin
supplements. However in the case of mineral intakes, we did not observe an association
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between supplement intakes 2-4 years before reference and PMS risk, thus suggesting
that self-medication with supplements was an unlikely explanation for our findings.
Participants in this study are members of the NHS2 cohort and are mostly white
women and more educated than the general population. It is possible that they have a
better diet quality than the general population, even though some of them had iron intakes
below the RDA. We have no reason to believe that mineral intake physiologically affects
PMS in women from this cohort differently than less educated women and women from
other races. Therefore, we can generalize these results to other premenopausal women
with the same range of intakes of minerals.
Conclusion
In this population, high intake of iron was associated with lower risk of
developing PMS. In contrast, high intake of potassium was associated with an increased
risk of PMS. There was no association between dietary intakes of magnesium, zinc,
copper, manganese and sodium and PMS. To our knowledge, this is the first study to
evaluate the association between dietary intakes of these specific minerals and
development of PMS.

3.5 Significance
Premenstrual syndrome has high prevalence and substantial impact on quality of
life but many currently recommended treatments have significant side effects and limited
efficacy. Potential effects of diet modification, particularly of mineral intakes, on PMS
prevention are important to be studied.
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The results of this study suggest a possible benefit of high intakes of iron and a
possible adverse effect of high potassium intakes on PMS incidence. Because this is the
first study to evaluate the effects or iron and other mineral intakes in PMS development,
further studies are needed to evaluate these associations, particularly randomized clinical
trials of the efficacy of iron supplementation for the prevention and treatment of PMS.

3.6 Human Subject Protection
This study has been approved by the University of Massachusetts, Amherst and
the Brigham and Women’s Hospital (BWH) institutional review boards.
Participants in the NHS2 are identified through a confidential identification
number only. Documents containing the names corresponding to each ID as well as the
questionnaires are kept separately in the Channing Laboratory in locked fire-proof
cabinets.
There are no invasive procedures involved in this sub-study. There are no known
risks involved in filling in questionnaires, except for the consequences of potential
disclosure of confidential data. Women will not benefit directly from participating in this
study.
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Table 3.1 Distribution of total intake of selected minerals 2 to 4 years before
reference year: NHS2 PMS Sub-study, 1991-2001.

Zinc (mg/d)
Magnesium (mg/d)
Copper (mg/d)
Potassium (mg/d)
Manganese (mg/d)
Iron (mg/d)
Sodium (mg/d)

Dietary
Reference
Intake1
8
310
0.9
4700
1.8
18
1500

Mean

Standard
Deviation

Median

Interquartile
Range

16.2
320
1.6
2967
3.8
24.7
2130.4

11.8
72
0.8
528
1.6
24.4
367.5

12.3
310
1.3
2928
3.5
15.1
2116.0

10.5 - 16.8
273 - 358
1.1 - 1.6
2613 - 3289
2.8 - 4.4
12.1 - 26.7
1886 - 2359

1

Dietary reference intake is the recommended dietary allowance (RDA) for women aged 20 to 40 years for all minerals,
except for potassium and sodium where the adequate intake (AI) was used instead.

Table 3.2 Distribution of intake of selected minerals from food sources 2
to 4 years before reference year: NHS2 PMS Sub-study, 1991-2001.
Mean
Zinc (mg/d)
Magnesium (mg/d)
Copper (mg/d)
Potassium (mg/d)
Manganese (mg/d)
Iron (mg/d)

11.9
305
1.3
2962
3.4
14.4

Standard
Deviation
3.2
59
0.3
527
1.1
5.4

Median
11.4
301
1.2
2925
3.3
13.1

Interquartile
Range
10.1 - 12.9
266 - 340
1.1 - 1.4
2609 - 3284
2.7 - 4.0
11.4 - 15.7

Table 3.3 Distribution of intake of selected minerals from supplement
sources1 2 to 4 years before reference year: NHS2 PMS Sub-study,
1991-2001.
Mean
Zinc (mg/d)
Magnesium (mg/d)
Copper (mg/d)
Potassium (mg/d)
Manganese (mg/d)
Iron (mg/d)

16.1
70
1.5
35
2.4
31.6

Standard
Deviation
14.3
52
0.8
85
2.0
31.6

1

Includes multivitamin and individual supplement users.
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Median
15.0
57
1.9
23
2.5
18.0

Interquartile
Range
8.5 - 20.0
30 - 100
1.1 -2.0
7 - 40
1.4 - 2.8
10.3 - 43.0

Table 3.4a Age-standardized characteristics of the population by zinc intake at
baseline: NHS2 PMS Sub-study, 1991-2001.
Total zinc intake in 1991, mg/d

1

Characteristics
Age in years2

Q1
(n=594)

Q2
(n=564)

Q3
(n=645)

Q4
(n=560)

Q5
(n=662)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Pvalue4

35.0(4.0)

33.8 (3.9)

<0.0001

23.6 (4.5) 24.4 (5.1) 24.4 (5.0) 24.2 (4.7)
21.1 (3.1) 21.6 (3.5) 21.3 (3.1) 21.2 (2.9)
12.5 (0.1) 12.4 (0.1) 12.5 (0.1) 12.4 (0.1)

0.0001
0.001
0.01

25.9 (0.2) 25.7 (0.2) 25.4 (0.2) 26.8 (0.2)

<0.0001

1.8 (0.1)

<0.0001

35.0 (4.0)

34.9 (4.1) 35.1 (4.1)

2

BMI (kg/m )
At baseline (1991) 23.5 (5.2)
At the age of 18 yrs 20.8 (3.3)
Age at menarche, years 12.6 (0.1)
Age at first birth, years3 26.1 (0.2)
Number of full-term
pregnancies
1.5 (0.1)
MET of physical
activity per week
21.8 (2.4)
History of tubal ligation
Oral contraceptive use
Current user
Ever user
Smoking Status
Current smoker
Past smoker
Ever used
antidepressants
History of severe
childhood trauma

1.8 (0.1)

1.8 (0.1)

1.5 (0.1)

24.6 (2.4) 20.7 (2.5) 23.0 (2.9) 25.6 (2.2)

0.49

%
16

%
20

%
19

%
21

%
13

Pvalue5
0.002

13
80

9
79

12
81

11
82

8
79

0.01
0.68

12
19

9
20

9
21

5
22

8
23

0.0003
0.45

7

6

8

8

7

0.61

12

8

10

11

10

0.18

1

All characteristics, except for age, standardized to the age distribution of participants in 1991.
2
For age, the value in parentheses is the standard deviation instead of the standard error.
3
Limited to parous women.
4
Calculated using the t statistic.
5
Calculated using the F statistic.
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Table 3.4b Age-standardized characteristics of the population by total
magnesium intake at baseline: NHS2 PMS Sub-study, 1991-2001.
Total magnesium intake in 1991, mg/d

1

Characteristics
Age in years2

Q1
(n=579)

Q2
(n=589)

Q3
(n=662)

Q4
(n=609)

Q5
(n=586)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Pvalue4

34.3 (4.2) 34.7 (4.1) 34.9 (4.1) 34.9 (3.9) 34.9 (4.0) <0.0001

2

BMI (kg/m )
At baseline (1991) 24.3 (0.2) 24.2 (0.2) 24.1 (0.2) 23.9 (0.2) 23.6 (0.2)
At the age of 18 yrs 20.9 (0.1) 21.1 (0.1) 21.2 (0.1) 21.5 (0.1) 21.3 (0.1)
Age at menarche, years 12.6 (0.1) 12.5 (0.1) 12.4 (0.1) 12.4 (0.1) 12.5 (0.1)

0.16
0.04
0.21

Age at first birth, years3 25.6 (0.2) 25.6 (0.2) 26.2 (0.2) 25.9 (0.2) 26.7 (0.2) <0.0001
Number of full-term
pregnancies
1.8 (0.1) 1.8 (0.1) 1.8 (0.1) 1.6 (0.1) 1.4 (0.1) <0.0001
MET of physical
activity per week
17.7 (2.4) 19.0 (2.4) 21.7 (2.3) 25.7 (2.4) 31.7(2.4) <0.0001
History of tubal ligation
Oral contraceptive use
Current user
Ever user
Smoking Status
Current smoker
Past smoker
Ever used
antidepressants
History of severe
childhood trauma

%
20

%
20

%
18

%
18

%
13

Pvalue5
0.02

12
82

11
79

10
80

9
80

9
81

0.28
0.77

8
13

10
20

8
21

9
22

7
28

0.40
<0.0001

8

7

7

6

8

0.85

10

9

9

14

10

0.04

1

All characteristics, except for age, standardized to the age distribution of participants in 1991.
2
For age, the value in parentheses is the standard deviation instead of the standard error.
3
Limited to parous women.
4
Calculated using the t statistic.
5
Calculated using the F statistic.
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Table 3.4c Age-standardized characteristics of the population by total copper
intake at baseline: NHS2 PMS Sub-study, 1991-2001.
Total copper intake in 1991, mg/d

1

Characteristics
Age in years2

Q1
(n=526)

Q2
(n=946)

Q3
(n=342)

Q4
(n=632)

Q5
(n=579)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Pvalue4

33.9 (4.2) 35.1 (4.0) 35.5 (4.0) 35.2 (3.9) 34.1 (4.1) <0.0001

2

BMI (kg/m )
At baseline (1991) 23.7 (0.2) 23.9 (0.2) 24.3 (0.3) 24.2 (0.2) 24.2 (0.2)
0.22
At the age of 18 yrs 20.9 (0.1) 21.0 (0.1) 21.3 (0.2) 21.7 (0.1) 21.2 (0.1) <0.0001
Age at menarche, years 12.6 (0.1) 12.5 (0.1) 12.4 (0.1) 12.4 (0.1) 12.4 (0.1)
0.04
Age at first birth, years3 26.0 (0.2) 25.9 (0.1) 25.8 (0.2) 25.5 (0.2) 26.8 (0.2) <0.0001
Number of full-term
pregnancies
1.8 (0.1) 1.9 (0.1) 1.7 (0.1) 1.5 (0.1) 1.5 (0.1) <0.0001
MET of physical
activity per week
18.4 (0.1) 20.8 (0.1) 20.0 (0.1) 25.3 (0.1) 29.8 (0.1) 0.003
History of tubal ligation
Oral contraceptive use
Current user
Ever user
Smoking Status
Current smoker
Past smoker
Ever used
antidepressants
History of severe
childhood trauma

%
18

%
19

%
16

%
19

%
15

Pvalue5
0.24

12
79

9
80

11
81

12
82

8
81

0.02
0.83

8
18

9
20

5
21

10
24

9
24

0.11
0.03

7

7

8

8

7

0.73

11

9

9

11

11

0.57

1

All characteristics, except for age, standardized to the age distribution of participants in 1991.
2
For age, the value in parentheses is the standard deviation instead of the standard error.
3
Limited to parous women.
4
Calculated using the t statistic.
5
Calculated using the F statistic.

188

Table 3.4d Age-standardized characteristics of the population by total potassium
intake at baseline: NHS2 PMS Sub-study, 1991-2001.
Total potassium intake in 1991, mg/d
Q1
(n=598)

Q2
(n=650)

Q3
(n=658)

Q4
(n=626)

Q5
(n=493)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Pvalue4

34.1(4.2)

34.2(4.0)

34.8(4.0)

35.0(4.0)

35.9(3.8)

<0.0001

BMI (kg/m )
At baseline (1991) 24.4 (0.2) 24.0 (0.2) 23.9 (0.2) 24.0 (0.2) 23.9 (0.2)
At the age of 18 yrs 20.9 (0.1) 21.1 (0.1) 21.2 (0.1) 21.1 (0.1) 21.8 (0.1)
Age at menarche, years 12.5 (0.1) 12.5 (0.1) 12.4 (0.1) 12.5 (0.1) 12.4 (0.1)

0.46
0.0004
0.37

1

Characteristics
Age in years2
2

Age at first birth, years3 25.9 (0.2) 26.1 (0.2) 26.2 (0.2) 25.7 (0.2) 26.3 (0.2)
0.14
Number of full-term
pregnancies
1.7 (0.1) 1.7 (0.1) 1.8 (0.1) 1.7 (0.1) 1.4 (0.1) <0.0001
MET of physical
activity per week
18.8 (0.1) 19.8 (0.1) 22.4 (0.1) 24.7 (0.1) 33.0 (0.1) 0.001
History of tubal ligation
Oral contraceptive use
Current user
Ever user
Smoking Status
Current smoker
Past smoker
Ever used
antidepressants
History of severe
childhood trauma

%
19

%
18

%
16

%
19

%
16

Pvalue5
0.387

13
83

9
80

10
79

10
80

9
81

0.05
0.39

7
16

7
18

7
22

10
21

12
30

0.01
<0.0001

9

8

7

6

6

0.33

10

9

11

9

13

0.16

1

All characteristics, except for age, standardized to the age distribution of participants in 1991.
2
For age, the value in parentheses is the standard deviation instead of the standard error.
3
Limited to parous women.
4
Calculated using the t statistic.
5
Calculated using the F statistic.
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Table 3.4e Age-standardized characteristics of the population by total manganese
intake at baseline: NHS2 PMS Sub-study, 1991-2001.
Total manganese intake in 1991, mg/d

1

Characteristics
Age in years2

Q1
(n=583)

Q2
(n=576)

Q3
(n=680)

Q4
(n=592)

Q5
(n=594)

Mean
(SE)
34.2(4.2)

Mean
(SE)
34.8(4.1)

Mean
(SE)
34.9(4.0)

Mean
(SE)
35.1(4.0)

Mean
(SE)
34.7(4.0)

Pvalue4
<0.0001

BMI (kg/m2)
At baseline (1991)

24.2 (0.2) 24.1 (0.2) 24.0 (0.2) 23.9 (0.2) 23.8 (0.2)
0.61
21.4(
21.0 (0.1) 21.1 (0.1) 21.2 (0.1) 21.2 (0.1)
0.36
(0.1)
At the age of 18 yrs
0.13
Age at menarche, years 12.5 (0.1) 12.5 (0.1) 12.4 (0.1) 12.5 (0.1) 12.3 (0.1)
3
0.02
Age at first birth, years 25.7 (0.2) 25.9 (0.2) 25.9 (0.2) 26.1 (0.2) 26.5 (0.2)
Number of full-term
1.8 (0.1) 1.8 (0.1) 1.7( (0.1) 1.6 (0.1) 1.5 (0.1) <0.0001
pregnancies
MET of physical
17.1 (0.1) 21.7 (0.1) 22.2 (0.1) 28.4 (0.1) 26.0 (0.1)
0.01
activity per week
History of tubal ligation
Oral contraceptive use
Current user
Ever user
Smoking Status
Current smoker
Past smoker
Ever used
antidepressants
History of severe
childhood trauma

%
22

%
17

%
18

%
14

%
17

Pvalue5
0.01

11
83

10
78

10
79

9
82

11
80

0.96
0.17

10
17

12
18

6
23

9
23

7
23

0.005
0.01

7

6

7

7

8

0.45

10

8

11

12

11

0.09

1

All characteristics, except for age, standardized to the age distribution of participants in 1991.
2
For age, the value in parentheses is the standard deviation instead of the standard error.
3
Limited to parous women.
4
Calculated using the t statistic.
5
Calculated using the F statistic.
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Table 3.4f Age-standardized characteristics of the population by total iron intake
at baseline: NHS2 PMS Sub-study, 1991-2001.
Total iron intake in 1991, mg/d

1

Characteristics
Age in years2

Q1
(n=546)

Q2
(n=576)

Q3
(n=600)

Q4
(n=625)

Q5
(n=678)

Mean
(SE)
34.8(4.1)

Mean
(SE)
35.2(4.1)

Mean
(SE)
35.1(4.0)

Mean
(SE)
34.9(4.0)

Mean
Pvalue4
(SE)
33.9(4.1) <0.0001

23.9 (0.2)
21.1 (0.1)
12.4 (0.1)
25.6 (0.2)

23.8 (0.2)
21.1 (0.1)
12.5 (0.1)
25.9 (0.2)

24.0 (0.2) 0.60
21.1 (0.1) 0.03
12.4 (0.1) 0.50
26.9 (0.2) <0.0001

1.8 (0.1)

1.7 (0.1)

1.6 (0.1)

0.03

26.8 (2.4) 23.6 (2.3) 25.6 (2.3)

0.04

BMI (kg/m2)
At baseline (1991) 24.2 (0.2) 24.1 (0.2)
At the age of 18 yrs 21.1 (0.1) 21.6 (0.1)
Age at menarche, years 12.5 (0.1) 12.4 (0.1)
Age at first birth, years3 25.6 (0.2) 25.8 (0.2)
Number of full-term
1.7 (0.1) 1.7 (0.1)
pregnancies
MET of physical
17.5 (2.5) 21.4 (2.4)
activity per week
History of tubal ligation
Oral contraceptive use
Current user
Ever user
Smoking Status
Current smoker
Past smoker
Ever used
antidepressants
History of severe
childhood trauma

%
20

%
19

%
20

%
17

%
15

Pvalue5
0.05

12
82

11
82

11
80

12
77

7
81

0.01
0.16

13
17

9
20

8
24

6
23

6
20

<0.0001
0.02

9

7

6

8

7

0.42

10

10

11

11

10

0.99

1

All characteristics, except for age, standardized to the age distribution of participants in 1991.
For age, the value in parentheses is the standard deviation instead of the standard error.
3
Limited to parous women.
4
Calculated using the t statistic.
5
Calculated using the F statistic.
2
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Table 3.4g Age-standardized characteristics of the population by total sodium
intake at baseline: NHS2 PMS Sub-study, 1991-2001.
Total sodium intake in 1991, mg/d

1

Characteristics
Age in years2

Q1
(n=579)

Q2
(n=589)

Q3
(n=662)

Q4
(n=609)

Q5
(n=)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

Mean
(SE)

34.6(4.1)

34.7(4.2)

34.5(4.0)

35.0(4.0)

Pvalue4

35.0(4.0) <0.0001

2

BMI (kg/m )
At baseline (1991) 23.7 (0.2) 23.7 (0.2) 23.7 (0.2) 24.2 (0.2) 24.8 (0.2) 0.0001
At the age of 18 yrs 21.0 (0.1) 21.0 (0.1) 21.2 (0.1) 21.2 (0.1) 21.5 (0.1) 0.04
Age at menarche, years 12.4 (0.1) 12.6 (0.1) 12.5 (0.1) 12.5 (0.1) 12.4 (0.1) 0.24
Age at first birth, years3 26.3 (0.2) 26.4 (0.2) 26.0 (0.2) 25.9 (0.2) 25.5 (0.2) 0.01
Number of full-term
pregnancies
1.4 (0.1) 1.6 (0.1) 1.8 (0.1) 1.8 (0.1) 1.8 (0.1) <0.0001
MET of physical
activity per week
24.8 (2.4) 23.2 (2.4) 28.0 (2.4) 18.8 (2.4) 20.1 (2.4) 0.03
History of tubal ligation
Oral contraceptive use
Current user
Ever user
Smoking Status
Current smoker
Past smoker
Ever used
antidepressants
History of severe
childhood trauma

%
16

%
17

%
18

%
19

%
18

Pvalue5
0.70

9
80

11
83

11
78

7
82

12
80

0.02
0.17

9
22

9
20

7
22

7
22

10
19

0.18
0.83

7

6

8

7

8

0.46

13

12

11

8

8

0.04

1

All characteristics, except for age, standardized to the age distribution of participants in 1991.
2
For age, the value in parentheses is the standard deviation instead of the standard error.
3
Limited to parous women.
4
Calculated using the t statistic.
5
Calculated using the F statistic.
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Table 3.5 Spearman correlation coefficients1 for total intake of selected
minerals: NHS2 PMS Sub-study, 1991-2001.
Zinc
Magnesium
Copper
Potassium
Manganese
Iron
Sodium
Calcium

Zinc
1.00
0.40
0.49
0.18
0.29
0.58
0.05
0.37

Magnesium Copper
1.00
0.64
0.72
0.65
0.46
0.10
0.47

1.00
0.42
0.62
0.51
0.14
0.23

Potassium Manganese

1.00
0.37
0.17
0.06
0.33

1.00
0.45
0.12
0.14

Iron

Sodium

1.00
0.11
0.29

1.00
0.13

1

All correlations are statistically significant at <0.0001, except for the correlation between sodium and zinc, which was
significant at 0.004

Table 3.6 Spearman correlation coefficients1 for intake of selected
minerals from food sources: NHS2 PMS Sub-study, 1991-2001.
Zinc
Magnesium
Copper
Potassium
Manganese
Iron
Calcium
1

Zinc
1.00
0.25
0.19
0.23
0.04
0.36
0.25

Magnesium Copper Potassium Manganese
1.00
0.61
0.80
0.61
0.44
0.44

1.00
0.55
0.56
0.38
0.03

1.00
0.41
0.27
0.37

1.00
0.50
-0.01

Iron

1.00
0.07

Correlations between calcium and copper, and between calcium and manganese were not statistically
significant. The correlation between zinc and manganese was significant at 0.05. All the other correlations
were statistically significant at <0.0001.

Table 3.7 Spearman correlation coefficients1 for intake of selected
minerals from supplements: NHS2 PMS Sub-study, 1991-2001.
Zinc
Magnesium
Copper
Potassium
Manganese
Iron
Calcium
1

Zinc
1.00
0.77
0.82
0.63
0.70
0.75
0.10

Magnesium Copper Potassium Manganese
1.00
0.83
0.78
0.84
0.64
0.09

1.00
0.73
0.83
0.68
0.09

1.00
0.86
0.49
0.01

1.00
0.55
0.03

Iron

1.00
0.12

The correlation between calcium and potassium was not statistically significant. The correlation between
calcium and manganese was significant at 0.03. All the other correlations were statistically significant at
<0.0001.
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Table 3.8 Age-adjusted relative risks (RR) and 95% confidence intervals (CI)
for total intake of selected minerals 2-4 years before reference year and risk of
premenstrual syndrome: NHS2 PMS Sub study, 1991-2001.
Q1
Zinc (mg/d)
Median
Case:Control Ratio
RR
95% CI
Magnesium (mg/d)
Median
Case:Control Ratio
RR
95% CI
Copper (mg/d)
Median
Case:Control Ratio
RR
95% CI
Potassium (mg/d)
Median
Case:Control Ratio
RR
95% CI
Manganese (mg/d)
Median
Case:Control Ratio
RR
95% CI
Iron (mg/d)
Median
Case:Control Ratio
RR
95% CI
Sodium(mg/d)
Median
Case:Control Ratio
RR
95% CI

Q2

Q3

Q4

Q5

Ptrend

9.2
206:405
1.00

10.8
12.2
182:386
227:417
0.92
1.07
(0.72-1.17) (0.84-1.34)

14.9
27.9
203:352
237:401
1.13
1.11
(0.89-1.44) (0.88-1.41)

237
191:370
1.00

280
311
223:418
216:435
1.04
0.98
(0.82-1.33) (0.77-1.25)

350
415
213:397
212:344
1.07
1.232
(0.84-1.36) (0.96-1.57)

1.0
182:395
1.00

1.2
1.3
268:515
138:321
1.17
0.98
(0.93-1.48) (0.75-1.27)

1.5
2.9
245:397
222:336
1.39
1.43
0.004
(1.09-1.76) (1.12-1.83)

2319
203:391
1.00

2684
2952
221:430
212:437
0.981
0.956
(0.78-1.24) (0.76-1.21)

3248
3717
209:393
210:313
1.063
1.37
0.009
(0.84-1.35) (1.07-1.75)

2.3
193:383
1.00

2.8
3.4
204:376
216:446
1.106
0.994
(0.87-1.41) (0.78-1.26)

4.2
5.8
219:407
223:352
1.09
1.32
(0.86-1.39) (1.03-1.68)

10.4
192:346
1.00

12.4
14.8
202:396
229:396
0.93
1.04
(0.73-1.19) (0.82-1.32)

21.7
49.2
220:409
212:417
0.97
0.89
(0.77-1.24) (0.70-1.13)

1684
201:402
1.00

1932
2116
192:412
213:392
0.93
1.10
(0.73-1.18) (0.87-1.39)

2308
2586
226:375
223:383
1.23
1.18
(0.97-1.56) (0.93-1.49)
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0.24

0.09

0.03

0.28

0.04

Table 3.9 Age-adjusted relative risks (RR) and 95% confidence intervals (CI)
for intake of selected minerals from food sources 2-4 years before reference
year and risk of premenstrual syndrome: NHS2 PMS Sub study, 1991-2001.
Q1
Zinc (mg/d)
Median
Case:Control Ratio
RR
95% CI
Magnesium (mg/d)
Median
Case:Control Ratio
RR
95% CI
Copper (mg/d)
Median
Case:Control Ratio
RR
95% CI
Potassium (mg/d)
Median
Case:Control Ratio
RR
95% CI
Manganese (mg/d)
Median
Case:Control Ratio
RR
95% CI
Iron (mg/d)
Median
Case:Control Ratio
RR
95% CI

Q2

Q3

Q4

Q5

Ptrend

8.9
203:363
1.00

10.3
11.4
12.6
14.9
202:419
230:412
218:373
202:397
0.86
0.99
1.03
0.89
(0.67-1.09) (0.78-1.25) (0.81-1.31) (0.70-1.14)

233
195:368
1.00

273
301
332
379
214:399
234:421
197:414
215:362
1.04
1.07
0.94
1.19
(0.82-1.32) (0.85-1.36) (0.73-1.19) (0.93-1.51)

1.0
234:477
1.00

1.1
1.2
1.4
1.6
186:381
195:363
244:454
196:289
1.03
1.15
1.151
1.47
0.002
(0.82-1.31) (0.92-1.45) (0.92-1.44) (1.51-1.87)

2316
204:387
1.00

2681
2951
3241
3700
218:432
222:440
205:379
206:326
0.95
0.98
1.07
1.27
(0.75-1.21) (0.78-1.24) (0.84-1.36) (0.99-1.62)

2.2
180:358
1.00

2.8
3.2
3.8
4.8
226:400
212:363
224:422
213:391
1.15
1.11
1.08
1.14
(0.88-1.50) (0.88-1.51) (0.89-1.52) (0.96-1.66)

10.1
190:371
1.00

11.6
12.9
14.8
19.3
207:371
213:382
242:404
203:436
1.11
1.09
1.18
0.92
(0.87-1.41) (0.86-1.40) (0.93-1.50) (0.72-1.17)
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0.74

0.34

0.03

0.53

0.31

Table 3.10 Age-adjusted relative risks (RR) and 95% confidence intervals
(CI) for intake of selected minerals from supplement sources 2-4 years
before reference year and risk of premenstrual syndrome: NHS2 PMS Sub
study, 1991-2001.
Supplement Users
Non-Users
Zinc (mg/d)
Median
Case:Control Ratio
RR
95% CI
Magnesium (mg/d)
Median
Case:Control Ratio
RR
95% CI
Copper (mg/d)
Median
Case:Control Ratio
RR
95% CI
Potassium (mg/d)
Median
Case:Control Ratio
RR
95% CI
Manganese (mg/d)
Median
Case:Control Ratio
RR
95% CI
Iron (mg/d)
Median
Case:Control Ratio
RR
95% CI
1

T1

T2

T3

0.0
755:1477
1.00

5.9
109:161
1.31
(1.01-1.69)

15.0
112:157
1.33
(1.03-1.73)

25.0
81:173
0.87
(0.66-1.15)

0.0
806:1594
1.00

14.0
93:114
1.59
(1.19-2.12)

57.0
57:98
1.13
(0.81-1.58)

100.0
101:162
1.19
(0.91-1.55)

0.0
827:1594
1.00

0.5
88:127
1.31
(0.99-1.75)

1.5
48:88
1.00
(0.70-1.44)

2.0
94:159
1.08
(0.83-1.42)

0.0
891:1715
1.00

6.00
59:80
1.42
(1.01-2.01)

23.0
45:65
1.34
(0.91-1.98)

40.0
62:108
1.09
(0.79-1.51)

0.0
870:1672
1.00

0.6
64:94
1.31
(0.94-1.82)

2.5
75:112
1.25
(0.92-1.69)

5.0
48:90
1.02
(0.71-1.46)

18.0
114:208
1.03
(0.80-1.32)

60.0
116:208
1.00
(0.78-1.28)

0.0
705:1350
1.00

10.0
122:202
1.15
(0.90-1.46)

Test for trend was conducted among users of supplements only.
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Ptrend1

0.03

0.14

0.28

0.25

0.26

0.43

Table 3.11 Multivariable adjusted RR1 and 95% CI for total mineral intake
2 to 4 years before reference year and PMS: NHS2 PMS Sub-study, 19912001.

Zinc
RR
95% CI
Magnesium
RR
95% CI
Copper
RR
95% CI
Potassium
RR
95% CI
Manganese
RR
95% CI
Iron
RR
95% CI
Sodium
RR
95% CI

Q1

Q2

Q3

Q4

Q5

Ptrend

1.00

0.97
(0.73-1.27)

0.99
(0.76-1.30)

0.99
(0.74-1.32)

0.95
(0.69-1.30)

0.75

1.00

1.10
(0.83-1.45)

1.13
(0.80-1.47)

1.08
(0.80-1.47)

1.30
(0.94-1.81)

0.16

1.00

1.20
(0.92-1.55)

1.01
(0.75-1.38)

1.30
(0.98-1.73)

1.34
(0.98-1.82)

0.12

1.00

1.06
(0.82-1.38)

1.08
(0.83-1.41)

1.16
(0.88-1.52)

1.53
(1.14-2.04)

0.004

1.00

1.08
(0.82-1.42)

0.97
(0.74-1.26)

1.06
(0.80-1.39)

1.31
(0.98-1.74)

0.06

1.00

0.88
(0.67-1.16)

0.92
(0.69-1.21)

0.78
(0.58-1.05)

0.69
(0.50-0.95)

0.03

1.00

0.91
(0.69-1.19)

0.99
(0.76-1.30)

1.51
(0.88-1.51)

1.06
(0.81-1.39)

0.28

1

Adjusted for age (<30, 30-34, 35-39 or ≥ 40 years), year of diagnosis (1993, 1994-1995, 1996-1996, 1998-1999 or 20002001), number of full-term pregnancies (0. 1-2, 3-4 or ≥ 5 pregnancies lasting at least 6 months), body mass index (<20.0,
20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9 or ≥ 30.0 kg/m2), pack-years of smoking (quintiles), tubal ligation (no vs. yes),
duration or oral contraceptive use (never, 1-23, 24-71, 72-119 or ≥ 120 months), antidepressant use (never vs. ever), history
of childhood trauma score (5, 6-10, 11-15, ≥ 16), intake of alcohol, vitamin B6, calcium and vitamin D (quintiles) at 2 to 4
years before reference year.
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Table 3.12 Multivariable adjusted RR1 and 95% CI for mineral intake
from food sources 2 to 4 years before reference year and PMS: NHS2 PMS
Sub-study, 1991-2001.
Zinc
Model 1: RR
95% CI
Model 2: RR
95% CI
Magnesium
Model 1: RR
95% CI
Model 2: RR
95% CI
Copper
Model 1: RR
95% CI
Model 2: RR
95% CI
Potassium
Model 1: RR
95% CI
Model 2: RR
95% CI
Manganese
Model 1: RR
95% CI
Model 2: RR
95% CI
Iron
Model 1: RR
95% CI
Model 2: RR
95% CI

Q1

Q2

1.00

0.91
(0.69-1.19)
0.89
(0.68-1.18)

0.97
0.98
(0.74-1.27) (0.74-1.30)
0.94
0.95
(0.71-1.24) (0.72-1.27)

0.83
0.26
(0.62-1.10)
0.86
0.48
(0.64-1.17)

1.13
(0.86-1.49)
1.09
(0.79-1.50)

1.24
1.05
(0.94-1.64) (0.78-1.41)
1.13
0.89
(0.78-1.65) (0.58-1.37)

1.29
0.21
(0.94-1.76)
0.99
0.72
(0.60-1.63)

1.13
(0.86-1.47)
1.08
(0.81-1.43)

1.13
1.12
(0.87-1.47) (0.87-1.45)
1.08
1.03
(0.80-1.46) (0.76-1.42)

1.28
0.14
(0.97-1.69)
1.16
0.56
(0.82-1.65)

1.02
(0.79-1.34)
0.98
(0.73-1.33)

1.10
1.14
(0.84-1.45) (0.87-1.52)
1.07
1.15
(0.76-1.51) (0.79-1.68)

1.42
0.02
(1.05-1.92)
1.43
0.06
(0.94-2.17)

1.13
(0.86-1.48)
1.09
(0.81-1.45)

1.10
1.10
(0.84-1.45) (0.83-1.45)
1.05
1.06
(0.77-1.43) (0.76-1.48)

1.18
0.36
(0.89-1.56)
1.11
0.66
(0.77-1.60)

1.04
(0.79-1.37)
0.99
(0.74-1.32)

1.08
1.09
(0.82-1.42) (0.83-1.44)
1.01
1.01
(0.75-1.36) 0.74-1.37)

0.85
0.16
(0.64-1.13)
0.80
0.13
(0.57-1.13)

1.00

1.00
1.00

1.00
1.00

1.00
1.00

1.00
1.00

1.00
1.00

Q3

1

Q4

Q5

Ptrend

Model 1. Adjusted for age (<30, 30-34, 35-39 or ≥ 40 years), year of diagnosis (1993, 1994-1995, 1996-1996, 1998-1999
or 2000-2001), number of full-term pregnancies (0. 1-2, 3-4 or ≥ 5 pregnancies lasting at least 6 months), body mass
index (<20.0, 20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9 or ≥ 30.0 kg/m2), pack-years of smoking (quintiles), tubal ligation
(no vs. yes), duration or oral contraceptive use (never, 1-23, 24-71, 72-119 or ≥ 120 months), antidepressant use (never vs.
ever), history of childhood trauma score (5, 6-10, 11-15, ≥ 16), intake of alcohol, vitamin B6, calcium and vitamin D
(quintiles) at 2 to 4 years before reference year.
Model 2. Model 1 additionally adjusted for the effect of the other minerals from food sources in quintiles.
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Table 3.13 Multivariable adjusted RR1 and 95% CI for mineral intake
from supplement sources 2 to 4 years before reference year and PMS:
NHS2 PMS Sub-study, 1991-2001.

Zinc
RR
95% CI
Magnesium
RR
95% CI
Copper
RR
95% CI
Potassium
RR
95% CI
Manganese
RR
95% CI
Iron
RR
95% CI

Non-Users

T1

Supplement users
T2

1.00

1.31
(0.97-1.77)

1.32
(0.95-1.85)

0.75
(0.52-1.10)

0.07

1.00

1.66
(1.18-2.32)

0.96
(0.65-1.42)

1.35
(0.97-1.89)

0.80

1.00

1.28
(0.92-1.78)

1.12
(0.74-1.72)

0.98
(0.69-1.38)

0.80

1.00

1.38
(0.93-2.05)

1.37
(0.88-2.14)

1.38
(0.93-2.05)

0.83

1.00

1.44
(0.99-2.08)

1.35
(0.95-1.92)

1.14
(0.75-1.73)

0.46

1.00

1.07
(0.80-1.43)

1.03
(0.75-1.41)

0.81
(0.58-1.11)

0.23

1

T3

Ptrend2

Adjusted for age (<30, 30-34, 35-39 or ≥ 40 years), year of diagnosis (1993, 1994-1995, 1996-1996, 1998-1999
or 2000-2001), number of full-term pregnancies (0. 1-2, 3-4 or ≥ 5 pregnancies lasting at least 6 months), body
mass index (<20.0, 20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9 or ≥ 30.0 kg/m2), pack-years of smoking (quintiles),
tubal ligation (no vs. yes), duration or oral contraceptive use (never, 1-23, 24-71, 72-119 or ≥ 120 months),
antidepressant use (never vs. ever), history of childhood trauma score (5, 6-10, 11-15, ≥ 16), intake of alcohol,
vitamin B6, calcium and vitamin D (quintiles) at 2 to 4 years before reference year and food intake of the
respective mineral.
2
Test for trend among users of supplements only.
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Table 3.14a Age and multivariable adjusted RR1 and 95% CI for potassium
intake from foods 2 to 4 years before reference and premenstrual physical
premenstrual symptoms: NHS2 PMS Sub-study, 1991-2001.
Q1

Q2

Q3

Q4

Q5

Ptrend

Bloating
Case-Control Ratio 129:243 131:279
144:261
132:231
138:196
Age adjusted RR
1.00
0.89
1.10
1.13
1.45
0.005
95% CI
(0.66-1.19) (0.82-1.48) (0.84-1.34) (1.07-1.98)
1
Multivariable RR
1.00
0.98
1.36
1.28
1.81
0.001
95% CI
(0.69-1.38) (0.95-1.94) (0.88-1.87) (1.21-2.71)
Swelling
Case-Control Ratio 35:361
45:397
56:398
41:343
55:297
Age adjusted RR
1.00
1.13
1.47
1.26
1.99
0.002
95% CI
(0.71-1.80) (0.94-2.29) (0.79-2.03) (1.27-3.12)
1
Multivariable RR
1.00
1.56
2.27
2.11
4.06
<.0001
95% CI
(0.91-2.68) (1.31-3.93) (1.16-3.84) (2.21-7.47)
Breast Tenderness
Case-Control Ratio
139:167
159:193
165:186
163:159
Age adjusted RR
1.00
0.99
1.10
1.29
1.44
0.008
95% CI
(0.73-1.35) (0.81-1.50) (0.94-1.77) (1.04-2.00)
Multivariable RR1
1.00
1.05
1.22
1.29
1.52
0.032
95% CI
(0.73-1.50) (0.84-1.77) (0.87-1.92) (1.00-2.33)
Cramping
Case-Control Ratio 61:318
76:359
65:364
74:315
73:281
Age adjusted RR
1.00
1.08
0.94
1.25
1.39
0.06
95% CI
(0.75-1.56) (0.65-1.38) (0.86-1.81) (0.95-2.02)
1
Multivariable RR
1.00
1.30
1.23
1.74
2.10
0.002
95% CI
(0.85-2.00) (0.78-1.93) (1.09-2.77) (1.29-3.43)
Diarrhea
Case-Control Ratio 85:316
67:359
89:350
83:310
82:268
Age adjusted RR
1.00
0.68
0.96
1.03
1.19
0.08
95% CI
(0.48-1.73) (0.67-1.34) (0.73-1.44) (0.84-1.68)
1
Multivariable RR
1.00
0.73
1.13
1.25
1.50
0.01
95% CI
(0.49-1.09) (0.76-1.69) (0.82-1.91) (0.96-2.35)
Fatigue
Case-Control Ratio 118:321 100:351
128:343
114:306
109:264
Age adjusted RR
1.00
0.77
1.04
1.06
1.20
0.06
95% CI
(0.56-1.04) (0.78-1.40) (0.78-1.44) (0.88-1.64)
Multivariable RR1
1.00
0.82
1.18
1.23
1.47
0.013
95% CI
(0.58-1.16) (0.83-1.68) (0.85-1.79) (0.99-2.19)
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Table 3.14a, continued.
Q1
Appetite
Case-Control Ratio 120:302
Age adjusted RR
1.00
95% CI
Multivariable RR1
1.00
95% CI
Insomnia
Case-Control Ratio 38:367
Age adjusted RR
1.00
95% CI
Multivariable RR1
1.00
95% CI
Acne
Case-Control Ratio 82:306
Age adjusted RR
1.00
95% CI
Multivariable RR1
1.00
95% CI
Back pain
Case-Control Ratio 77:314
Age adjusted RR
1.00
95% CI
Multivariable RR1
1.00
95% CI

Q2

Q3

Q4

Q5

Ptrend

120:312
125:307
112:266
139:220
0.93
1.03
1.09
1.67
0.0004
(0.69-1.26) (0.77-1.39) (0.80-1.49) (1.23-2.26)
0.98
1.17
1.15
1.85
0.001
(0.69-1.38) (0.82-1.68) (0.78-1.68) (1.25-2.76)
35:404
42:412
50:353
49:301
0.82
0.99
1.38
1.63
0.004
(0.50-1.33) (0.62-1.57) (0.88-2.16) (1.04-2.56)
1.03
1.33
1.96
3.00
<0.001
(0.61-1.74) (0.78-2.25) (1.15-3.34) (1.70-5.30)
81:342
78:334
67:304
66:259
0.85
0.91
0.89
1.08
(0.60-1.20) (0.64-1.30) (0.61-2.28) (0.74-1.56)
1.02
1.20
1.14
1.52
(0.68-1.54) (0.78-1.84) (0.72-1.80) (0.94-2.47)

0.68
0.09

80:361
82:353
84:303
92:270
0.87
0.95
1.15
1.43
0.01
(0.62-1.24) (0.67-1.34) (0.81-1.62) (1.02-2.02)
1.02
1.21
1.61
2.09
0.0002
(0.68-1.53) (0.80-1.84) (1.04-2.48) (1.34-3.28)

1

Adjusted for age (<30, 30-34, 35-39 or ≥ 40 years), year of diagnosis (1993, 1994-1995, 1996-1996, 1998-1999 or 20002001), number of full-term pregnancies (0. 1-2, 3-4 or ≥ 5 pregnancies lasting at least 6 months), body mass index (<20.0,
20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9 or ≥ 30.0 kg/m2), pack-years of smoking (quintiles), tubal ligation (no vs. yes),
duration or oral contraceptive use (never, 1-23, 24-71, 72-119 or ≥ 120 months), antidepressant use (never vs. ever), history of
childhood trauma score (5, 6-10, 11-15, ≥ 16), intake of alcohol, vitamin B6, calcium and vitamin D (quintiles) and potassium
intake from supplements, at 2 to 4 years before reference year.
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Table 3.14b Age and multivariable adjusted RR1 and 95% CI for potassium
intake from foods 2 to 4 years before reference and premenstrual psychological
premenstrual symptoms: NHS2 PMS Sub-study, 1991-2001.
Q1
Depression
Case-Control Ratio
Age adjusted RR
95% CI
Multivariable RR1
95% CI
Irritability
Case-Control Ratio
Age adjusted RR
95% CI
Multivariable RR1
95% CI
Mood
Case-Control Ratio
Age adjusted RR
95% CI
Multivariable RR1
95% CI
Angry
Case-Control Ratio
Age adjusted RR
95% CI
Multivariable RR1
95% CI
Confusion
Case-Control Ratio
Age adjusted RR
95% CI
Multivariable RR1
95% CI
Cry
Case-Control Ratio
Age adjusted RR
95% CI
Multivariable RR1
95% CI

89:354
1.00
1.00

188:244
1.00
1.00

131:317
1.00
1.00

130:332
1.00
1.00

19:384
1.00
1.00

102:315
1.00
1.00

Q2

Q3

Q4

Q5

96:407
84:415
92:357
101:301
0.93
0.83
1.06
1.40
(0.68-1.29) (0.60-1.15) (0.77-1.47) (1.01-1.93)
1.06
1.00
1.27
1.60
(0.74-1.53) (0.68-1.48) (0.85-1.89) (1.06-2.43)
178:256
184:265
172:224
181:197
0.90
0.93
1.05
1.29
(0.68-1.17) (0.71-1.21) (0.79-1.38) (0.98-1.71)
0.99
1.12
1.17
1.61
(0.72-1.37) (0.81-1.55) (0.83-2.33) (1.12-2.33)
152:367
152:366
127:320
160:268
0.99
1.03
1.01
1.55
(0.75-1.30) (0.78-1.37) (0.75-1.35) (1.16-2.06)
1.13
1.15
1.15
1.92
(0.82-1.56) (0.82-1.60) (0.80-1.64) (1.33-2.78)
130:381
134:388
116:343
121:291
0.85
0.92
0.92
1.17
(0.64-1.13) (0.69-1.22) (0.68-1.24) (0.87-1.58)
0.91
0.99
0.95
1.31
(0.66-1.26) (0.71-1.39) (0.66-1.35) (0.89-1.91)
20:428
23:426
21:375
20:322
0.88
1.03
1.11
1.25
(0.47-1.67) (0.56-1.91) (0.59-2.08) (0.66-2.37)
1.05
1.42
1.53
1.93
(0.51-2.16) (0.68-2.96) (0.71-3.29) (0.85-4.37)
110:356
114:356
112:310
127:255
0.94
1.01
1.15
1.61
(0.69-1.28) (0.74-1.37) (0.84-1.57) (1.18-2.20)
1.04
1.14
1.26
1.86
(0.73-1.48) (0.80-1.64) (0.86-1.84) (1.25-2.75)
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Ptrend

0.023
0.013

0.038
0.006

0.003
0.001

0.23
0.15

0.30
0.07

0.001
0.001

Table 3.14b, continued.
Q1
Alone
Case-Control Ratio 79:360
Age adjusted RR
1.00
95% CI
Multivariable RR1
1.00
95% CI
Forgetfulness
Case-Control Ratio 40:379
Age adjusted RR
1.00
95% CI
Multivariable RR1
1.00
95% CI
Anxiety
Case-Control Ratio 72:364
Age adjusted RR
1.00
95% CI
Multivariable RR1
1.00
95% CI
Sensibility
Case-Control Ratio 73:355
Age adjusted RR
1.00
95% CI
Multivariable RR1
1.00
95% CI

Q2

Q3

Q4

Q5

82:404
79:412
64:359
87:305
0.89
0.90
0.85
1.41
(0.64-1.26) (0.64-1.27) (0.59-1.22) (1.00-1.99)
0.96
1.00
0.95
1.58
(0.65-1.43) (0.66-1.50) (0.61-1.48) (1.01-2.45)
35:415
47:429
38:367
47:312
0.77
1.05
1.00
1.48
(0.48-1.24) (0.67-1.63) (0.63-1.59) (0.95-2.31)
0.88
1.33
1.22
1.93
(0.51-1.51) (0.78-2.25) (0.70-2.16) (1.09-3.44)
67:411
72:418
59:365
73:314
0.80
0.89
0.84
1.23
(0.56-1.15) (0.62-1.27) (0.58-1.22) (0.86-1.76)
0.98
1.08
1.04
1.63
(0.65-1.47) (0.71-1.66) (0.71-1.66) (0.66-1.64)
65:380
82:400
64:344
95:291
0.81
1.01
0.93
1.69
(0.56-1.17) (0.72-1.44) (0.65-1.35) (1.19-2.38)
0.90
1.14
1.04
1.88
(0.60-1.36) (0.75-1.71) (0.67-1.62) (1.20-2.95)

1

Ptrend

0.07
0.04

0.04
0.01

0.20
0.04

0.001
0.003

Adjusted for age (<30, 30-34, 35-39 or ≥ 40 years), year of diagnosis (1993, 1994-1995, 1996-1996, 1998-1999 or 20002001), number of full-term pregnancies (0. 1-2, 3-4 or ≥ 5 pregnancies lasting at least 6 months), body mass index (<20.0,
20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9 or ≥ 30.0 kg/m2), pack-years of smoking (quintiles), tubal ligation (no vs. yes),
duration or oral contraceptive use (never, 1-23, 24-71, 72-119 or ≥ 120 months), antidepressant use (never vs. ever), history of
childhood trauma score (5, 6-10, 11-15, ≥ 16), intake of alcohol, vitamin B6, calcium and vitamin D (quintiles) and potassium
intake from supplements, at 2 to 4 years before reference year.
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Table 3.15 Age and multivariate adjusted RR and 95% CI for zinc/copper and
calcium/magnesium molar ratios: NHS2 PMS Sub-study, 1991-2001
Q1

Q2

Q3

Q4

Q5

Ptrend

1

Total Intakes

Calcium/Magnesium molar ratio
Median
Case-Control Ratio
Age-adjusted RR
95% CI
Multivariate RR

1.21

1.56

1.87

2.23

2.89

211:392
1.00

236:368
1.18

202:402
0.91

216:388
0.99

190:414
0.83

1.00

95% CI
Median
Case-Control Ratio
Age-adjusted RR
95% CI
Multivariate RR
95% CI

(0.94-1.49) (0.71-1.15) (0.78-1.26)
1.38
0.97
1.01

(0.65-1.05)
0.92
0.15

(1.06-1.80) (0.74-1.28) (0.77-1.34)
Zinc/Copper molar ratio

(0.69-1.23)

6.8

8

9

10.3

13.9

220:384
1.00

217:386
0.98

219:382
0.99

191:418
0.78

208:394
0.88

1.00

0.03

(0.77-1.24) (0.78-1.26) (0.62-0.99)
0.84
0.92
0.71
(0.64-1.09) (0.71-1.20) (0.54-0.93)

0.15

(0.70-1.12)
0.76
0.05
(0.58-1.00)

Food intake only2
Calcium/Magnesium molar ratio
Median
Case-Control Ratio
Age-adjusted RR
95% CI
Multivariate RR

1.15

1.48

1.73

2.04

2.52

211:392
1.00

221:383
1.06

238:366
1.17

204:400
0.91

181:423
0.74

1.00

95% CI
Median
Case-Control Ratio
Age-adjusted RR
95% CI
Multivariate RR
95% CI

(0.84-1.34) (0.93-1.48) (0.71-1.15)
1.09
1.26
0.9

(0.58-0.95)
0.74
0.02

(0.83-1.42) (0.96-1.66) (0.67-1.19)
Zinc/Copper molar ratio

(0.54-1.00)

6.6

7.9

9

10.2

12.4

228:372
1.00

208:396
0.86

219:290
0.9

199:402
0.79

201:404
0.77

1.00

0.004

(0.68-1.08) (0.72-1.14) (0.62-1.00)
0.71
0.83
0.72
(0.55-0.93) (0.64-1.08) (0.54-0.94)

1

0.03

(0.61-0.98)
0.69
0.02
(0.53-0.90)

Multivariable RR were adjusted for age, year of diagnosis, number of full-term pregnancies (lasting at least 6 months), body
mass index, pack-years of smoking, tubal ligation, duration or oral contraceptive use, antidepressant use, history of
childhood trauma score , intake of alcohol, vitamin B6, and vitamin D 2 to 4 years before reference year. For zinc/copper
ratios, RR were additionally adjusted for total calcium intakes in quintiles
2
Multivariable RR were additionally adjusted for the corresponding molar ratios from supplemental sources.
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Table 3.16 Stratified RR1 and 95% CI for total mineral intake 2 to 4 years before
reference year and PMS by age at diagnosis: NHS2 PMS Sub-study, 1991-2001.
Q1

Q2

Q3

Q4

Q5

Pvalue2

Case:Control 92:152
RR
1.00
95% CI
Case:Control 114:253
RR
1.00
95% CI
Magnesium Case:Control 106:157
Age < 40
RR
1.00
95% CI

91:146
102:159
89:136
133:189 0.79
1.00
1.03
1.09
0.97
(0.66-1.53) (0.68-1.58) (0.70-1.72) (0.60-1.57)
91:243
125:258
114:216
104:212
1.12
0.99
1.01
1.25
(0.78-1.62) (0.70-1.42) (0.70-1.47) (0.28-1.92)
114:177
89:173
96:144
102:131 0.72
0.94
0.88
0.82
0.57
(0.63-1.41) (0.56-1.38) (0.51-1.32) (0.34-0.94)

Age ≥ 40

Case:Control 85:213
RR
1.00
95% CI
Case:Control 98:178
RR
1.00
95% CI
Case:Control 84:217
RR
1.00
95% CI

109:241
127:262
117:253
110:213
0.86
0.9
0.94
0.9
(0.59-1.25) (0.61-1.33) (0.62-1.41) (0.58-1.40)
124:212
56:93
109:150
120:149 0.63
0.79
0.80
0.7
0.59
(0.54-1.16) (0.50-1.29) (0.46-1.07) (0.38-0.92)
144:303
82:228
136:247
102:187
0.88
1.12
0.77
0.88
(0.61-1.26) (0.74-1.69) (0.52-1.14) (0.57-1.37)

Potassium
Age < 40

Case:Control 116:161
RR
1.00
95%CI

124:205
99:178
91:139
77:99
0.43
1.05
1.03
0.89
0.64
(0.72-1.53) (0.68-1.56) (0.58-1.38) (0.40-1.03)

Age ≥ 40

Case:Control 87:230
RR
1.00
95%CI

97:225
113:259
118:254
133:214
0.79
0.82
0.74
0.58
(0.54-1.15) (0.56-1.20) (0.50-1.09) (0.39-0.87)

Zinc
Age < 40
(n=1289)
Age ≥ 40
(n=1735)

Copper
Age < 40
Age ≥ 40

Manganese Case:Control
Age < 40
RR
95%CI
Age ≥ 40
Case:Control
RR
95%CI
Iron
Case:Control
Age < 40
RR
95%CI
Age ≥ 40
Case:Control
RR
95%CI

99:171
1.00
94:212
1.00
91:139
1.00
101:207
1.00

95:146
0.86
(0.57-1.30)
109:230
1.02
(0.70-1.48)
86:140
1.19
(0.77-1.85)
116:256
1.12
(0.78-1.61)

1

104:163
0.79
(0.53-1.18)
112:283
1.35
(0.93-1.95)
104:155
1.08
(0.70-1.66)
125:241
1.10
(0.76-1.60)

100:162
0.86
(0.57-1.31)
119:245
1.02
(0.70-1.49)
110:160
0.94
(0.59-1.48)
110:249
1.70
(1.14-2.54)

109:140 0.72
0.56
(0.36-0.86)
114:212
1.08
(0.72-1.60)
116:188 0.61
1.16
(0.71-1.90)
96:229
1.76
(1.14-2.71)

Adjusted for age (continuous), year of diagnosis, number of full-term pregnancies, BMI, pack-years of smoking, tubal ligation,
duration of oral contraceptive use, antidepressant use, history of childhood trauma score, intake of alcohol, vitamin B6, calcium
and vitamin D at 2 to 4 years before reference year.
2
P-value for likelihood ratio test of the interaction terms of age (<40 or ≥40 years) by quintiles of each mineral.
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Table 3.17 Stratified RR1 and 95% CI for total mineral intake 2 to 4 years before
reference year and PMS by BMI: NHS2 PMS Sub-study, 1991-2001.
Q1

Q2

Q3

Q4

Q5

Pvalue2

Case:Control 132:279 117:257
122:254
106:209
145:266 0.12
RR
1.00
0.98
0.94
0.91
0.88
95% CI
(0.70-1.38) (0.67-1.32) (0.63-1.31) (0.59-1.30)
Case:Control 68:109
56:122
95:155
91:128
91:130
RR
1.00
0.77
0.96
1.12
1.06
95% CI
(0.50-1.27) (0.60-1.54) (0.68-1.83) (0.59-1.88)
MagnesiumCase:Control 111:230 127:268
123:277
127:259
134:231 0.90
BMI<25
RR
1.00
0.98
1.01
1.05
1.21
95% CI
(0.69-1.40) (0.69-1.46) (0.71-1.55) (0.80-1.82)
Zinc
BMI<25
(n=1890)
BMI≥25
(n=1048)

BMI≥25

Copper
BMI<25
BMI≥25

Case:Control 76:133
90:138
85:144
81:126
69:103
RR
1.00
1.30
1.32
1.40
1.62
95% CI
(0.82-2.06) (0.81-2.15) (0.83-2.34) (0.91-2.91)
Case:Control 113:266 156:350
77:194
141:232
135:223 0.42
RR
1.00
1.13
1.06
1.41
1.42
95% CI
(0.82-1.57) (0.72-1.56) (0.98-2.02) (0.96-2.09)
Case:Control 63:117 106:150
56:112
93:158
83:107
RR
1.00
1.47
1.03
1.16
1.38
95% CI
(0.93-2.32) (0.61-1.74) (0.72-1.88) (0.80-2.37)

Potassium Case:Control 121:232 126:295
127:275
127:254
121:209 0.98
BMI<25
RR
1.00
0.81
0.90
1.04
1.19
95%CI
(0.58-1.13) (0.63-1.28) (0.73-1.50) (0.82-1.74)
BMI≥25

Case:Control
RR
95%CI

64:125
1.00

79:145
91:129
74:148
78:124
1.54
1.20
1.45
2.27
(0.98-2.43) (0.75-1.93) (0.89-2.35) (1.34-3.83)

Manganese Case:Control 107:235 109:245
126:292
137:255
143:238 0.45
BMI<25
RR
1.00
1.04
0.93
1.12
1.37
95%CI
(0.72-1.49) (0.65-1.31) (0.79-1.59) (0.95-1.98)
BMI≥25
Case:Control 80:138
89:118
85:144
72:140
75:104
RR
1.00
1.26
1.06
0.98
1.25
95%CI
(0.81-1.95) (0.69-1.65) (0.62-1.57) (0.76-2.05)
Iron
Case:Control 107:224 123:253
126:239
136:267
130:282 0.42
BMI<25
RR
1.00
1.02
1.08
0.93
0.71
95%CI
(0.72-1.50) (0.75-1.56) (0.63-1.36) (0.47-1.07)
BMI≥25
Case:Control 76:111
74:134
94:135
77:134
80:130
RR
1.00
0.77
0.82
0.65
0.68
95%CI
(0.48-1.22) (0.51-1.30) (0.39-1.08) (0.39-1.19)
1

Adjusted for age, year of diagnosis, number of full-term pregnancies, BMI (continuous), pack-years of smoking, tubal ligation,
duration of oral contraceptive use, antidepressant use, history of childhood trauma score, intake of alcohol, vitamin B6, calcium
and vitamin D at 2 to 4 years before reference year.
2
P-value for likelihood ratio test of the interaction terms of BMI (<25 or ≥25 years) by quintiles of each mineral.
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Table 3.18 Stratified RR1 and 95% CI for total mineral intake 2 to 4 years before
reference year and PMS by smoking: NHS2 PMS Sub-study, 1991-2001.
Q1
Zinc
Ever smoker
(n=897)
Never smoker
(n=2120)
Magnesium
Ever smoker

Case:Control
RR
95%CI
Case:Control
RR
95%CI
Case:Control
RR
95%CI

Never smoker Case:Control
RR
95%CI
Copper
Case:Control
Ever smoker RR
95%CI
Never smoker Case:Control
RR
95%CI
Potassium
Ever smoker

Case:Control
RR
95%CI

Q3

Q4

Q5

Pvalue2

79:116
1.00

71:84
91:101
69:95
96:95
0.71
1.25
1.17
0.78
1.39
(0.76-2.06) (0.72-1.89) (0.46-1.31) (0.78-2.46)
126:289 111:303
136:314
133:257
141:304
1.00
0.88
0.94
1.03
0.78
(0.63-1.23) (0.67-1.31) (0.73-1.47) (0.53-1.16)
56:71
80:96
81:114
96:106
93:104
0.37
1.00
1.19
1.41
1.49
1.63
(0.69-2.05) (0.80-2.49) (0.83-2.68) (0.87-3.06)
135:298
1.00

143:320
134:321
117:290
118:238
1.07
1.03
0.95
1.21
(0.77-1.47) (0.73-1.45) (0.66-1.38) (0.82-1.80)
59:87
106:111
52:81
99:122
90:90
0.93
1.00
1.45
1.17
1.44
1.62
(0.87-2.41) (0.65-2.09) (0.84-2.47) (0.90-2.93)
123:308 162:402
86:237
144:275
132:245
1.00
1.06
0.91
1.23
1.20
(0.78-1.45) (0.63-1.32) (0.87-1.72) (0.82-1.75)
62:80
1.00

Never smoker Case:Control
RR
95%CI

141:311
1.00

Case:Control
RR
95%CI
Never smoker Case:Control
RR
95%CI
Iron
Case:Control
Ever smoker RR
95%CI
Never smoker Case:Control
RR
95%CI

23:33
1.00

Manganese
Ever smoker

Q2

75:93
75:106
100:102
94:110
0.59
1.03
1.41
1.89
1.53
(0.71-2.04) (0.83-2.40) (1.10-3.22) (0.89-2.65)
146:336
137:329
108:290
115:201
1.08
1.00
0.94
1.67
(0.79-1.48) (0.72-1.39) (0.66-1.33) (1.15-2.43)

31:22
1.87
(0.73-4.81)
170:349 173:353
1.00
1.02
(0.77-1.34)
33:33
26:27
1.00
1.00
(0.40-2.50)
159:312
175:368
1.00
1.00
(0.76-1.33)

1

31:23
1.67
(0.64-4.36)
184:423
0.91
(0.69-1.19)
29:18
1.10
(0.41-2.98)
199:377
1.00
(0.75-1.33)

27:24
1.53
(0.57-4.09)
191:381
1.07
(0.81-1.41)
19:21
0.44
(0.12-1.53)
201:386
0.91
(0.68-1.24)

21:20
0.20
2.00
(0.69-5.75)
202:330
1.31
(0.98-1.75)
26:23
0.77
0.85
(0.25-2.93)
186:939
0.70
(0.51-0.97)

Adjusted for age, year of diagnosis, number of full-term pregnancies, BMI, tubal ligation, duration of oral contraceptive use,
antidepressant use, history of childhood trauma score, intake of alcohol, vitamin B6, calcium and vitamin D at 2 to 4 years before
reference year.
2
P-value for likelihood ratio test of the interaction terms of smoking (ever vs. never) by quintiles of each mineral.
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Table 3.19 Stratified RR1 and 95% CI for total mineral intake 2 to 4 years before
reference year and PMS by alcohol intake: NHS2 PMS Sub-study, 1991-2001.
Q1
Q2
Q3
Q4
Q5
Pvalue2
Zinc
Case:Control 131:237 108:238
137:237
114:199
137:226 0.97
Drinker
RR
1.00
0.80
0.95
0.90
0.92
(n=1764)
95% CI
(0.57-1.12) (0.68-1.34) (0.63-1.29) (0.62-1.37)
Non-drinker Case:Control 75:168
74:151
90:180
89:153
100:175
(n=1255)
RR
1.00
1.19
1.15
1.16
1.04
95% CI
(0.78-1.83) (0.76-1.75) (0.75-1.80) (0.63-1.71)
Magnesium Case:Control 97:166
128:240
137:278
136:234
129:219 0.57
Drinker
RR
1.00
1.04
0.98
1.13
1.22
95% CI
(0.72-1.51) (0.67-1.43) (0.76-1.67) (0.79-1.87)
Non-drinker Case:Control
RR
95% CI
Copper
Case:Control
Drinker
RR
95% CI
Non-drinker Case:Control
RR
95% CI

94:204
1.00

95:178
79:157
77:163
83:125
1.16
1.12
1.21
1.59
(0.78-1.73) (0.73-1.74) (0.77-1.92) (0.98-2.60)
93:193
161:298
79:202
164:253
130:191 0.22
1.00
1.23
0.90
1.38
1.52
(0.87-1.73) (0.61-1.34) (0.96-1.98) (1.01-2.30)
89:202
107:217
59:119
81:144
92:145
1.00
1.08
1.19
1.26
1.40
(0.74-1.58) (0.75-1.88) (0.82-1.93) (0.89-2.20)

Potassium Case:Control
Drinker
RR
95%CI

103:187
1.00

133:229
123:272
135:245
133:204 0.18
1.14
0.92
1.20
1.56
(0.80-1.62) (0.64-1.31) (0.83-1.73) (1.06-2.30)

Non-drinker Case:Control
RR
95%CI
Manganese Case:Control
Drinker
RR
95%CI
Non-drinker Case:Control
RR
95%CI
Iron
Case:Control
Drinker
RR
95%CI
Non-drinker Case:Control
RR
95%CI

100:204
1.00

88:201
89:165
0.95
1.25
(0.64-1.39) (0.83-1.88)

96:171
1.00

126:214
1.09
(0.76-1.57)
97:212
78:162
1.00
1.00
(0.67-1.49)
116:200 126:233
1.00
1.06
(0.75-1.50)
76:146
76:163
1.00
0.87
(0.56-1.35)

1

135:276
0.93
(0.65-1.32)
81:170
0.96
(0.65-1.43)
138:238
0.96
(0.68-1.36)
91:158
0.97
(0.63-1.49)

74:148
77:109
1.21
1.91
(0.78-1.86) (1.21-3.02)
141:266
0.99
(0.69-1.42)
78:141
1.21
(0.81-1.83)
133:239
0.91
(0.63-1.32)
87:170
0.78
(0.49-1.24)

129:210 0.05
1.19
(0.80-1.76)
94:142
1.49
(0.98-2.25)
114:227 0.92
0.71
(0.47-1.06)
98:190
0.69
(0.42-1.12)

Adjusted for age, year of diagnosis, number of full-term pregnancies, BMI, pack-years of smoking, tubal ligation, duration of
oral contraceptive use, antidepressant use, history of childhood trauma score, intake of vitamin B6, calcium and vitamin D at 2
to 4 years before reference year.
2
P-value for likelihood ratio test of the interaction terms of drinking (yes vs. no) by quintiles of each mineral.
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CHAPTER 4
DIETARY INTAKE AND BLOOD LEVELS OF SELECTED
MICRONUTRIENTS AND PREMENSTRUAL SYNDROME
IN A COLLEGE-AGED POPULATION

4.1 Background

4.1.1 Introduction
Premenstrual syndrome (PMS) is a disorder that can affect women at any age
between menarche and menopause. It is characterized by the presence of at least one
physical and one psychological symptom, restricted to the luteal phase, that adversely
affect life activities and social relationships. Although the true prevalence of PMS is
currently unknown, it has been estimated that 15% of women of reproductive age in the
USA meet established clinical criteria for PMS. Current treatments for PMS include oral
contraceptives, gonadotropin-releasing hormone agonists, and antidepressants, all of
which have significant side effects (1).
The pathophysiology of PMS remains unclear, but it is suspected that diet may
play a role in the development of this disorder. Dietary intakes of some micronutrients
like calcium and vitamin D have been already identified as potential risk factors (2). We
propose to evaluate the association between dietary intakes of vitamin B6, riboflavin,
folate, vitamin B12, magnesium, zinc, sodium and potassium and premenstrual syndrome
among young adult women.
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4.1.2 Physiology of the relationship between micronutrients and premenstrual
syndrome
Because of the variety of symptoms present in PMS, many systems may be
involved in its pathophysiology. Neurotransmitters, such as serotonin, gamma-amino
butyric acid (GABA), and melatonin are associated with symptoms of anxiety, depression
and fatigue, and may be affected by cyclical ovarian hormonal changes (3, 4). Some
studies have suggested that women with PMS have lower levels of serotonin (5, 6),
melatonin (7), and GABA (8, 9) compared to women without PMS, but other studies (10,
11) have not observed these associations.
Micronutrients may play a role in the development of PMS through their
involvement in the metabolism of neurotransmitters and hormones. For example,
riboflavin is needed to activate vitamin B6, which is a cofactor in the generation of
serotonin from the amino acid tryptophan (12). Vitamins B12, B6, and folate are
associated with the formation of S-adenosyl-methionine and tetrahydrobiopterin, both of
which are required for the metabolism of serotonin and dopamine (13, 14). Magnesium is
required for the conversion of serotonin into melatonin (15). Magnesium and zinc interact
with the glutamate receptor NMDA, which is associated with depression (16-18). The
potassium brain pore, TREK-1, has been also associated with depression (19, 20).
Potassium and sodium intakes are regulators of the extracellular and intracellular fluid
balance through the renin-angiotensin-aldosterone system, thereby potentially associated
to symptoms of bloating and edema (21). Nevertheless, the role of these micronutrients in
PMS development is still unclear.
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4.1.3 Epidemiologic evidence for the association between micronutrients and
premenstrual syndrome
The epidemiologic studies of vitamin B6, riboflavin, folate, and vitamin B12 and
PMS have been described before in chapter 2. Studies of mineral intakes have been
described in chapter 3. Briefly, we are going to summarize the findings of the most
relevant studies.
a) Micronutrient supplementation and PMS
Vitamin B6 and magnesium are the most studied micronutrient supplements in the
treatment of PMS. Several randomized clinical trials of vitamin B6 supplementation (2227) have found an improvement in PMS symptoms with doses ranging from 50 to 500
mg/day, but others have not found beneficial effects (28-30). Randomized clinical trials
of magnesium supplementation have found beneficial (31, 32) or null (33-35) effects on
the treatment of PMS symptoms.
A study evaluating the effects of potassium on PMS symptoms and weight gain
did not observe a significant benefit of potassium supplementation (36). In a randomized
cross-over study of four diets with different combinations of electrolyte contents, the
authors found that diets high in potassium and low in sodium resulted in reduced
depression symptoms, less fatigue and higher vigor compared to diets low in potassium
and moderate in sodium (37).
Other randomized clinical trials have evaluated the effects of supplements
containing multiple micronutrients such as B6, riboflavin, and magnesium on symptoms
of PMS, and observed significant improvement of symptoms (38-40).
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Limited evidence also suggests that folate, vitamin B12 and zinc supplements
may be effective in treatment of depression (13, 14, 41-44). This association is relevant
for research on PMS because depression potentially shares some etiologic features with
PMS.

b) Micronutrient status and PMS
Although micronutrient deficiencies in the US are uncommon, it has been
suggested that women with PMS have lower levels of vitamin B6, magnesium and zinc.
Very few studies have evaluated these relationships and results have been inconsistent
with regard to the assessment methods used.
Few studies (45-47) have evaluated plasma levels of pyridoxal 5’-phosphate
(PLP), the active form of vitamin B6, in women with and without PMS, but no significant
differences were reported. In a cross-sectional study conducted by Ritchie et al. (46)
blood samples were collected from 41 women with moderate to severe PMS and 95
women with none or only mild symptoms. The authors found that mean plasma PLP was
similar in both groups (mean ± standard deviation (SD)=39.6 ± 23.0 nmol/l in cases, and
40.6 ± 23.3 nmol/l in controls).
Magnesium levels in serum and blood cells have been evaluated in women with
PMS with inconclusive results (47, 48). Khine et al.(33) used a magnesium loading test
for measuring magnesium deficiency in 17 women with premenstrual dysphoric disorder
(PMDD) and 14 women without PMDD . The authors found that the magnesium
retention after infusion was similar in cases and in controls (mean ± SD = 31.5 ± 25 %
urinary magnesium retention in cases vs. 27.9± 19 % urinary magnesium retention
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controls) and concluded that there was no evidence of a magnesium deficiency in women
with PMDD.
In a study conducted by Shamberger et al. (49) magnesium, zinc, copper, and
potassium levels were evaluated in hair samples of women diagnosed with PMS (n = 46)
and compared to women without PMS (n = 50) . The authors found that women with
PMS had significantly lower potassium levels in hair as compared to women without
PMS (potassium = 15.7 ± 15.2 parts per million (ppm) in cases vs. 31.3 ± 28.4 parts per
million (ppm) in controls; p < 0.05). There were no significant differences in
concentrations of copper, sodium, zinc and magnesium (magnesium= 104 ± 85.1 ppm in
cases, and 111.7 ± 66 ppm in controls).
Blood levels of micronutrients may fluctuate across the menstrual cycle
differently in women with PMS and in women without PMS.(50, 51) Das et al.(50)
conducted a study among 20 healthy women aged 25 to 35 years old with regular
menstrual cycles and reportedly not suffering from PMS. Using basal body temperature
as the reference, blood samples were collected at four different points of their menstrual
cycle: follicular, ovulatory and luteal phases, and the first day of menses. Blood levels of
zinc, magnesium, selenium and manganese were assessed. Compared to the ovulatory
phase, during the luteal phase participants had lower levels of zinc (85 ± 0.6 µg/ml vs. 80
± 0.6 µg/ml; p<0.01) and higher levels of magnesium (1.54 ± 0.06 mEq/L vs. 1.65 ± 0.07
mEq/L; p<0.01).
Although only few studies have evaluated the relationships of micronutrients and
PMS, there is some evidence that blood levels of certain micronutrients may be different
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during the luteal phase in women suffering from PMS compared to women without PMS
and that some micronutrient supplements may help in relieving PMS symptoms. The role
of dietary intakes of vitamin B6, riboflavin, folate, vitamin B12, magnesium, zinc,
potassium, and sodium and premenstrual syndrome remains unknown.

4.1.4 Summary
Many systems may be involved in the pathophysiology of this PMS, including
neurotransmitters such as serotonin, GABA, glutamate and melatonin, as well as other
systems like the renin-angiotensin-aldosterone system (3).Vitamin B6, riboflavin, folate,
vitamin B12, magnesium, zinc, potassium and sodium are involved in the metabolical
pathways of these neurotransmitters and hormones. Therefore, they may play a role in
the development of premenstrual syndrome.
To date, few studies have evaluated micronutrient status in women with PMS
using blood (45-47, 50, 51), blood cells (48, 49), hair samples (49), or functional tests
(33), but results remain controversial. Vitamin B6 and magnesium supplements are the
best studied for treatment of premenstrual symptoms, and although some studies have
found that supplements of B6 (22-26) or magnesium (31, 32) may reduce PMS
symptoms, other studies have not found beneficial effects (28-30, 33-35). Potassium
supplementation had no significant effects on premenstrual symptoms, but diets with high
potassium may be associated to lower fatigue and a decrease in depressive symptoms.
Folate, B12, and zinc have not been directly studied in relation to PMS, but they may be
associated with depression (13, 14, 41-43)
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Therefore, the role of micronutrients and PMS deserves further investigation. In
this study, we evaluated the association between dietary intakes of vitamin B6, riboflavin,
folate, vitamin B12, magnesium, zinc, potassium, sodium, and iron, and PMS among
young adult women.

4.1.5 Specific Aims and Hypotheses
Specific aim:
To evaluate the association between dietary intakes and blood levels of vitamin B6,
riboflavin, folate, vitamin B12, magnesium, zinc, sodium, potassium, and iron, and PMS
among young adult women.
Secondary aims:
-

To examine the relationship between dietary intakes of vitamin B6, riboflavin,
folate, vitamin B12, magnesium, zinc, sodium, potassium, and iron, and PMS.

-

To evaluate the association between blood levels of vitamin B6, folate, vitamin
B12, magnesium, and ferritin, and PMS.

Hypotheses:
There is an inverse relationship between dietary intakes of vitamin B6, riboflavin, folate,
vitamin B12 magnesium, zinc, potassium, and iron and premenstrual syndrome. High
dietary intakes of sodium are associated with increased risk of having PMS. Blood levels
of vitamin B6, folate, vitamin B12 and magnesium are inversely associated with PMS.
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4.2 Methods

4.2.1 Study design and population
To examine the association between micronutrient intake and premenstrual
symptoms and PMS we conducted a cross-sectional study among participants in the
University of Massachusetts Vitamin D Status Study (UMass Vitamin D Study).
The UMass Vitamin D Study was conducted from March 2006 to June 2008
(Phase 1) and from January 2010 to May 2010 (Phase 2) at the University of
Massachusetts. We recruited 186 women during phase one and 51 during phase two
through advertisements and fliers posted in area colleges.
Women were ineligible for the study if they had one or more of the following
characteristics:
-

Pregnant or not currently menstruating

-

Experiencing untreated depression

-

Reported history of high blood pressure, elevated cholesterol, kidney, liver, digestive,
rheumatologic, thyroid or bone diseases, hyperparathyroidism, cancer, type 1 or type
2 diabetes; or polycystic ovaries

-

Taking currently corticosteroids, anabolic steroids, anticonvulsants, cimetidine or
propanolol.
Participants had a single clinic visit scheduled on a morning during the 5 to 7 days

before anticipated start of next menses (late luteal phase). At this visit, a trained research
assistant measured anthropometric factors and blood pressure of each participant.
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Participants completed a food frequency questionnaire, a questionnaire on menstrual
symptom experience, and a questionnaire on lifestyle and demographic factors. After
this, participants had blood samples taken at the University Health Services by a trained
phlebotomist and a DXA scan to evaluate their body composition and bone mineral
density.

4.2.2 Exposure assessment
Dietary micronutrient intake:
To obtain information on dietary intakes of micronutrients, participants completed
a modified version of the Harvard Food Frequency Questionnaire (FFQ). Each food item
had specific portion sizes according to the natural portions or standard weight and
volumes commonly consumed in the U.S. Participants were asked how often, on average,
they consumed foods of that specified amount during the previous 2 months with 9
response options: "6 + per day", "4 to 6 per day", "2 to 3 per day", "1 per day", "5 to 6 per
week", "2 to 4 per week", "1 per week", "1 to 3 per month" and "never or less than once
per month".
The FFQ included additional questions about vitamin and mineral supplements
used. Participants were asked to report whether they currently took multivitamins, how
many they took per week (<2, 3-5, 6-9, ≥10 tablets) and the specific brand used. Use of
vitamin B6 and dosage (<50, 50 – 99, 100 – 149, ≥150 mg/day) and zinc use and dosage
(<25, 25–74, 75-100, ≥101 mg/day) were also queried. Additional questions on regular
use of folate, B complex, magnesium and potassium supplements were included.
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FFQs were analyzed at Harvard University. For each nutrient, total intake was
calculated by multiplying the frequency of intake of a specific portion size of each food
and supplement by its nutrient contents and then summing across all items. Finally,
adjustment for total calorie intake was performed using the residual method (52).

Validity and Reproducibility of Exposure Assessment:
The validity and reproducibility of the FFQ has been studied before.(53-56) In
1985, Willett et al.(53) conducted a validation study among 194 members of the Nurses’
Health Study. A 61-item semi quantitative FFQ was administered twice with an interval
of one year (1980 to 1981). During that period four 1-week diet records were also
collected to serve as a ‘gold’ standard because they are minimally dependent on memory
and allow direct measurement of food quantities. Participants were instructed by a trained
dietitian on how to record detailed information on food and beverages consumed for a
one-week period, using a provided dietetic scale.
Reproducibility was measured by comparing nutrient scores from both
questionnaires. Intraclass correlation coefficients ranged from 0.49 for vitamin A without
supplements to 0.71 for sucrose. Validity was calculated by comparing nutrient intake
assessed by the FFQ to nutrient intake assessed by the average nutrient score of the four
one-week diet records. Correlation coefficients between the second FFQ and the mean
nutrient intake from the four diet records were high, and ranged from 0.36 for vitamin A
without supplements to 0.75 for total vitamin C. Overall the food frequency questionnaire
has high validity and reproducibility.(53)
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Blood levels of vitamin B6, folate, vitamin B12, magnesium and iron:
Vitamin B6 was measured as pyridoxal-5’phosphate (PLP) in plasma. For plasma,
fasting venous blood samples were collected for each participant into heparin-treated
vacutainers (Becton Dickinson) for plasma and kept in ice for no more than 1 to 2 hours.
Plasma was then separated by centrifugation at 3000 x g for 15 minutes, aliquoted into
cryotubes, and stored at -80˚C until needed for biomarker assessment.
For vitamin B6 analyses, frozen samples were transferred on dry ice to the
laboratory of Dr. Jacob Selhub, at Tufts University, where plasma PLP concentration was
measured using a radioactive assay described by Shin et al. in 1983 (57). In this method,
radioactive tyrosine is decarboxylated to tyramine by the PLP-dependent enzyme,
tyrosine decarboxylase. The activity of this enzyme is linearly dependent on PLP
concentration. The coefficient of variation (CV) for this assay in Dr. Selhub’s laboratory
is 10%.
Folate, vitamin B12, magnesium, and ferritin were measured in serum. For serum,
fasting venous blood was collected into serum-separator vacutainers (Becton Dickinson)
and kept on ice for one to two hours, which allowed time for a clot to form. Serum was
then separated by centrifugation at 3000 x g for 15 minutes, aliquoted into cryotubes, and
stored at -80˚C until needed for biomarker assessment.
Folate and vitamin B12 concentrations were determined using a commercially
available radioimmunoassay kit (SimulTRAC B12 /FOLATE - SNB 57Co/125I, MP
Biomedicals (06B257117, Orangeburg, NY). Samples were assayed in duplicate for each
subject; duplicates with greater than 8% difference in either folate or vitamin B12
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radioactive counts were re-run to improve precision. Counts were plotted on a lognormal curve of standards to ascertain serum concentrations.
Magnesium concentrations were measured using a AAS-Graphite Furnace (AASGF) (Perkin-Elmer 4100 ZL, Perkin-Elmer, Norwalk, CT). The Perkin-Elmer 4100 ZL
AAS was equipped with a longitudinal Zeeman background correction and a pyrolytically
coated transversely heated graphite atomizer with an integrated L’vov platform.
Serum ferritin levels were determined using a commercially available enzyme
immunoassay (EIA) kit (RAMCO Laboratories, TX). The absorbance was read at 490 nm
and a background correction wavelength of 630 nm using a 96-well plate reader (Dynex
Technologies, Chantilly, VA). Absorbance values were entered into the Spectro Ferritin
MT- calculation program provided by RAMCO laboratories for calculation of ferritin
concentrations.

Validity of blood level measurements:
We used standard methods for measurements of vitamin B6, folate, vitamin B12,
magnesium, and ferritin. PLP is the active form of vitamin B6, and it comprises over half
the total body pool. PLP levels reflect short-term intake better than long-term intake.(52)
In 1984, Schuster et al. conducted a study among 19 men and women in a metabolic unit,
where they received a controlled diet and vitamin B6 supplements. Plasma PLP levels
had a correlation of r=0.61 with vitamin B6 intake from the previous day.(58) Serum
folate levels also reflect short-term intake, compared to red blood cell levels.(52) In a
study conducted by Selhub et al. among 385 members of the Framingham Heart Study
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cohort, serum folate levels (determined using a radioassay kit from Ciba-Corning) had a
correlation of r=0.43 with dietary folate intakes.(59) Magnesium serum levels are
homeostatically controlled, and therefore weakly correlated with dietary intakes (12, 52).

4.2.3 Outcome assessment
Participants self-reported current menstrual symptom experience on a
questionnaire based on the “Calendar of Premenstrual Experiences” (COPE) designed by
Mortola et al.(60). The questionnaire included a list of 26 menstrual symptoms including
abdominal bloating, breast tenderness, fatigue, tendency to cry easily among others.
Participants were asked to indicate which symptoms they experienced “most months of
the year, for at least several days before their menstrual period begins”, and the severity
of each symptom (not at all, mild, moderate, and severe). Women were asked to report
when during the cycle their symptoms usually began, when they ended, and to indicate it
they were present in the week after menses ended. The questionnaire also inquired about
overall symptom severity, with response options of “minimal” (no effect on normal
activities), “mild” (some but not that troublesome), “moderate (interferes with normal
activities’) and “severe” (intolerable, prevents normal activities). Additionally,
participants were asked whether or not the symptoms resulted in them experiencing
“relationship discord with spouse or partner”, “difficulties in parenting”, “poor work
performance/attendance” and “social isolation”, and if so, the severity of the problem (not
a problem mild, moderate, or severe).
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Participants were classified as PMS cases if met the following criteria based on
those established by Mortola et al.(60).
1. At least one physical and one affective symptom
2. Overall symptom severity “moderate” or “severe” OR
Impact of symptoms on life activities “moderate” or “severe” OR
3. One or more individual symptoms rated as “severe”
4. Symptoms begins within 14 days of start of menstruation and ends within 4 days
of start of menses
5. Symptoms absent in the week after menstruation
From the 237 women participating in the first two phases, 56 (23.6 %) met these criteria.
We also used menstrual symptom questionnaire information to identify a
comparison group of women to serve as controls if they met the following criteria:
1. Individual symptom severity “none” or “mild” for all symptoms
2. Overall symptoms severity rated as “none”, “minimal” or “mild”
3. Impact of symptoms on life activities and relationships of “not a problem” or
“mild” for all items
4. Confirmed no previous clinical diagnosis of PMS
Among women participating in the study, 60 (25.3 %) met these criteria

Validity of outcome assessment
The validity of this approach for assessing PMS symptoms was evaluated
previously by Bertone-Johnson et al.(61) among participants from the Nurses’ Health
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Study II PMS Sub-study. Women who reported a diagnosis of PMS for the first time in
2001 (n=138) and controls whose reference year was 2001 (n = 377) completed a
retrospective questionnaire about premenstrual symptoms and PMS diagnosis during the
2-years prior to diagnosis or reference year. Potential cases were classified into four
groups: 1) women who met the Mortola criteria and kept prospective symptom charts as
part of their diagnosis (Chart/Mortola cases = 36) ; 2) women who kept prospective
charts as part of their diagnosis but did not meet the Mortola criteria (Chart cases = 31);
3) women who met the Mortola criteria but did not keep prospective symptom charts as
part of their diagnosis (Mortola cases = 30); and 4) women who neither met Mortola
criteria, nor kept prospective charts (self-report-only cases = 38). The first group was
considered the most accurate diagnostic group and was used as an “alloyed gold
standard” for comparisons with the other groups. Potential controls were classified in
“confirmed controls” if they met the control criteria detailed before (no symptoms or only
mild symptoms with no interference on normal life activities) and “unconfirmed
controls” otherwise. The authors found that both “Chart/Mortola cases” and “Mortola
cases” were similar with regard to symptom timing and severity, as well as to the
presence of physical symptoms. The groups only differed in the number of affective
symptoms reported (5.3 for the “Chart/Mortola cases” and 4.3 for the “Mortola cases”,
p=0.04). In contrast, the other 2 case groups (“Chart cases” and “Self-report-only” cases)
differed in multiple ways from the alloyed gold standard “Chart/Mortola cases”. The
authors concluded that women who did not report prospective symptom charting as part
of their diagnosis but who met the Mortola criteria were essentially identical to those who
reported prospective charting and who met the modified Mortola criteria for PMS (61).
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4.2.4 Covariate assessment
We collected information on several demographic and lifestyle factors on a selfreported questionnaire, such as date of birth, current and past use of oral contraceptives,
use of antidepressants, smoking and alcohol use.
Age was calculated from the date of birth reported in the questionnaire. At the
study visit, weight and height were measured by a trained research assistant using a
calibrated scale and a stadiometer. Participants were required to wear minimal clothing
and to remove shoes. BMI was calculated by dividing the weight in kilograms by the
height in meters squared.
Aspects of reproductive history such as use of oral contraceptives (OCs) are also
potential confounders of the association between micronutrients and PMS. In the lifestyle
questionnaire, participants reported whether they ever used OCs, how many years they
used them, if they were currently taken OCs and the type or formula used. Additionally,
participants reported whether they had ever been pregnant and if they currently use
contraceptive implants, injectable contraceptives, or intrauterine devices.
Cigarette smoking and alcohol use may also be associated with PMS(62, 63).
Participants were asked in the questionnaire whether they smoke currently, the frequency
and type of cigarettes currently smoked, the age at which they started smoking, if they no
longer smoked, the age at which they quit. Additional information on environmental
tobacco exposure was also collected. Information on alcohol intake, frequency and type
of alcohol ingested was also collected in the FFQs.
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Participants also completed detailed information regarding their physical activity
including the time they spent each week walking, jogging, running, bicycling, swimming,
participating in aerobics/dancing, tennis/racket sport, yoga/Pilates and weight training in
the previous two months. We calculated total MET-hours per week of activity.
Other micronutrients such as calcium and vitamin D were measured in the FFQ
and were considered as potential confounders. For example, calcium and vitamin D and
are known to interact with magnesium and zinc absorption and excretion (12) and been
associated with a decreased risk of developing PMS (2).

4.2.5 Data Analysis
Univariate analyses:
We presented the total number of participants as well as the number and
percentage of women who fulfilled the criteria for becoming cases and controls in table
4.1. For all participants, we described the distribution of intakes of all selected
micronutrients by reporting the mean, standard deviation (SD), median and interquartile
range of the total dietary intakes (Table 4.2) as well as for dietary intakes from food
sources only (Table 4.3). Additionally, we reported the mean, SD, median and
interquartile ranges of blood levels of vitamin B6, folate, vitamin B12, magnesium, zinc,
and ferritin for the 182 participants for which we have information available (Table 4.4).
Bivariate analyses:
The covariates age, age at menarche, BMI, physical activity, smoking ever vs.
never, current oral contraceptive use, and current antidepressant use were cross-tabulated
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with PMS status (Table 4.5). For the continuous covariates we reported means and SDs
for each category and compared their distributions using t-tests. For the categorical
covariates we reported the frequency and percentage of women in each category and used
chi-square tests for comparisons. We also compared the distribution of covariates by
tertiles of selected micronutrient intakes using generalized linear models (Tables 4.6a to
4.6k).
We assessed the degree of correlation among the total intake of micronutrients
using Spearman correlation coefficients (Table 4.7) as well the correlation among intakes
from food sources only (Table 4.8). Additionally, we assessed the correlations between
blood levels and total dietary intakes of vitamin B6, folate, vitamin B12, magnesium, and
iron (Table 4.9a) as well as the correlations among each other (Table 4.9b).
Using logistic regression, we calculated age-adjusted odds ratios (OR) and 95%
confidence intervals (CI) for prevalent PMS and total micronutrient intake by tertiles
using the lowest tertile as the reference (Table 4.10). To assess dose-response
relationships, we calculated p for trends by including the median intake in each category
as a continuous variable in the regression model. Additionally, we calculated ageadjusted odds ratios, 95% CIs and p for trends for dietary intakes from food sources only
(Table 4.11) and for blood levels of selected micronutrients (Table 4.12).

Multivariable analyses:
We further adjusted the logistic regression models for age, smoking (ever vs.
never), use of multivitamins (yes vs. no) and total vitamin D intake (<100 vs. ≥100
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IU/day). Multivariate adjusted odds ratios, 95% CIs and p-values for total intakes, food
intakes and blood samples are presented in tables 4.13, 4.14, and 4.15, respectively.
Also, we evaluated the association between PMS and continuous total
micronutrient intake. Age and multivariable adjusted odds ratios and 95% CIs are
presented in table 3.16.

Continuous PMS symptom score:
To evaluate PMS symptom presence and severity in all participants, we calculated
a symptom score by adding the severity of the 26 symptoms reported ("none"=0,
"mild"=1, "moderate"=2, or "severe"=3). Participants were categorized in three groups
according to their total PMS symptom scores. We evaluated the association between
PMS symptoms and total micronutrient intakes using linear regression. Regression
coefficients, standard errors and p-values were reported in table 3.17. The same analysis
was conducted for micronutrient intakes from food sources only and blood levels of
selected micronutrients (Tables 3.18 and 3.19).

4.3 Results
The total number of participants in the UMass Vitamin D Study were 237 (Table
4.1). From these women, 211 reported the presence of at least one physical and one
affective symptom. After applying other criteria for PMS definition, we identified 56
women as PMS cases. From the remaining women, 60 of them were identified as
controls according to our control criteria.
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The mean total intakes of thiamin, riboflavin, niacin, vitamin B6, folate, vitamin
B12, magnesium, zinc, and iron were above the recommended dietary intakes for women
aged 20 to 40 years ( Table 4.2). For example, the mean total thiamin intake was 3.0
mg/d and the RDA was 1.1 mg/d. Mean total potassium intakes were below the AI (mean
= 3551 mg/d vs. AI = 4700 mg/d) whereas mean sodium intake was above the AI (mean
= 2170 mg/d, AI for sodium = 1500 mg/d). For micronutrient intakes from food sources
only, all participants had mean intakes above the recommended levels, except for iron,
which was slightly below the RDA (mean iron intake from foods=17.1 mg/day vs.
RDA=18 mg/day, Table 4.3)
For 182 participants from phase 1 of the study, blood concentrations of vitamin
B6, folate, vitamin B12, magnesium, zinc and ferritin were assessed (Table 4.4). Mean
levels of vitamin B6, folate and vitamin B12 were 73 pmol/L, 33.1 nmol/L, and 709.2
pmol/L, respectively. Mean levels of magnesium, zinc and ferritin were 21.7 mg/L, 0.06
mg/ml, and 26.9 ng/ml, respectively.
We compared baseline characteristics of the 56 cases and 60 controls (Table 4.5).
Overall, cases and controls were similar with regard to age, age at menarche, body mass
index (BMI), physical activity, alcohol intake, total vitamin D intake, use of multivitamin
supplements, oral contraceptives and selective serotonin reuptake inhibitors. Cases were
more likely than controls to be current smokers (12.5% vs. 3.3%; p=0.09) or to have ever
smoked (33.9% vs. 6.7%; p<0.001).
We then compared the characteristics of the participants by tertiles of total intakes
of B vitamin, magnesium, zinc, potassium, sodium and iron (Tables 4.6a to 4.6k).
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Overall, women with high intakes of the selected micronutrients had higher intakes of
vitamin D and higher use of multivitamins (range of p=0.04 to <0.0001) than women
with lower intakes. Women with higher intakes or thiamin, riboflavin, folate, zinc, and
iron had lower intakes of alcohol (p=0.07 to <0.0001) than women with lower
micronutrient intakes. Women with higher intakes of vitamin B6, magnesium and zinc
had higher physical activity (p=0.03 to 0.0001) than women with lower intakes.
We also evaluated the correlations between total micronutrients (Table 4.7). The
highest correlation was observed between total niacin and total vitamin B6 intakes
(Spearman correlation coefficient (r) = 0.82, p<0.0001). Thiamin had high correlations
with riboflavin, vitamin B6 and folate (r = 0.79, 0.79 and 0.81 respectively, p<0.0001). In
general, sodium and potassium intakes were not highly correlated with intakes of other
micronutrients, though the correlation of potassium and magnesium was high (r = 0.77,
p<0.0001). The lowest correlation was observed between sodium and zinc (r=0.07, not
significant), and sodium and vitamin B12 (r= 0.12, not significant).
Correlations were also high for micronutrient intakes from foods sources only
(Table 4.8). The highest correlations were observed among potassium and magnesium,
and among iron and folate (r = 80, p<0.0001 for both). Food intake of thiamin was
highly correlated with folate intake (r=0.77, p<0.0001) and with iron intake (r=0.78,
p<0.0001). Food intake of vitamin B12 were not significantly correlated with thiamin (r
=0.13), folate (r=0.01), and magnesium (r=-0.02) intakes.
Dietary intakes of vitamin B6, folate and vitamin B12 were highly correlated with
their respective blood levels (r=0.40, 0.51, and 0.32, respectively, p<0.0001; Table 4.9a).
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There were no statistically significant correlations between dietary intakes of magnesium,
zinc, and iron and their respective blood levels. Blood levels of vitamin B12 were highly
correlated with blood levels of folate (r = 0.87, p<0.0001; Table 4.9b) and moderately
correlated with vitamin B6 (r=0.49, p<0.0001). There was an inverse correlation between
blood levels of magnesium and blood levels of zinc (r=-0.20, p=0.01).
In age-adjusted logistic regression analyses, we found no association between
total intakes of thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, magnesium,
sodium, and potassium and prevalence of PMS (Table 4.10). Women in the highest tertile
of zinc intake (median = 22.2 mg/day) had a lower risk of having PMS (OR=0.39,
95%CI=0.16-0.94, p trend = 0.07) as compared to women in the lowest tertile (median =
10.7 mg/day). In age-adjusted analyses of micronutrients from food sources only, we
found no association between any of these micronutrients and PMS (Table 4.11).
Although the odds ratios for the highest tertile of zinc intake from foods only was only
marginally significant (OR=0.41, 95%CI = 0.16, 1.01), there was a significant trend of
lower prevalence with increased zinc intake (p trend = 0.04).
Blood levels of vitamin B6, folate, vitamin B12, zinc, and ferritin were not
associated with PMS prevalence in age-adjusted analysis (Table 4.12). However, women
with the highest levels of magnesium in blood (n=26, median=25.6 mg/L) had a higher
prevalence of PMS (OR = 3.21, 95% CI = 1.09 - 9.41) as compared to women with the
lowest levels (median=16.7 mg/L).
After additional adjustment for smoking status (ever vs. never), use of
multivitamins (yes vs. no) and total vitamin D intake (<100 vs. ≥100 IU/day), we
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observed no significant association between total intake of any selected micronutrients
and PMS prevalence (Table 4.13). In the multivariable-adjusted analyses restricted to
food sources only, we observed a non-significant reduced prevalence of PMS in women
with high intakes of zinc (OR = 0.40, 95% CI = 0.15 - 1.09) with a marginally significant
trend (p trend = 0.06, Table 4.14). In the multivariable-adjusted analyses of blood levels
and PMS, we observed no significant association between vitamin B6, folate, vitamin
B12, zinc, and ferritin levels and PMS prevalence (Table 4.15). Similarly to the ageadjusted analyses, we observed that women with high levels of magnesium in blood had a
higher prevalence of PMS (OR = 4.20, 95% = 1.24 - 14.23, p trend = 0.01) as compared
to women with the lowest levels.
We did not find that intakes of selected micronutrients assessed continuously
were associated with PMS risk in age and multivariable adjusted analyses (Table 4.16).
In addition, we used linear regression to evaluate the association between dietary
intakes and blood levels of selected micronutrients and PMS symptoms among all study
participants. We observed that total intakes thiamin and riboflavin were significantly
associated with a higher PMS symptom score in multivariable analyses (p=0.01 for both,
Table 4.17). In age and multivariable analyses restricted to food sources only, we
observed no significant associations between thiamin, riboflavin, niacin, folate, vitamin
B12, magnesium, potassium, and iron intakes and PMS prevalence (Table 4.18). An
increase of 1 mg/day of vitamin B6 from foods was associated with a lower PMS
symptom score (age-adjusted β ± SE = -1.89 ± 0.86, p-value = 0.03; multivariableadjusted β ± SE = -1.65 ± 0.84, p-value = 0.05). Similarly, an increase of 1 mg/day of
zinc from foods was associated with a lower PMS symptom score ( age-adjusted β ± SE
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= -0.41 ± 0.16, p-value = 0.01; multivariable-adjusted β ± SE = -0.31 ± 0.16, p-value =
0.05).
Among women who had information on blood levels of selected micronutrients,
there was no association between vitamin B6, folate, vitamin B12, zinc, and ferritin blood
levels and PMS prevalence (Table 4.19). Blood levels of magnesium (mg/L) were
associated with increased prevalence of PMS in age and multivariable adjusted models
(age-adjusted β ± SE = 0.43 ± 0.19, p-value = 0.02; multivariable-adjusted β ± SE = 0.48
± 0.18, p-value = 0.01).

4.4 Discussion
In this cross-sectional study, we found that total zinc intake, and zinc intake from
foods was marginally associated with lower prevalence of PMS. In addition, each 1
mg/day increase in vitamin B6 from foods was associated with a modestly lower PMS
symptom score. Contrary to our main hypothesis, we found that each 1 mg/day increase
in thiamin and riboflavin intakes was associated with 32% and 30% higher prevalence of
PMS, respectively. Although we found no association between vitamin B6, folate,
vitamin B12, zinc, and ferritin blood levels and PMS, we observed that higher
magnesium blood levels were associated with higher prevalence of PMS.
Previous studies have suggested that women with PMS may have lower levels of
zinc(51) and that zinc serum levels fluctuate during the menstrual cycle (50). Zinc may
interact with neurotransmitters involved in mood regulation(41, 43). In a recent study,
zinc supplements did not show improvement of mood compared to multivitamins only
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among normal women (42). However, zinc supplementation has shown beneficial effects
in patients with treatment resistant-depression when given in conjunction with
imipramine, a tricyclic antidepressant (44). The results of our study suggest that zinc
intake may be associated with lower PMS risk.
Vitamin B6 supplements have been suggested as potential treatments for
PMS(24), and some studies(22, 26, 34) have found that vitamin B6 supplements up to
100 mg/day are effective in treating PMS symptoms. Although we did not find a
significant association between dietary vitamin B6 intakes by tertiles and PMS, we
observed a significant protective effect of vitamin B6 consumption on premenstrual
symptoms in our linear regression analysis among all study participants.
In 1997, Das et al.(50) conducted a study among 20 healthy women reportedly not
suffering from PMS. Blood levels of zinc, magnesium, selenium and manganese were
evaluated at four different points of their cycle according to their basal body temperature:
follicular, ovulatory and luteal phases, and the first day of menses. Compared to the
ovulatory phase, during the luteal phase participants had lower levels of zinc (85 ± 0.6
µg/ml vs. 80 ± 0.6 µg/ml; p<0.01) and higher levels of magnesium (1.54 ± 0.06 mEq/L
vs. 1.65 ± 0.07 mEq/L; p<0.01)(50). Similartly, Chuong (51) observed that women with
PMS had lower serum levels of zinc during the luteal phase compared to the follicular
phase (90.3 ± 4.1 µg/dL vs. 100.2 ± 3.6µg/dL; p < 0.05) and to serum zinc levels during
the luteal phase of women without PMS (107.8 ± 7.8 µg/dL, p < 0.05). In our study, we
found a positive association between magnesium blood levels and PMS prevalence
during the luteal phase. Because we did not have blood samples from other times during
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the menstrual cycle of the participants, we cannot compare the observed blood levels with
blood levels during other phases of the menstrual cycle.
Chocolate is a significant source of magnesium (100 mg of magnesium by 100 g
of chocolate, and 520 mg of magnesium by 100 g of cocoa powder)(64). The increased
magnesium blood levels observed among participants with PMS could reflect increased
intake of chocolate among women with PMS. Cravings is one of the several symptoms of
PMS(65) and women with premenstrual disorders may have a higher reward sensitivity
from high-fat high-sugar foods like chocolate than women without PMS (66).
Additionally, chocolate consumption could be motivated in part by magnesium
deficiency (64).
Study Limitations
We assessed dietary intakes based on self-report using a modified version of the
Harvard FFQ and on blood levels of certain micronutrients. In this study, we selected a
period of 2 months of previous intake to reflect recent micronutrient intake and to reflect
micronutrient blood levels. The Harvard FFQ has been validated before in a population of
female nurses (52, 53), which may be similar to college-students with regard of certain
characteristics like high education and social status. Dietary intakes based on self-report
may be affected by recall. Although a period of 2 months may lead to better recall than
the usual 1 year period, it could be affected by temporal events like exam periods during
the school year. Although some misclassification of self-reported dietary intakes,
misclassification is usually not extensive enough to misclassify participants in the highest
tertile to the lowest. Micronutrient intakes were assessed at Harvard University, and
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independently of the outcome status. Nevertheless, because of the cross-sectional nature
of the study, outcome status might have influenced dietary choices, as food cravings is
one of the symptoms of PMS. Cravings of high-fat high-sugar foods like chocolate,
which is rich in magnesium and other micronutrients, is reported to be higher among
women with premenstrual disorders than among women without them (66). This could
have bias the results against the null value.
Blood samples were collected during the late luteal phase at the University Health
Services. Procedures for biomarker assessment were standard and previously validated.
For all biomarkers, laboratory staff at the Department of Nutrition was blinded to PMS
status. In our study we found a moderately high correlation between reported intakes and
blood samples of vitamin B6 (r = 0.40, p <0.0001), folate (r = 0.51, p <0.0001) and
vitamin B12 (r = 0.32, p < 0.0001), but no significant correlations between magnesium,
zinc and iron blood levels and reported intakes. In a study conducted among 385
members of the Framingham Heart Study cohort, serum folate levels had a correlation of
r=0.43 with dietary folate intakes (59). Plasma magnesium levels are under homeostatic
control and represent only a small proportion of the body magnesium pools (12, 52).
Other measures such a magnesium loading test and intracellular magnesium are
recommended for better assessment of magnesium status, but were not feasible for this
study. Misclassification due to measurement error would not be associated with the
outcome therefore leading to underestimation of the results. Nevertheless, because of the
cross-sectional nature of the study, blood levels may be affected by PMS treatments, like
oral contraceptives and antidepressants. Women taking oral contraceptives may have
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lower levels of vitamin B6 and other B vitamins(67, 68). Further adjustment of our
results by oral contraceptive use did not change the odds ratios substantially.
For this study, we did not use prospective charting of symptoms, as recommended
by the American College of Obstetricians (ACOG) for clinical diagnosis of PMS.(1)
Instead, premenstrual syndrome was assessed using a retrospective questionnaire that has
been validated before in a sub-group of women participating in the NHS2 PMS Substudy, who may be similar to college students with regard to socio economic status and
education. Although women in the NHS2 PMS Sub-study who participated in the
validation study were older than the UMass Vitamin D Study population, it is unlikely
that the small age difference affects the reports on PMS symptoms. Additionally, to
minimize misclassification we used standard criteria by Mortola et al.(60) for case
selection and we selected only women with mild or no symptoms as the controls, thereby
selecting women in the extreme ends of the range of menstrual symptom experience.
Because outcome assessment was conducted separately from micronutrient assessment,
any misclassification would be non-differential and would lead to an underestimation of
the results.
Our study questionnaires measured a variety of variables that could be associated
with both PMS and micronutrient intake. Although we selected as covariates those
factors that were strongly associated with PMS and that substantially changed the odds
ratios when added to the regression models, it is possible that residual confounding
occurs due to unknown risk factors.
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Because most of the participants were students at the School of Public Health, it is
possible that participants in this study have a higher diet quality than the general
population. Nevertheless, we have no reason to believe that the associations of
micronutrients and PMS would be different in other populations of the same age. The
results from this study can be generalized to young, premenopausal women with
micronutrient intakes within the same range.
In summary, we found a marginal association between zinc intake and lower
prevalence of PMS. Additionally, we observed that blood magnesium levels were higher
in women with PMS compared to women without PMS, potentially because of increased
intakes of high-fat high-sugar foods like chocolate, which are rich in magnesium. Further
studies are needed to evaluate the association between these micronutrients and PMS.

4.5 Significance
Premenstrual symptoms have a high prevalence in women of reproductive age
and may be associated with micronutrient intakes. Assessment of micronutrient intakes
and status and premenstrual symptoms in a college age population contributes to a better
understanding of PMS in how dietary factors relate to PMS in young adulthood.

4.6 Human Subject Protection
This research has been approved by the University of Massachusetts, Amherst.
Participants were informed on a written consent statement about the project title, the
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principal investigators, the sponsors of the project, the purpose of the study and
procedures involved and the risks associated with them. After reading this statement,
participants signed the informed consent.
Participants were allowed to drop the study at any point of the clinic visit, and
later if they decide that their samples should not be used for future research, they may
contact the principal investigator and samples will be discarded in immediately.
To provide confidentiality, study participants were identified on all study
materials by a confidential identification number (ID) only. Documents containing the
names corresponding to each ID as well as the questionnaires are kept separately in the
School of Public Health in locked fire-proof cabinets. Nutritional, demographic and
lifestyle data by ID is stored in the J-drives of the computers of the School of Public
Health and may be accessed only by authorized research assistants with a password.
The collection of blood was an invasive procedure used in this study. For having
blood drawn, risks include pain at the site of needle entry, occasional bruising at the site,
and rarely, fainting. Risk of infection is minimal since only sterile one-time-use
equipment was used. Other procedures involved blood pressure assessment, urine
collection, undergoing studies of genetic factors and a DXA scan.
Participants had no direct benefit from participating in this study besides
receiving information on their blood sugar levels, the results of the dietary assessment
and their body composition by the DXA scan.
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Table 4.1 Criteria for selection of premenstrual syndrome (PMS) cases and controls:
The UMass Vitamin D Study, 2006 - 2010.
N

%

Total number of participants

237

1) Participants with at least one physical and one affective symptoms

211 89.03%

2)

- Overall symptom severity ‘moderate’ or ‘severe’; or

39

16.46%

- Impact of symptoms on life activities ‘moderate’ or severe’ ; or

25

10.55%

- One or more individual symptoms rated as ‘severe’

48

20.25%

3) Symptoms begins within 14 days of start of menstruation and ends within 4

197 85.28%

days of start of menses
4) Symptoms absent in the week after menstruation

213 92.21%

PMS cases1

56

23.63%

64

27.71%

1) Participants with individual symptom severity ‘none’ or ‘mild’ for all
symptoms
2) Overall symptoms severity rated as ‘none’, ‘minimal’ or ‘mild’
3) Impact of symptoms on life activities and relationships of ‘not a problem’ or
‘mild’ for all items

198 83.54%
212 89.45%

4) Confirmed no previous clinical diagnosis of PMS

229 96.62%

PMS controls2

60

1

Participants must meet all four criteria for being considered as PMS cases.

2

Participants must meet all four criteria for being considered as PMS controls
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25.32%

Table 4.2 Distribution of total micronutrient intake (n=237): The UMass Vitamin
D Study 2006-2010.

Thiamin (mg/d)
Riboflavin (mg/d)
Niacin (mg/d)
Vitamin B6 (mg/d)
Folate (µg/d)
Vitamin B12 (µg/d)
Magnesium (mg/d)
Zinc (mg/d)
Potassium (mg/d)
Iron (mg/d)
Sodium (mg/d)

Dietary Reference
Intake1
1.1
1.1
14
1.3
400
2.4
310
8
4700
18
1500

Mean
3.0
3.8
32.4
4.6
760
12.6
404
17.4
3551
23.2
2170

Standard
Deviation
5.3
5.4
13.4
9.1
336
44.0
115
12.7
950
15.2
477

Median
2.0
2.9
28.7
2.7
692
7.4
389
13.8
3447
18.3
2129

Interquartile
Range
1.6 - 2.9
2.2 - 3.7
23.3 - 38.1
2.2 - 4.1
505 - 945
4.9 - 10.7
334 - 457
11.8 - 18.6
2967 - 4039
14.3 - 26.0
1917 - 2455

1

Dietary reference intake is the recommended dietary allowance (RDA) for women aged 20 to 40 years for all
nutrients, except for potassium and sodium where the adequate intake (AI) was used instead.

Table 4.3 Distribution of micronutrient intake from food sources (n=237):
The UMass Vitamin D Study, 2006-2010.

Thiamin (mg/d)
Riboflavin (mg/d)
Niacin (mg/d)
Vitamin B6 (mg/d)
Folate (µg/d)
Vitamin B12 (µg/d)
Magnesium (mg/d)
Zinc (mg/d)
Potassium (mg/d)

1.8
2.5
25.8
2.4
626
6.0
389
12.9
3525

Standard
Deviation
0.6
0.8
7.8
0.8
259
3.4
103
4.1
955

Iron (mg/d)

17.1

5.9

Mean
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1.7
2.4
24.6
2.3
562
5.4
371
12.1
3443

Interquartile
Range
1.5 -2.0
2.0 - 2.8
21.1 - 29.1
2.0 - 2.7
325 - 716
3.9 - 7.3
325 - 444
10.7 - 14.2
2940 - 4020

15.3

13.4 - 19.5

Median

Table 4.4 Distribution of selected micronutrient levels in blood (n=182):
The UMass Vitamin D Study, 2006-2010.
Mean
Vitamin B6 (nmol/L)
Folate (nmol/L)
Vitamin B12 (pmol/L)
Magnesium (mg/L)
Zinc (mg/ml)
Ferritin (ng/ml)

91.8
33.1
709.2
21.7
0.06
26.9

Standard
Deviation
52.1
26.0
222.2
4.2
0.02
21.4

Median
91.8
29.0
658.2
22.4
0.06
22.0

Interquartile
Range
44.2-136.6
23.1 - 35.3
554.3 - 823.8
18.0 - 25.2
0.05-0.07
11.4 - 34.5

Table 4.5 Selected characteristics of participants by PMS case/control
status: The UMass Vitamin D Study, 2006 - 2010.
Cases
Mean (SD)
21.3 (2.9)
12.4 (1.4)
22.7 (3.0)

Controls
Mean (SD)
21.8 (3.1)
12.6 (1.3)
22.6 (3.4)

173.6 (64.4)

170.5 (68.7)

0.84

Total alcohol intake (g/day)

7.4 (7.0)

5.4 (7.7)

0.15

Total vitamin D intake (IU/day)

360 (275)

433 (335)

0.20

N (%)

N (%)

Pvalue2

25 (45.2%)

34 (56.8%)

0.22

19 (33.9%)
7 (12.5%)

4 (6.7%)
2 (3.3%)

<0.001
0.09

35 (62.5%)
24 (44.4%)
3 (5.9%)

35 (59.3%)
24 (42.3%)
2 (3.5%)

0.83
0.72
0.67

Age (years)
Age at menarche
BMI (kg/m2)
MET hours/week of physical
activity

Multivitamin supplement use
Smoking status
Ever smoker
Current smoker
Oral contraceptive use
Ever used
Current user
Current use of antidepressants
1

Pvalue1
0.36
0.40
0.90

Calculated using the t statistic.
Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where
the Fisher exact test was used instead.
2
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Table 4.6a Characteristics of participants by total thiamin intake in tertiles: The
UMass Vitamin D Study, 2006 - 2010.
Thiamin intake, mg/d
T1
T2
T3
Mean (SD)
Mean (SD)
Mean (SD)
Age (years)
Age at menarche
BMI (kg/m2)
MET (hr/week) of physical
activity
Total alcohol intake (g/day)
Total vitamin D intake
(IU/day)
Multivitamin supplement
use
Smoking status
Ever smoker
Current smoker
Oral contraceptive use
Ever used
Current user
Current use of
antidepressants

21.7 (3.3)
12.3 (1.4)
23.1 (3.2)

21.1 (2.4)
12.7 (1.3)
23.3 (2.9)

21.9 (3.4)
12.4 (1.4)
22.7 (3.3)

Pvalue1
0.29
0.16
0.44

168.3 (66.8)

184.1 (78.1)

177.5 (62.5)

0.36

8.6 (11.1)

6.1 (6.4)

4.9 (6.1)

0.01

235.3 (170.4)

303.6 (232.8)

596.0 (334.9)

<0.0001

N (%)

N (%)

N (%)

Pvalue2

10 (12.7)

26 (33.3)

70 (88.6)

<0.0001

12 (15.2)
4 (5.1)

15 (19.0)
4 (5.1)

8 (10.1)
3 (3.8)

0.29
0.91

42 (53.2)
32 (42.1)

41 (52.6)
29 (39.7)

48 (60.8)
37 (47.4)

0.52
0.62

3 (4.0)

1 (1.4)

6 (7.9)

0.16

1

Calculated using the F statistic.
Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the Fisher
exact test was used instead.
2
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Table 4.6b Characteristics of participants by total tiboflavin intake in tertiles:
The UMass Vitamin D Study, 2006 - 2010.
Riboflavin intake, mg/d
T1
T2
T3
Mean (SD)
Mean (SD)
Mean (SD)
Age (years)
Age at menarche
BMI (kg/m2)
MET (hr/week) of physical
activity
Total alcohol intake (g/day)
Total vitamin D intake
(IU/day)
Multivitamin supplement
use
Smoking status
Ever smoker
Current smoker
Oral contraceptive use
Ever used
Current user
Current use of
antidepressants

21.2 (2.7)
12.4 (1.4)
23.2 (3.2)

21.8 (3.1)
12.6 (1.2)
23.1 (3.1)

21.7 (3.4)
12.5 (1.4)
22.8 (3.3)

Pvalue1
0.47
0.58
0.65

165.9 (66.2)

186.0 (73.6)

178.0 (67.7)

0.19

7.8 (10.7)

7.0 (7.4)

4.8 (6.0)

0.07

187.8 (143.9)

322.9 (217.4)

624.2 (317.3)

<0.0001

N (%)

N (%)

N (%)

Pvalue2

11 (13.9)

32 (41.0)

63 (79.7)

<0.0001

12 (15.2)
4 (5.1)

14 (17.7)
4 (5.1)

9 (11.4)
3 (3.8)

0.53
0.91

37 (47.4)
29 (39.7)

47 (59.5)
30 (39.5)

47 (59.5)
39 (50.0)

0.22
0.33

3 (4.1)

2 (2.7)

5 (6.8)

0.48

1

Calculated using the F statistic.
Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the Fisher
exact test was used instead.
2
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Table 4.6c Characteristics of participants by total niacin intake in tertiles: The
UMass Vitamin D Study, 2006 - 2010.

Age (years)

T1
Mean (SD)
21.8 (3.0)

Niacin intake, mg/d
T2
T3
Mean (SD)
Mean (SD)
21.3 (2.9)
21.6 (3.3)

Pvalue1
0.59

Age at menarche

12.3 (1.4)

12.7 (1.2)

12.5 (1.5)

0.17

BMI (kg/m2)

23.2 (3.0)

23.0 (2.9)

22.9 (3.6)

0.83

MET (hr/week) of physical
activity

169.0 (67.5)

182.0 (72.1)

178.4 (68.7)

0.49

Total alcohol intake (g/day)

6.5 (7.1)

7.7 (10.6)

5.5 (6.5)

0.25

217.6 (156.1)

333.3 (272.3)

584.1 (316.5)

<0.0001

N (%)

N (%)

N (%)

Pvalue2

14 (17.9)

26 (32.9)

66 (83.5)

<0.0001

17 (21.5)

11 (13.9)

7 (8.9)

0.08

4 (5.1)

4 (5.1)

3 (3.8)

0.91

Ever used

40 (51.3)

46 (58.2)

45 (57.0)

0.65

Current user

25 (35.2)

37 (47.4)

36 (46.2)

0.26

2 (2.7)

3 (4.2)

5 (6.5)

0.57

Total vitamin D intake
(IU/day)
Multivitamin supplement
use
Smoking status
Ever smoker
Current smoker
Oral contraceptive use

Current use of
antidepressants
1

Calculated using the F statistic.
Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the Fisher
exact test was used instead.
2
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Table 4.6d Characteristics of participants by total vitamin B6 intake in tertiles:
The UMass Vitamin D Study, 2006 - 2010.

Age (years)

Vitamin B6 intake, mg/d
T1
T2
T3
Mean (SD)
Mean (SD)
Mean (SD)
21.5 (2.9)
21.4 (2.9)
21.8 (3.3)

Pvalue1
0.68

Age at menarche

12.4 (1.3)

12.5 (1.4)

12.5 (1.4)

0.66

BMI (kg/m2)

22.9 (2.6)

23.0 (3.4)

23.2 (3.4)

0.81

MET (hr/week) of physical
activity

178.4 (72.0)

161.0 (61.4)

190.3 (71.9)

0.03

Total alcohol intake (g/day)

7.1 (10.0)

6.5 (7.8)

6.0 (6.8)

0.67

214.1 (147.7)

302.8 (191.7)

618.1 (346.2)

<0.0001

N (%)

N (%)

N (%)

Pvalue2

13 (16.5)

27 (34.6)

66 (83.5)

<0.0001

15 (19.0)

12 (15.2)

8 (10.1)

0.29

4 (5.1)

4 (5.1)

3 (3.8)

0.91

Ever used

38 (48.1)

43 (55.1)

50 (63.3)

0.16

Current user

27 (37.0)

33 (43.4)

38 (48.7)

0.35

1 (1.3)

4 (5.7)

5 (6.6)

0.25

Total vitamin D intake
(IU/day)
Multivitamin supplement
use
Smoking status
Ever smoker
Current smoker
Oral contraceptive use

Current use of
antidepressants
1

Calculated using the F statistic.
Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the Fisher
exact test was used instead.
2
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Table 4.6e Characteristics of participants by total folate intake in tertiles: The
UMass Vitamin D Study, 2006 - 2010.

Age (years)

T1
Mean (SD)
21.2 (2.8)

Folate intake, µg/d
T2
T3
Mean (SD)
Mean (SD)
21.7 (3.0)
21.8 (3.4)

Pvalue1
0.40

Age at menarche

12.5 (1.3)

12.5 (1.5)

12.5 (1.3)

0.95

BMI (kg/m2)

22.6 (3.0)

23.7 (3.3)

22.8 (3.1)

0.09

MET (hr/week) of physical
activity

170.9 (73.1)

171.8 (66.7)

186.8 (67.9)

0.27

Total alcohol intake (g/day)

7.2 (10.7)

7.7 (7.7)

4.6 (5.4)

0.04

263.1 (164.4)

349.5 (309.2)

522.3 (334.4)

<0.0001

N (%)

N (%)

N (%)

Pvalue2

13 (16.5)

36 (46.2)

57 (72.2)

<0.0001

Ever smoker

9 (11.4)

10 (12.7)

16 (20.3)

0.24

Current smoker

3 (3.8)

2 (2.5)

6 (7.6)

0.40

Ever used

40 (50.6)

45 (57.7)

46 (58.2)

0.57

Current user

35 (46.7)

32 (42.1)

31 (40.8)

0.75

3 (4.0)

2 (2.8)

5 (6.6)

0.61

Total vitamin D intake
(IU/day)
Multivitamin supplement
use
Smoking status

Oral contraceptive use

Current use of
antidepressants
1

Calculated using the F statistic.
Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the Fisher
exact test was used instead.
2
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Table 4.6f Characteristics of participants by total vitamin B12 intake in tertiles:
The UMass Vitamin D Study, 2006 - 2010.
Vitamin B12 intake, µg/d
T1
T2
T3
Mean (SD)
Mean (SD)
Mean (SD)
Age (years)
Age at menarche
BMI (kg/m2)
MET (hr/week) of physical
activity
Total alcohol intake (g/day)
Total vitamin D intake
(IU/day)
Multivitamin supplement
use
Smoking status
Ever smoker
Current smoker
Oral contraceptive use
Ever used
Current user
Current use of
antidepressants
1

Pvalue1

21.5 (3.0)
12.4 (1.4)
22.7 (3.0)

21.3 (2.6)
12.6 (1.2)
23.4 (3.1)

21.9 (3.5)
12.4 (1.5)
23.0 (3.4)

0.43
0.45
0.33

163.9 (64.1)

177.4 (70.2)

188.3 (72.3)

0.09

6.8 (7.4)

7.7 (10.6)

5.1 (6.2)

0.14

159.1 (123.3)

356.7 (204.6)

619.2 (323.8)

<0.0001

N (%)

N (%)

N (%)

Pvalue2

10 (12.8)

36 (45.6)

60 (75.9)

<0.0001

15 (19.0)
5 (6.3)

10 (12.7)
3 (3.8)

10 (12.7)
3 (3.8)

0.44
0.80

41 (52.6)
24 (33.8)

39 (49.4)
33 (42.3)

51 (64.6)
41 (52.6)

0.13
0.07

1 (1.4)

5 (6.7)

4 (5.3)

0.35

Calculated using the F statistic.
2
Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the Fisher
exact test was used instead.
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Table 4.6g Characteristics of participants by total magnesium intake in tertiles:
The UMass Vitamin D Study, 2006 - 2010.

Age (years)

Magnesium intake, mg/d
T1
T2
T3
Mean (SD)
Mean (SD)
Mean (SD)
20.6 (2.2)
22.3 (3.5)
21.8 (3.1)

Pvalue1
0.002

Age at menarche

12.5 (1.5)

12.4 (1.3)

12.5 (1.2)

0.83

BMI (kg/m2)

23.3 (3.4)

23.2 (3.0)

22.7 (3.0)

0.43

MET (hr/week) of physical
activity

158.5 (70.0)

183.5 (68.9)

188.2 (66.3)

0.02

Total alcohol intake (g/day)

6.8 (10.6)

6.4 (7.2)

6.4 (6.8)

0.93

279.0 (235.0)

396.0 (268.1)

460.0 (354.4)

0.0005

N (%)

N (%)

N (%)

Pvalue2

26 (32.9)

37 (46.8)

43 (55.1)

0.02

Ever smoker

9 (11.4)

9 (11.4)

17 (21.5)

0.12

Current smoker

5 (6.3)

1 (1.3)

5 (6.3)

0.24

Ever used

40 (50.6)

45 (57.0)

46 (59.0)

0.55

Current user

35 (46.7)

36 (46.8)

27 (36.0)

0.31

6 (7.9)

3 (4.1)

1 (1.4)

0.17

Total vitamin D intake
(IU/day)
Multivitamin supplement
use
Smoking status

Oral contraceptive use

Current use of
antidepressants
1

Calculated using the F statistic.
Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the Fisher
exact test was used instead.
2
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Table 4.6h Characteristics of participants by total zinc intake in tertiles: The
UMass Vitamin D Study, 2006 - 2010.

Age (years)

T1
Mean (SD)
21.6 (2.9)

Zinc intake, mg/d
T2
T3
Mean (SD)
Mean (SD)
21.4 (3.0)
21.7 (3.3)

Pvalue1
0.83

Age at menarche

12.3 (1.4)

12.6 (1.1)

12.5 (1.6)

0.25

BMI (kg/m2)

22.9 (3.2)

23.2 (2.8)

22.9 (3.5)

0.78

MET (hr/week) of physical
activity

153.4 (57.5)

199.9 (75.3)

176.1 (67.0)

0.0001

Total alcohol intake (g/day)

6.7 (6.5)

8.4 (11.4)

4.5 (5.3)

0.01

255.8 (239.7)

318.9 (197.6)

560.3 (347.8)

<0.0001

N (%)

N (%)

N (%)

Pvalue2

21 (26.6)

24 (30.4)

61 (78.2)

<0.0001

16 (20.3)

12 (15.2)

7 (8.9)

0.13

7 (8.9)

2 (2.5)

2 (2.5)

0.12

Ever used

39 (49.4)

46 (59.0)

46 (58.2)

0.41

Current user

24 (34.3)

40 (51.3)

34 (43.0)

0.11

2 (2.7)

2 (2.8)

6 (7.9)

0.33

Total vitamin D intake
(IU/day)
Multivitamin supplement
use
Smoking status
Ever smoker
Current smoker
Oral contraceptive use

Current use of
antidepressants
1

Calculated using the F statistic.
Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the
Fisher exact test was used instead.
2
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Table 4.6i Characteristics of participants by total potassium intake in tertiles:
The UMass Vitamin D Study, 2006 - 2010.

Age (years)

Potassium intake, mg/d
T1
T2
T3
Mean (SD)
Mean (SD)
Mean (SD)
21.3 (2.8)
21.7 (2.9)
21.7 (3.4)

Pvalue1
0.72

Age at menarche

12.7 (1.6)

12.3 (1.2)

12.4 (1.2)

0.09

BMI (kg/m2)

23.5 (3.1)

22.7 (3.4)

22.9 (3.0)

0.28

MET (hr/week) of physical
activity

163.9 (65.6)

179.5 (76.0)

186.3 (65.2)

0.12

Total alcohol intake (g/day)

8.0 (11.1)

6.5 (6.7)

5.1 (6.0)

0.09

432.1 (304.1)

0.04

Total vitamin D intake
(IU/day)

314.3 (294.8)

388.6

(288.4
)

N (%)

N (%)

N (%)

Pvalue2

30 (38.0)

40 (50.6)

36 (46.2)

0.27

Ever smoker

9 (11.4)

10 (12.7)

16 (20.3)

0.24

Current smoker

4 (5.1)

2 (2.5)

5 (6.3)

0.63

Ever used

41 (51.9)

43 (55.1)

47 (59.5)

0.63

Current user

33 (44.6)

38 (50.0)

27 (35.1)

0.17

5 (6.8)

4 (5.3)

1 (1.4)

0.33

Multivitamin supplement
use
Smoking status

Oral contraceptive use

Current use of
antidepressants
1

Calculated using the F statistic.
Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the
Fisher exact test was used instead.
2
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Table 4.6j Characteristics of participants by total sodium intake in tertiles: The
UMass Vitamin D Study, 2006 - 2010.

Age (years)

Sodium intake, mg/d
T1
T2
T3
Mean (SD)
Mean (SD)
Mean (SD)
21.3 (3.0)
21.5 (3.0)
21.9 (3.2)

Pvalue1
0.37

Age at menarche

12.6 (1.6)

12.5 (1.3)

12.4 (1.2)

0.70

BMI (kg/m2)

23.3 (3.2)

22.9 (3.2)

23.0 (3.1)

0.73

MET (hr/week) of physical
activity

180.7 (67.2)

177.3 (70.5)

171.7 (71.1)

0.72

Total alcohol intake (g/day)

6.0 (10.3)

7.4 (7.3)

6.2 (7.0)

0.53

350.5 (265.1)

431.2 (345.6)

353.3 (275.3)

0.16

N (%)

N (%)

N (%)

Pvalue2

35 (44.9)

34 (43.0)

37 (46.8)

0.89

Ever smoker

6 (7.6)

13 (16.5)

16 (20.3)

0.07

Current smoker

3 (3.8)

4 (5.1)

4 (5.1)

0.91

Ever used

39 (49.4)

48 (61.5)

44 (55.7)

0.31

Current user

31 (41.3)

39 (52.7)

28 (35.9)

0.10

5 (6.8)

3 (4.1)

2 (2.7)

0.48

Total vitamin D intake
(IU/day)
Multivitamin supplement
use
Smoking status

Oral contraceptive use

Current use of
antidepressants
1

Calculated using the F statistic.
Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the
Fisher exact test was used instead.
2
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Table 4.6j Characteristics of participants by total iron intake in tertiles: The
UMass Vitamin D Study, 2006 - 2010.

Age (years)

T1
Mean (SD)
21.1 (2.9)

Iron intake, mg/d
T2
T3
Mean (SD)
Mean (SD)
21.8 (3.1)
21.7 (3.2)

Pvalue1
0.24

Age at menarche

12.5 (1.2)

12.4 (1.5)

12.6 (1.4)

0.63

BMI (kg/m2)

23.0 (3.3)

23.4 (2.9)

22.8 (3.2)

0.52

MET (hr/week) of physical
activity

165.2 (70.0)

182.7 (66.2)

182.0 (71.3)

0.21

Total alcohol intake (g/day)

8.2 (11.2)

6.6 (6.9)

4.8 (5.4)

0.04

318.8 (244.3)

314.8 (272.0)

501.3 (336.2)

<0.0001

N (%)

N (%)

N (%)

Pvalue2

22 (27.8)

25 (32.1)

59 (74.7)

<0.0001

15 (19.0)

12 (15.2)

8 (10.1)

0.29

7 (8.9)

3 (3.8)

1 (1.3)

0.09

Ever used

48 (60.8)

43 (55.1)

40 (50.6)

0.44

Current user

37 (48.7)

30 (41.1)

31 (39.7)

0.49

2 (2.7)

2 (2.7)

6 (8.2)

0.18

Total vitamin D intake
(IU/day)
Multivitamin supplement
use
Smoking status
Ever smoker
Current smoker
Oral contraceptive use

Current use of
antidepressants
1

Calculated using the F statistic.
Calculated using the chi-square statistic, except for smoking variables and use of antidepressants, where the
Fisher exact test was used instead.
2
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Table 4.7 Spearman correlation coefficients for total micronutrient intake: The
UMass Vitamin D Study, 2006-2010.
Thiamin

Riboflavin

Niacin

Vitamin
Vitamin
Folate
Mg
B6
B12

Zinc

Na

Thiamin

1.00

Riboflavin

0.79

1.00

Niacin

0.67

0.68

1.00

Vitamin B6

0.79

0.76

0.82

1.00

Folate

0.81

0.64

0.57

0.72

1.00

Vitamin B12

0.56

0.74

0.64

0.74

0.41

1.00

0.47

0.38

0.23†

0.38

0.60

0.13‡

1.00

0.52

0.62

0.61

0.62

0.44

0.59

0.27

0.22†

0.25

0.16‡

0.13‡

0.34

0.12§

0.25† 0.07§

0.29

0.35

0.13‡

0.30

0.45

0.15‡

0.77 0.18‡ 0.24†

0.61

0.47

0.46

0.54

0.66

0.34

0.40

Magnesium
(Mg)
Zinc
Sodium (Na)
Potassium
(K)
Iron

‡ Statistically significant at p<0.05
§ Not significant
Otherwise, all correlations are statistically significant at <0.0001
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K

1.00

0.58

1.00
1.00

0.25† 0.22†

Table 4.8 Spearman correlation coefficients for micronutrient intake from
food sources: The UMass Vitamin D Study, 2006-2010.
Thiamin

Riboflavin

Niacin

Vitamin
Vitamin
Folate
B6
B12

Mg

Zinc

Thiamin

1.00

Riboflavin

0.53

1.00

Niacin

0.34

0.33

1.00

Vitamin B6

0.57

0.48

0.66

1.00

Folate

0.77

0.42

0.28

0.55

1.00

0.13§

0.48

0.38

0.46

0.01§

1.00

0.56
0.28

0.39
0.52

0.22‡
0.59

0.42
0.58

0.64
0.18‡

-0.02§
0.65

1.00
0.21

1.00

0.42
0.78

0.49
0.46

0.18‡
0.49

0.46
0.61

0.52
0.80

0.15‡
0.16‡

0.80
0.53

0.26
0.37

Vitamin
B12
Magnesium
(Mg)
Zinc
Potassium
(K)
Iron
‡

p-value statistically significant at <0.05
Not significant
Otherwise all correlations are statistically significant at <0.0001

§
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K

1.00
0.38

Table 4.9a Spearman correlation coefficients for vitamin B6, folate, vitamin
B12, magnesium, zinc, and iron dietary intakes with respective blood levels:
The UMass Vitamin D Study, 2006-2010.
Dietary Intake
Biomarker

Vitamin B6

Vitamin B6
Folate
Vitamin
B12
Magnesium
Zinc
Ferritin

0.40†

†

Folate

Vitamin B12

Magnesium

Zinc

Iron

0.51†
0.32†
0.12
-0.02
0.06

p-value statistically significant at <0.0001

Table 4.9b Spearman correlation coefficients for vitamin B6, folate, vitamin
B12, magnesium, zinc, and ferritin blood levels: The UMass Vitamin D Study,
2006-2010.
Biomarker
Vitamin B6
Folate
Vitamin B12
Magnesium
Zinc
Ferritin
‡
†

Vitamin B6

Folate

Vitamin B12

Magnesium

Zinc

Ferritin

1.00
0.42†
0.49†
0.17‡
0.17‡
0.08

1.00
0.87†
0.16‡
0.25‡
0.09

1.00
0.19‡
0.13
0.08

1.00
-0.20‡
-0.01

1.00
0.11

1.00

p-value statistically significant at <0.05
p-value statistically significant at <0.0001
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Table 4.10 Case control ratios, age-adjusted odds ratios (OR) and 95%
confidence intervals (CI) for total micronutrient intake and PMS: The UMass
Vitamin D Study, 2006-2010.
Thiamin (mg/d)
Median
Case-Control Ratio
OR
95% CI
Riboflavin (mg/d)
Median
Case-Control Ratio
OR
95% CI
Niacin (mg/d)
Median
Case-Control Ratio
OR
95% CI
Vitamin B6 (mg/d)
Median
Case-Control Ratio
OR
95% CI
Folate (µg/d)
Median
Case-Control Ratio
OR
95% CI
Vitamin B12 (µg/d)
Median
Case-Control Ratio
OR
95% CI
Magnesium (mg/d)
Median
Case-Control Ratio
OR
95% CI

1st Tertile

2nd Tertile

3rd Tertile

1.4
20:20
1.00

1.7
19:17
1.13
(0.46-2.79)

2.2
17:23
0.70
(0.29-1.72)

1.8
20:19
1.00

2.4
24:15
1.09
(0.43-2.73)

3
12:26
0.65
(0.27-1.60)

19.1
23:16
1.00

24.6
16:22
1.46
(0.59-3.64)

32
17:22
0.44
(0.17-1.12)

1.9
23:16
1.00

2.2
16:22
0.49
(0.20-1.23)

2.9
17:22
0.55
(0.22-1.36)

428.2
16:21
1.00

562.4
19:18
1.32
(0.53-3.33)

839.7
21:21
1.22
(0.49-3.02)

3.2
18:20
1.00

5.4
19:19
1.17
(0.47-2.92)

8.4
19:21
1.06
(0.43-2.62)

297.7
17:16
1.00

371.3
17:24
0.60
(0.23-1.54)

487.2
22:30
0.89
(0.34-2.32)
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Ptrend

0.38

0.36

0.07

0.26

0.75

0.92

0.98

Table 4.10, continued.
Zinc (mg/d)
Median
Case-Control Ratio
OR
95% CI
Potassium (mg/d)
Median
Case-Control Ratio
OR
95% CI
Iron (mg/d)
Median
Case-Control Ratio
OR
95% CI

10.1
21:18
1.00

12.1
22:14
1.35
(0.54-3.40)

15.1
13:28
0.41
(0.16-1.01)

2685.9
16:17
1.00

3443
22:20
1.12
(0.45-2.81)

4271.20
18:23
0.78
(0.30-1.98)

12.6
15:17
1.00

15.3
21:23
0.95
(0.37-2.42)

21.9
20:20
1.09
(0.43-2.79)

265

0.04

0.56

0.79

Table 4.11 Case control ratios, age-adjusted odds ratios (OR) and 95%
confidence intervals (CI) for micronutrient intake from food sources and PMS:
The UMass Vitamin D Study, 2006-2010.
Thiamin (mg/d)
Median
Case-Control Ratio
OR
95% CI
Riboflavin (mg/d)
Median
Case-Control Ratio
OR
95% CI
Niacin (mg/d)
Median
Case-Control Ratio
OR
95% CI
Vitamin B6 (mg/d)
Median
Case-Control Ratio
OR
95% CI
Folate (µg/d)
Median
Case-Control Ratio
OR
95% CI
Vitamin B12 (µg/d)
Median
Case-Control Ratio
OR
95% CI
Magnesium (mg/d)
Median
Case-Control Ratio
OR
95% CI

1st Tertile

2nd Tertile

3rd Tertile

1.4
20:20
1.00

1.7
19:17
1.13
(0.46-2.79)

2.2
17:23
0.70
(0.29-1.72)

1.8
20:19
1.00

2.4
24:15
1.09
(0.43-2.73)

3
12:26
0.65
(0.27-1.60)

19.1
23:16
1.00

24.6
16:22
1.46
(0.59-3.64)

32
17:22
0.44
(0.17-1.12)

1.9
23:16
1.00

2.2
16:22
0.49
(0.20-1.23)

2.9
17:22
0.55
(0.22-1.36)

428.2
16:21
1.00

562.4
19:18
1.32
(0.53-3.33)

839.7
21:21
1.22
(0.49-3.02)

3.2
18:20
1.00

5.4
19:19
1.17
(0.47-2.92)

8.4
19:21
1.06
(0.43-2.62)

297.7
17:16
1.00

371.3
17:24
0.60
(0.23-1.54)

487.2
22:30
0.89
(0.34-2.32)
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Ptrend

0.38

0.36

0.07

0.26

0.75

0.92

0.98

Table 4.11, continued.
Zinc (mg/d)
Median
Case-Control Ratio
OR
95% CI
Potassium (mg/d)
Median
Case-Control Ratio
OR
95% CI
Iron (mg/d)
Median
Case-Control Ratio
OR
95% CI

10.1
21:18
1.00

12.1
22:14
1.35
(0.54-3.40)

15.1
13:28
0.41
(0.16-1.01)

2685.9
16:17
1.00

3443
22:20
1.12
(0.45-2.81)

4271.20
18:23
0.78
(0.30-1.98)

12.6
15:17
1.00

15.3
21:23
0.95
(0.37-2.42)

21.9
20:20
1.09
(0.43-2.79)
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0.04

0.56

0.79

Table 4.12 Case control ratios, age-adjusted odds ratios and 95% confidence
intervals (CI) for vitamin B6, folate, B12, magnesium, zinc, and ferritin blood
levels and PMS: The UMass Vitamin D Study, 2006-2010.
Vitamin B6 (nmol/L)
Median
Case:control ratio
OR
95% CI
Folate (nmol/L)
Median
Case:control ratio
OR
95% CI
Vitamin B12 (pmol/L)
Median
Case:control ratio
OR
95% CI
Magnesium (mg/L)
Median
Case:control ratio
OR
95% CI
Zinc (mg/ml)
Median
Case:control ratio
OR
95% CI
Ferritin (ng/ml)
Median
Case:control ratio
OR
95% CI

1st Tertile

2nd Tertile

3rd Tertile

Ptrend

33.2
15:14
1.00

54.1
10:16
0.59
(0.20-1.74)

95.1
16:12
1.23
(0.43-3.51)

0.55

21.8
13:11
1.00

29.0
16:14
0.93
(0.31-2.74)

39.8
12:16
0.59
(0.19-1.80)

0.32

503.4
14:12
1.00

658.2
16:13
0.96
(0.32-2.83)

931.3
12:19
0.48
(0.16-1.42)

0.14

16.7
11:23
1.00

22.3
17:12
2.89
(1.02-8.13)

25.6
16:10
3.21
(1.09-9.41)

0.02

0.05
12:10
1.00

0.06
17:16
0.84
(0.28-2.51)

0.07
15:16
0.76
(0.25-2.28)

0.62

8.5
16:14
1.00

22.4
9:16
0.48
(0.16-1.42)

41.0
19:15
1.01
(0.37-2.78)

0.85
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Table 4.13 Multivariate adjusted odds ratios1 and 95% CI for total
micronutrient intake and PMS: The UMass Vitamin D Study, 2006-2010.
Thiamin
OR
95% CI
Riboflavin
OR
95% CI
Niacin
OR
95% CI
Vitamin B6
OR
95% CI
Folate
OR
95% CI
Vitamin B12
OR
95% CI
Magnesium
OR
95% CI
Zinc
OR
95% CI
Sodium
OR
95% CI
Potassium
OR
95% CI
Iron
OR
95% CI

1st Tertile

2nd Tertile

3rd Tertile

Ptrend

1.00

0.73
(0.25-2.13)

1.12
(0.32-3.92)

0.73

1.00

0.67
(0.22-1.99)

1.29
(0.38-4.33)

0.52

1.00

0.74
(0.26-2.10)

0.81
(0.25-2.61)

0.79

1.00

0.53
(0.19-1.50)

0.87
(0.28-2.72)

0.88

1.00

1.25
(0.42-3.72)

1.15
(0.38-3.46)

0.87

1.00

0.73
(0.23-2.25)

1.43
(0.43-4.76)

0.41

1.00

0.97
(0.34-2.75)

0.67
(0.24-1.89)

0.39

1.00

0.45
(0.16-1.27)

0.49
(0.17-1.40)

0.23

1.00

1.35
(0.48-3.77)

1.21
(0.48-3.19)

0.92

1.00

1.40
(0.51-3.85)

0.69
(0.24-1.97)

0.39

1.00

1.82
(0.63-5.26)

1.82
(0.49-4.11)

0.65

1

Adjusted for age, smoking (ever vs. never), use of multivitamins (yes vs. no) and total vitamin D intake
(<100 vs. ≥100 IU).
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Table 4.14 Multivariate adjusted odds ratios1 and 95% CI for
micronutrient intake from food sources and PMS: The UMass Vitamin
D Study, 2006-2010.
Thiamin
OR
95% CI
Riboflavin
OR
95% CI
Niacin
OR
95% CI
Vitamin B6
OR
95% CI
Folate
OR
95% CI
Vitamin B12
OR
95% CI
Magnesium
OR
95% CI
Zinc
OR
95% CI
Potassium
OR
95% CI
Iron
OR
95% CI

1st Tertile

2nd Tertile

3rd Tertile

Ptrend

1.00

0.92
(0.34-2.46)

0.57
(0.21-1.52)

0.24

1.00

0.95
(0.35-2.61)

0.66
(0.24-1.84)

0.42

1.00

1.66
(0.61-4.51)

0.51
(0.18-1.42)

0.17

1.00

0.39
(0.14-1.08)

0.40
(0.14-1.12)

0.11

1.00

0.99
(0.36-2.71)

0.65
(0.23-1.84)

0.37

1.00

2.32
(0.69-7.80)

1.96
(0.59-6.46)

0.42

1.00

0.81
(0.29-2.27)

0.68
(0.23-1.97)

0.48

1.00

1.08
(0.38-3.02)

0.40
(0.15-1.09)

0.06

1.00

1.47
(0.53-4.06)

0.66
(0.23-1.88)

0.38

1.00

0.56
(0.20-1.61)

0.79
(0.29-2.19)

0.92

1

Adjusted for age, smoking (ever vs. never), use of multivitamins (yes vs. no) and total vitamin D
intake (<100 vs. ≥100 IU).
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Table 4.15 Multivariate adjusted odds ratios1 and 95% CI for vitamin B6,
folate, vitamin B12, magnesium, zinc, and ferritin blood levels and PMS:
The UMass Vitamin D Study, 2006-2010.
Vitamin B6
OR
95% CI
Folate
OR
95% CI
Vitamin B12
OR
95% CI
Magnesium
OR
95% CI
Zinc
OR
95% CI
Ferritin
OR
95% CI
1

1st Tertile

2nd Tertile

3rd Tertile

Ptrend

1.00

0.79
(0.24-2.61)

1.64
(0.51-5.30)

0.32

1.00

1.41
(0.40-4.94)

0.94
(0.27-3.27)

0.81

1.00

1.51
(0.43-5.32)

0.92
(0.27-3.15)

0.71

1.00

3.31
(1.03-10.72)

4.20
(1.24-14.23)

0.01

1.00

1.00
(0.30-3.30)

0.97
(0.28-3.30)

0.96

1.00

0.37
(0.11-1.26)

0.96
(0.32-2.89)

0.92

Adjusted for age, smoking (ever vs. never), and total vitamin D intake (<100 vs ≥100 UI).

271

Table 4.16 Age and multivariate estimates for the association of total intake of
micronutrients (continuous) and PMS: The UMass Vitamin D Study, 20062010.

Thiamin (1 mg/day)
Riboflavin (1 mg/day)
Niacin (1 mg/day)
Vitamin B6 (1 mg/day)
Folate (100 µg/day)
Vitamin B12 (1 µg/day)
Magnesium (10 mg/day)
Zinc (1 mg/day)
Potassium (1000 mg/day)
Iron (1 mg/day)
Sodium (100 mg/day)
1

Age-adjusted
OR
95% CI
1.14
(0.88-1.48)
1.08
(0.90-1.68)
0.98
(0.95-1.01)
1.04
(0.97-1.11)
1.00
(0.90-1.10)
1.02
(0.96-1.08)
1.01
(0.98-1.04)
0.99
(0.96-1.02)
1.04
(0.72-1.50)
1.01
(0.99-1.03)
1.02
(0.95-1.09)

Multivariate adjusted1
OR
95% CI
1.25
(0.92-1.68)
1.18
(0.90-1.55)
1.00
(0.97-1.03)
1.05
(0.98-1.11)
1.00
(0.90-1.11)
1.05
(0.97-1.13)
1.01
(0.97-1.04)
1.00
(0.97-1.03)
0.99
(0.66-1.49)
1.01
(0.99-1.04)
1.03
(0.96-1.11)

Adjusted for age, smoking (ever vs. never) and total vitamin D intake (<100 vs. ≥100 IU).

Table 4.17 Age and multivariate estimates for the association between total
micronutrient intake (continuous) and PMS symptom score (continuous): The
UMass Vitamin D Study, 2006-2010.

Thiamin (1 mg/day)
Riboflavin (1 mg/day)
Niacin (1 mg/day)
Vitamin B6 (1 mg/day)
Folate (100 µg/day)
Vitamin B12 (1 µg/day)
Magnesium (10 mg/day)
Zinc (1 mg/day)
Potassium (1000 mg/day)
Iron (1 mg/day)
Sodium (100 mg/day)

Age-adjusted
β
SE
Pvalue
0.22
0.12
0.07
0.20
0.12
0.11
-0.04
0.05
0.47
0.06
0.07
0.41
-0.04
0.20
0.83
0.002
0.01
0.90
-0.02
0.06
0.78
-0.03
0.05
0.52
-0.43
0.69
0.54
0.03
0.04
0.48
-0.05
0.14
0.73

1

Multivariate adjusted1
β
SE
Pvalue
0.32
0.12
0.01
0.30
0.12
0.01
0.05
0.06
0.35
0.09
0.07
0.23
0.14
0.22
0.53
0.003
0.01
0.83
-0.01
0.06
0.82
0.05
0.02
0.68
-0.60
0.69
0.39
0.08
0.04
0.09
-0.01
0.14
0.92

Adjusted for age, smoking (ever vs. never), use of multivitamins (yes vs. no) and total vitamin D intake (<100 vs.
≥100 IU).

272

Table 4.18 Age and multivariate estimates for the association between
micronutrient intake from food sources (continuous) and PMS symptom score
(continuous): The UMass Vitamin D Study, 2006-2010.

Thiamin (1 mg/d)
Riboflavin (1 mg/d)
Niacin (1 mg/d)
Vitamin B6 (1 mg/d)
Folate (100 µg/d)
Vitamin B12 (1 µg/d)
Magnesium (10 mg/d)
Zinc (1 mg/d)
Potassium (1000 mg/d)
Iron (1 mg/d)

β
-0.68
-1.20
-0.16
-1.89
-0.17
-0.30
-0.05
-0.41
-0.70
-0.13

Age-adjusted
Pvalue
SE
1.14
0.55
0.83
0.15
0.08
0.06
0.86
0.03
0.25
0.50
0.19
0.12
0.06
0.42
0.16
0.01
0.68
0.30
0.11
0.24

Multivariate adjusted1
Pvalue
β
SE
-0.56
1.11
0.62
-0.79
0.83
0.34
-0.12
0.08
0.16
-1.65
0.84
0.05
-0.26
0.25
0.29
-0.18
0.20
0.37
-0.07
0.06
0.28
-0.31
0.16
0.05
-0.82
0.68
0.23
-0.10
0.11
0.35

1

Adjusted for age, smoking (ever vs. never), use of multivitamins (yes vs. no) and total vitamin D intake (<100
vs. ≥100 IU).

Table 4.19 Age and multivariate estimates for the association between blood levels
of vitamin B6, folate, vitamin B12, magnesium, zinc, and ferritin, and PMS
symptom score (continuous): The UMass Vitamin D Study, 2006-2010.

Vitamin B6 (nmol/L)
Folate (nmol/L)
Vitamin B12 (pmol/L)
Magnesium (mg/L)
Zinc (mg/ml)
Ferritin (ng/ml)
1

Age-adjusted
β
SE
Pvalue
-0.01
0.01
0.62
-0.01
0.03
0.63
-0.004
0.004
0.22
0.43
0.19
0.02
-62.00
47.36
0.19
-0.03
0.04
0.51

Multivariate adjusted1
β
SE
Pvalue
-0.001
0.01
0.95
-0.02
0.03
0.42
-0.003
0.004
0.43
0.48
0.18
0.01
-54.55
46.87
0.25
-0.03
0.04
0.47

Adjusted for age, smoking (ever vs. never) and total vitamin D intake (<100 vs .≥100 IU).
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